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Abstract 
As a result of the evolution of antimicrobial resistant bacteria there is a pressing need for 
novel classes of antibiotics. This project aimed, in part, to design and synthesise a new family 
of pyrazole ligands, their zinc(II) complexes and to evaluate their antmicrobial activity. The 
overall goal was to improve the antimicrobial activity of both ligand and metal salt through 
the formation of the corresponding zinc complex. The first pyrazole ligands synthesized were 
unable to coordinate with zinc(II) salts. We believe this was due to steric hindrance generated 
by the relatively large pyrazaole ligands. Several smaller pyrazole ligands were synthesized, 
some of which successfully complexed with zinc suggesting that steric hindrance had indeed 
been a factor for the first set of ligands. A family of zinc complexes were generated 
employing the family of smaller pyrazole liagnds. All the pyrazole-zinc complexes, pyrazole 
ligands and zinc salts were evaluated for activity against S.aureus and E.coli. Generally, the 
susceptibility test results showed that most pyrazole ligands did not exhibit potent activity 
against either E. coli or S. aureus. All of the zinc complexes exhibited good antibacterial 
activity against both E. coli and S. aureus at 100 μg/mL. As we had expected the zinc 
complexes greatly improved the antibacterial activity of the pyrazole ligands. However, most 
zinc complexes were as active as the zinc salts alone indicating that the addition of the 
pyrazole ligands did not improve the activity of the zinc salts. 
 
Organosulfones are widely used in the field of pharmaceuticals and ploymers. Traditional 
methodologies for synthesizing biphenyl sulfones include Suzuki-Miyaura coupling, 
Friedel-Crafts and other multistep reactions. These methodologies require catalysts, solvents 
and some require long reaction times. We have developed a novel solvent-free methodology 
for synthesizing fluorescent biphenyl sulfones with a relatively short reaction time and in 
good yields. This methodology exploits an interesting electrocyclisation of bissulfonyl trienes. 
A new family of substituted biphenyl sulfones resulted. UV-absorption, emission and 
excitation spectra were generated for the family of biphenyl sulfones and their photophysical 
characterisitics studied (e.g. Stokes shift, quantum yield, molar extinction coefficients). The 
biphenyl sulfones with NO2 substituents did not exhibit fluorescence due to the strong 
electron withdrawing nature of the NO2 group. Other substituted biphenyl sulfones exhibited 
highly solvatochromic emissions, probably via twisted intramolecular charge transfer (TICT) 
states. The biphenyl N,N-dimethyl-4'-(phenylsulfonyl)-[1,1'-biphenyl]-4-amine was found to 
show a very high quantum yield in toluene and dichloromethane (Φ close to 0.9); large 
Stokes shifts and high molar extinction coefficient in ethylene glycol (ε > 80 000 M-1cm-1). 
The HOMO-LUMO gaps of a family biphenyl sulfones were plotted against their Stokes 
shifts (in chloroform) giving an excellent linear correlation (R
2
 = 0.9978). These results 
suggested that the underlying photophysical processes are similar for all our biphenyl 
sulfones, where stronger electron donating groups generate smaller HOMO-LUMO gaps and 
red-shifted emissions, as compared to weaker electron donating groups.  
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List of abbreviations 
                
Anal. Calc.   Analytical calculation 
Ar   Aryl 
Br Broad 
t-Bu   tert-Butyl 
CDCl3 Deuterated chloroform 
cm Centimetre 
cm
-1
 Wavenumbers 
d   Doublet 
°C   Degrees Celsius 
dd   Doublet of doublets 
Δ Reflux temperature 
δ    Chemical shift 
DMF   N,N-Dimethylformamide 
D6-DMSO Deuterated dimethyl sulphoxide 
dt   Doublet of triplets 
ESI Electronspray ionization 
EtOH Ethanol 
ET
30 Reichardt’s solvent plarity parameter 
FTIR Fourier Transform Infrared 
FDA The U.S. Food and Drug Administration 
HCl Hydrochloric acid 
HOMO Highest occupied molecular orbital 
HOBT Hydroxybenzotriazole 
Hz Hertz 
J Coupling constant 
KBr Potassium bromide 
KOH Potassium hydroxide 
λ  
LUMO 
Wavelength (nm)  
Lowest unoccupied molecular orbital 
M Molar 
m Multiplet 
Me Methyl 
MeOH Methanol 
MeCN Acetonitrile 
MIC Minimium inhibitory concentration 
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MIC50 The minimium inhibitory concentration that results 
in a 50 % kill 
MIC100 The minimium inhibitory concentration that results 
in a 100 % kill 
min Minute 
mL Millilitre 
mmol Millimole 
m.p. Melting point 
μL  Microlitre 
NMR Nuclear magnetic resonance 
nm Nanometre 
ppm Parts per million 
q Quartet 
s Singlet 
t Triplet 
TBTU O-(Benzotriazol-1-yl)-N,N,N,N-tetramethyluronium 
tetrafluoroborate 
TICT Twisted intramolecular charge transfer 
UV/vis Ultraviolet/visible 
Φ Quantum yield 
Cca coumarin-3-carboxylate 
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Chapter 1: Introduction to the synthesis of pyrazole ligands, their 
metal complexes and evaluation of their antibacterial activity 
 
1.1 A brief history of antimicrobial agents 
 
Antimicrobial agent is a general term that refers to a group of drugs including antibiotics, 
antifungals, antiprotozoals, and antivirals. In recent time, the resistance of bacteria has grown 
worldwide and is driving the demand for the development of novel antimicrobial agents. The 
first antimicrobial agent was salvarsan, which was synthesized by a German doctor, Ehrlich, 
in 1910. Salvarsan was used as a therapy for syphilis and showed low toxicity levels. This 
discovery opened what is known as the century of antimicrobial chemotherapy. The second 
class of synthetic antimicrobial agents developed were the sulfonamides. The first 
sulfonamide drug, Prontosil, was invented by Domagk in 1935, and was found to be active 
against Streptococcus pyogenes.
1,2
  
 
Alexander Fleming discovered penicillin in 1928, when he found that the growth of 
Staphylococcus aureus was inhibited around a contaminated growth of blue mold. This 
indicated that a substance produced by the microorganism was able to inhibit the growth of 
Staphylococcus aureus. Due to the lack of suitable technology, the active substance, 
penicillin, was not identified until the 1940s when Chain Ernst Boris and Howard Walter 
Florey, and their group, extracted and purified penicillin, for the first time. Penicillin was 
successfully put into clinical use in the 1940s and saved the lives of many wounded soldiers 
in World War II.
3
 The structure of penicillin was subsequently modified generating 
methicillin and ampicillin in the 1960s, which have broader antibacterial activity spectrums.
4
  
 
In 1943 streptomycin was isolated from the soil bacterium Streptomyces griseus by a 
graduate student, Albert Schatz, in the laboratory of Selman Abraham Waksman at Rutgers 
University.
1, 5
 Streptomycin was used for the treatment of tuberculosis. After that, 
chloramphenicol was isolated by David Gottlieb from the bacterium Streptomyces venezuelae 
and introduced into clinical practice in 1949. The tetracyclines were discovered as natural 
products by Benjamin Minge Duggar in 1945 and prescribed in 1948. Macrolides and 
aminoglycosides were discovered in the 1950s and glycopeptides in 1956. Nalidixic acid was 
the first synthetic quinolone antibiotic and was discovered by George Lesher as a byproduct 
of chloroquine manufacture in the 1960s. Nalidixic acid was put into clinical use from 1967 
but was only active against Gram-negative bacteria and its use was limited to the treatment of 
urinary tract infections.
1,6
 The cephems, including cephalosporins and cephamycins were 
developed in 1960s.
1,7 
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Modern antimicrobial agent development involves many lines of research: not only is an 
excellent antibacterial spectrum and excellent efficacy required but also excellent 
pharmacokinetic and safety profiles. For example: nalidixic acid, the first class of synthetic 
quinolone antibiotic, as previously described, was limited to the treatment of urinary tract 
infections. This was a result of its low blood concentration, poor distribution and fast 
metabolism in the human body. A late generation quinolone, norfloxacin had improved 
pharmacokinetic properties, good tissue distribution and was more metabolically stable. It 
also had a broader antibacterial spectrum and was active against both Gram-positive and 
Gram-negative bacteria.
1
 A second example can be found with the cephalosporins. 
Cephcephaloglycin, a first-generation cephalosporin antibiotic, was metabolized quickly, and 
required a high blood concentration to function well. A late generation cephalosporin, 
cefalexin, had much improved pharmacokinetic properties with a superior oral-bioavailability 
and was more metabolically stable.  
 
1.2 Antimicrobial agents 
 
There are four main classes of antimicrobial agents based on their mechanism of reaction, 1) 
the agents that inhibit bacterial cell wall biosynthesis, 2) the agents that inhibit protein 
biosynthesis, 3) the agents that inhibit deoxyribonucleic acid (DNA) or ribonucleic acid 
(RNA) synthesis, 4) the agents that inhibit folate synthesis.
8 
 
1.2.1 Agents that inhibit bacterial cell wall biosynthesis 
 
In regard to antimicrobial development the cell wall is one of the most important 
compositions in bacteria cells as it is not found in mammalian cells. As a result, bacterial cell 
wall biosynthesis is a promising and exploited target for antimicrobial chemotherapy. The 
β-lactams and glycopeptides are two families of antimicrobial agents, whose activity is 
derived from their ability to inhibit bacterial cell wall biosynthesis.
9
  
 
 
1.2.1.1 β-Lactams 
 
The bacterial cell wall is formed through transpeptidation reactions which are catalyzed by 
peptidoglycan transpeptidases.
10
 β-Lactam antibiotics inhibit the growth of bacteria by the 
covalent binding to the active site of peptidoglycan transpeptidases (penicillin binding 
proteins), which catalyze the transpeptidation reactions. As a result, the transpeptidation 
reactions cannot occur, leading to the inhibition of bacterial cell biosynthesis and cell death.
11
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Penicillin was discovered by Alexander Fleming, also called penicillin G, and was the first 
antibiotic applied to clinical use.1 It was effective against Gram-positive organisms and since 
it was first discovered its structure has been modified greatly in order to improve its potency, 
oral bioavailability, antibacterial spectrum of activity, and to decrease its sensitivity to 
β-lactamases. These modifications generated methicillin, ampicillin and piperacillin, Figure 
1.1.1. Methicillin was developed by Beecham in 1959,
4
 with decreased sensitivity to 
β-lactamases. The replacement of two hydrogen atoms by two methoxy groups on the ortho 
position of the phenyl ring introduced additional steric hindrance and protected the β-lactam 
ring from being cleaved by β-lactamases. Ampicillin has broader antibacterial spectrum of 
activity when compared to penicillin G. This additional activity stemmed from the inclusion 
of an amino group on the amide side chain and was essential for activity against 
Gram-negative bacteria. Piperacillin also showed improved potency and decreased sensitivity 
to β-lactamases resulting from the modification of the amino group on the amide side chain. 
 
 
Cephalosporin compounds were first isolated from cultures of Cephalosporium acremonium 
found in a sewer in Sardinia in 1948 by Italian scientist Giuseppe Brotzu.
1
 The 
cephalosporins were applied to clinical use in 1960s and are active predominantly against 
Gram-positive organisms. Thousands of derivatives have been made since then, and 
successive generations have increased activity against Gram-negative organisms. The first 
generation of cephalosporins was active against Gram-positive organisms and Escherichia 
Coli. The second generation of cephalosporins had decreased sensitivity to β-lactamases, and 
an extended antibacterial spectrum. They were active against both Gram-positive and 
Gram-negative organisms. The third generation of cephalosporins improved their efficacy 
against Gram-negative bacteria, but their antimicrobial activity against Gram-positive 
organisms was generally lower than first generation. They had broader antibacterial spectrum 
and decreased sensitivity to β-lactamases compared to the second generation. The fourth 
generations of cephalospoins are zwitter ions that can penetrate the outer membrane of 
Gram-negative bacteria, and they also showed improved resistance to β-lactamases compared 
to the third generation.
12
 The core structure of cephalosporins is shown in Figure 1.1.2. 
Together with cephamycins, which are very similar to the cephalosporins, they constitute a 
subgroup of β-lactam antibiotics called cephems. 
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Figure 1.1.1 Penicillin structures 
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Figure 1.1.2 Core structures of cephalosporins and cabapenems 
 
Carbapenems, which include imipenem (FDA approved in 1985),
13
 panipenem (Japanese 
approval 1993) and meropenem (FDA approval 1996), were the last resort treatment for 
many bacterial infections.
14
 The unsaturated pentacyclic ring structure attached to the core 
β-lactam structure made them highly resistant to β-lactamases,15 but they exhibited low 
bioavailability.
16
 Bacterial resistance to the carbapenems has been growing since the 
appearance of the New Delhi metallo-β-lactamase, “NDM-1” in India.17 The core structure 
of a carbapenem is shown in Figure 1.1.2. 
 
Monobactams are compounds whose β-lactam ring is not fused to another ring. They are only 
active against Gram-negative organisms, and the only commercially available monobactam is 
Aztreonam, Figure 1.1.3. Aztreonam was approved by the FDA in 1986. It is resistant to 
some β-lactamases and only highly active against susceptible Gram-negative bacteria 
including Pseudomonas aeruginosa.
18
  
 
 
Figure 1.1.3 Structure of Aztreonam  
 
1.2.1.2 Glycopeptide antibiotics 
 
Glycopeptide antibiotics are a class of antibiotics composed of glycosylated cyclic or 
polycyclic nonribosomal peptides, which exhibit excellent activity against Gram-positive 
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bacteria, especially methicillin-resistant Staphylococcus aureus.
19
 These antibiotics inhibit 
the growth of bacteria by crossing the bacterial cell wall of Gram-positive bacteria, and 
binding to the terminal acyl-D-alanyl-D-alanine of the peptidoglycan precursor. As a result, 
transpeptidation reactions are blocked due to the introduced steric hindrance, and 
subsequently the biosynthesis of the bacteria cell wall is inhibited.
8
 Significant glycopeptide 
antibiotics include vancomycin, teicoplanin, and bleomyin. Vancomycin, Figure 1.1.4, was 
the first glycopeptide antibiotic and was isolated from a soil sample collected in the interior 
jungles of Borneo by Edmund Kornfeld (Eli Lilly) in 1953.
20
  
 
 
 
Figure 1.1.4 Structure of Vancomycin 
 
1.2.2 Agents that inhibit protein biosynthesis 
 
These agents act by blocking one or more steps of protein biosynthesis, which occurs on 30S 
or 50S ribosomal subunits. For example, streptomycin binds to the small 16S rRNA of 30S 
subunits of the bacterial ribosome, interfering with the binding of formyl-methionyl-tRNA to 
the 30S subunit, which leads to codon misreading, and inhibiting protein synthesis.
21
 The 
major families of these protein biosynthesis inhibitors are aminoglycosides, macrolides, and 
tetracylines. 
 
Antibiotic aminoglycosides found use primarily against infections involving aerobic, 
Gram-negative bacteria, such as Pseudomonas, Acinetobacter and Enterobacter. The most 
frequent use of aminoglycosides was empiric therapy for serious infections such as 
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septicemia, complicated intra-abdominal infections, complicated urinary tract infections and 
nosocomial respiratory tract infections. They have also been used in combination with 
β-lactam antibiotics to treat some Gram-positive bacteria. The most common β-lactam 
antibiotic used in combination with aminoglycosides is ampicillin.
22
 Streptomycin, Figure 
1.1.5, was the first in the class of aminoglycosides. It was isolated from soil bacterium 
Streptomyces griseus in the laboratory of Selman Abraham Waksman at Rutgers University 
by Albert Schatz in 1943.
5
  
 
 
 
      
Figure 1.1.5 Structure of Streptomycin 
 
Antibiotic macrolides are active against Gram-positive bacteria, have relatively broad 
spectrum of antimicrobial activity and newer macrolide agents continue to be developed. 
Erythromycin, Figure 1.1.6, was the first macrolide and was isolated from the metabolic 
products of a strain of Streptomyces erythreus by J. M. McGuire (Eli Lilly). Erythromycin 
has been used since the early 1950s.
23
 Ketolides, a subfamily of macrolides, are used to treat 
respiratory tract infections caused by macrolide-resistant bacteria. Telithromycin, Figure 
1.1.6, the first ketolide antibiotic for clinical use, was reached the market (Germany and 
Spain) as Ketek late in 2001.
24
 
 
              
 
Figure 1.1.6 Structures of Erythromycin and Telithromycin 
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Antibiotic tetracyclines are considered to be broad-spectrum antibiotics, but due to their side 
effect, they are rarely choosen as a treatment.
25
 The first member of tetracyclines was 
chlortetracycline, Figure 1.1.7, and was discovered by Benjamin Duggar who isolated the 
substance from Streptomyces aureofaciens in 1945.
26
 
 
 
 
 
Figure 1.1.7 Structure of Chlortetracycline 
 
1.2.3 Agents that inhibit deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) 
synthesis 
 
There are two main families of antibiotics that inhibit DNA and RNA synthesis, the 
quinolone and rifampicin familes. Quinolones were a family of synthetic broad-spectrum 
antibiotics. They act by binding to the bacterial DNA gyrase or topoisomerase IV, and 
prevent DNA from unwinding and duplicating, thereby inhibiting biosynthesis of DNA.22 
Nalidixic acid was the first quinolone antimicrobial agent synthesized by George Lesher in 
1960s,
1,6
 and was only active against Gram-negative bacteria. Since nalidixic acid achieves 
only low blood concentration, poor distribution and is rapid metabolism, it was limited to the 
treatment of urinary tract infections. Quinolones were not widely used until the discovery of 
fluoroquinolones in 1980s.
27
 Norfloxacin, which came to market in 1984, had improved 
pharmacokinetic properties e.g. good tissue distribution and was more metabolically stable. It 
also had a broader antibacterial spectrum and was active against both Gram-positive and 
Gram-negative bacteria.
1
 Levofloxacin, which is described as a third-generation 
fluoroquinolone, is the enantiomer of ofloxacin (a second-generation fluoroquinolone) and 
exhibits higher antimicrobial activity and weaker side effects.
1,28
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 Figure 1.1.8 Evolution of quinolone antimicrobials 
 
Rifamycins were first isolated from a fermentation culture of Streptomyces mediterranei by 
Piero Sensi and Maria Teresa Timbal in 1957.
22
 They act by binding to the β-subunit of 
DNA-directed RNA polymerase thus inhibiting the initiation of chain formation in RNA 
synthesis.
22 
Rifamycins were widely used for the treatment of many diseases, and have been 
widely used in the treatment of pathogenic bacteria that have become resistant to commonly 
used antibiotics. Of all the rifamycins discovered, rifamycin B, Figure 1.1.9, was the first to 
come to the market in 1958 and it was widely used for the treatment of drug-resistant 
tuberculosis.
29
  
 
 
Figure 1.1.9 Structure of Rifamycin B 
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1.2.4 Agents that inhibit folate synthesis 
 
Folate is very important to the survival of all living organisms, as it serves as the source of 
methyl, formyl and other single carbon fragments in the biosynthesis of purine nucleotides in 
DNA synthesis.
30
 The way human and bacteria obtain folate is very different. Humans obtain 
folate through their diet, while bacteria obtain folate through biosynthesis. This makes folate 
a very attractive target for antimicrobial chemotherapy.
31
 There are two enzymes that are 
targeted: dihydropeteroate (DHPS), an enzyme which sulfonamides act on, and dihydrofolate 
reductase (DHFR), an enzyme which trimethoprim act on, Figure 1.2.1. Sulfonamides inhibit 
DHPS, which catalyzes the conversion of p-aminobenzoic acid (PABA) to dihydroteroate.
32
 
Trimethoprim inhibit DHFR which converts dihydrofolate into tetrahydrofolate.
33
 Most of 
the sulfonamide drugs are no longer in use, as bacteria rapidly acquire resistance to them. 
One of the most commonly used sulfonamides was sulfamethoxazole, Figure 1.2.1, which 
was often used in combination with trimethoprim. This combination was primarily active 
against Streptococcus, Staphylococcus aureus, Escherichia coli and Haemophilus influenzae 
amongst others.
34
 
 
 
   
           
                                 
Figure 1.2.1 Structure of folate, sulfamethoxazole and trimethoprim. 
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1.2.5 Zinc metallotherapeutics 
 
Zinc containing compounds have been reported to have antimicrobial activity, e.g. 
metal-containing thin films have been incorporated into wound dressings or on surfaces to 
kill microbes and bacteria in the UK. Andrew Johnson, at the University of Bath, created 
such a thin film by synthesizing zinc and copper Schiff-base complexes. The zinc complex 
was found to be particularly successful, and exhibited very high activity against 
Staphylococcus aureus and Pseudomonas aeruginosa, Figure 1.2.2.
35
  
 
    
 
Figure 1.2.2 Structure of Johnson’s zinc complexes.35  
 
A pyrazole-zinc complex has been reported by Naveen V. Kulkarni in India and is active 
against E.coli and Pseudomonas aeruginosa, Figure 1.2.3.
46
 The mechanism through which 
zinc produces its antimicrobial effect was unknown until a possible mechanism was proposed 
by Christopher A. McDevitt in 2011.
36
 This report discussed how manganese was found to be 
essential for the growth and virulence of Streptococcus pneumoniae. Zinc was found to be 
able to prevent manganese uptake and thereby inhibit the bacterial growth.
36
  
 
 
 
Figure 1.2.3 Structure of pyrazole-zinc complex
46
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An enaminone-zinc complex, Figure 1.2.4, has been reported by Tariq Mahmud. The 
enaminone-zinc complex was tested against bacteria using the disc-diffusion method. They 
reported the enaminone-zinc complex was very active against E.coli and active against 
S.aureus.
37
  
 
 
 
Figure 1.2.4 Structure of Enaminone-zinc complex
37
 
 
A Zn(II) complex with N-heteroaromatic Schiff base ligands, Figure 1.2.5, exhibiting 
antibacterial activity has been reported by Nenad R. Filipovi. This zinc complex was also 
tested against bacteria using the disc-diffusion method. The zinc complex exhibited relatively 
strong activity against G. stearothermophilus, showing a zone of inhibition of 16 mm. 
Chloramphenicol was used as a standard and which showed a zone of inhibition of 19 mm.
38
  
 
 
Figure 1.2.5 Structure of Nenad R. Filipovi’s zinc complex38 
 
Another example of a zinc complex exhibiting antibacterial activity can been found in the 
work of Ajay K. Singh. Here the zinc complexes were synthesized by reacting zinc acetate 
with Schiff base ligands. The antibacterial activity of these zinc complexes were measured in 
three terms: percentage inhibition, minimum inhibitory concentration and zone of inhibition 
(mm). The most active zinc complex, Figure 1.2.6, inhibited 45.4 % growth of E. coli at 10 
μg/mL; 59.1 % growth at 100 μg/mL and 70.9 % growth of E.coli at 200 μg/mL. The paper 
concluded that the complexation of the zinc with the Schiff base increased the antibacterial 
activity.
39
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Figure 1.2.6 Structure of Ajay K. Singh’s most potent zinc complex39 
 
 
Zinc salts themselves also exhibit excellent antimicrobial activity. Umaira Faiz reported zinc 
sulfate inhibited the growth of a total of 100 bacterial enteric pathogens (for example, E.coli, 
Salmonellae, Vibrio cholera, etc) and most of the bacteria were inhibited at a concentration 
of 0.06 mg/mL to 0.5 mg/mL of zinc.
40
 
 
Other metals are also reported to have antimicrobial activity. Silver containing compounds 
are very toxic to microorganisms, e.g. Ag(I) complexes of hydroxy-substituted coumarin 
carboxylates as developed by Bernadette S. Creaven and co-workers at the Institute of 
Technology, Tallaght. These silver complexes exhibited both antibacterial and antifungal 
activities against methillin-resistant Staphylococcus aureus and Candida albicans. Of these 
silver complexes [Ag(Cca)], Figure 1.2.7, is the most potent.
41
 These silver complexes 
mainly act against fungal pathogens by disrupting the cytochrome synthesis, inhibiting 
respiration, reducing ergosterol biosynthesis and increasing the membrane permeability.
42
 
Copper containing compounds have also been report to have antimicrobial activity, e.g. 
copper complexes of N- (butyl(ethyl)carbamothioyl)-4-nitrobenzamide, Figure 1.2.8. This 
copper complex is reported to have high antibacterial activity against the Gram-positive 
bacteria, Staphylococcus aureus and Staphylococcus epidermidis.
43
 
 
 
 
Figure 1.2.7 Structure of the Cca ligand
41
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Figure 1.2.8 Structure of copper complex of 
N-(butyl(ethyl)carbamothioyl)-4-nitrobenzamide
43
 
 
 
1.3 The need for novel antimicrobial agents 
 
In recent times the widespread emergence of bacterial resistance to antimicrobial agents, 
many of which were developed in the twentieth century, is causing great concern particularly 
when one couples this with the paucity of new antimicrobial drugs. Some scientists have 
predicted a return to a pre-antibiotic era and a looming medical disaster.
44
 
Microorganisms exhibit resistance to antimicrobial agents by four main mechanisms: 1) drug 
inactivation or modification, 2) alteration of target site, alteration of metabolic pathway, 3) 
reduced drug accumulation, 4) preventing the penetration of the penicillins into the cell by 
building a permeability barrier. For example, bacteria build resistance to penicillins by 1) 
cleavage of the β-lactam ring by β-lactamases or penicillinases, 2) reduce the target affinity to 
penicillins by alter the PBPs (penicillin binding proteins).
45
 
Due to the capacity of bacteria to acquire resistance to antimicrobial agents, some formerly 
effective antimicrobial agents are no longer useful. For example, most sulfonamides 
antibiotics are no longer effective as bacteria rapidly acquired resistance to them. Penicillin G 
was initially effective against Staphylococcus aureus, but resistant strains producing 
penicillinase have developed. The penicillinase-stable penicillin, methicillin, was developed 
to combat this but soon methicillin-resistant Staphylococcus aureus was isolated. Since 1990s, 
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nosocomial infection or hospital-acquired infection with methicillin-resistant Staphylococcus 
aureus has become a significant problem.  
As a result there is a pressing need to discovery new antimicrobial agents to fight this 
emergence of antimicrobial resistance. 
1.4 Project aims for antimicrobial section 
This project, in part, aims to 1) synthesize and fully characterize a number of 
pyrazole/pyrazole-thiourea ligands, 2) use these ligands to generate novel zinc-pyrazole 
complexes and have them fully characterized; 3) evaluate the antibacterial activity of ligands 
and the zinc complexes against E.Coli (Gram-negative bacteria) and Staphylococcus aureus 
(Gram-positive bacteria).  
 
 
  
 
 
 
24 
 
Chapter 2 Results and Discussion of the synthesis of pyrazole 
ligands, their metal complexes and the evaluation of their 
antibacterial activity 
 
2.1 Introduction 
We decided to focus our work on pyrazole derivatives for several reasons. They are versatile 
ligands and can coordinate with many transition metal ions. Furthermore, the nucleophilicity 
and steric accessibility of pyrazole nitrogens can be altered by appropriate ring substitutions, 
allowing one to tailor their structure to suit metal complex formation. Pyrazoles are also 
relatively easy to synthesize and derivatize and have reported antimicrobial activity.
46
 We 
initially focused on zinc as the metal for our complexes as it has reported antimicrobial 
activity and it is NMR friendly and hence the complexes are easier to characterize (compared 
to using paramagnetic metals e.g. copper).
35
 
2.2 Synthesis of pyrazole ligands and their zinc (II) complexes 
 
The first pyrazole we decided to synthesize was compound 1, Figure 2.1.1.  
 
 
Figure 2.1.1 Structure of 1  
 
This pyraozle had been made previously in our research group and was relatively easy to 
synthesize. 1 was prepared following the steps shown in Figure 2.1.2.  
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Figure 2.1.2 Synthesis of 1  
 
In step 1, ethyl acetoacetate and N,N-dimethylformamide dimethylacetal were stirred at room 
temperature for 16 hours generating 2. Compound 2 was purified using flash chromatography 
and its structure confirmed by a singlet with an intergration of 6H at 3.04 ppm in the 
1
H 
NMR spectrum, indicating the presence of the (CH3)2NCHC moiety and a singlet with an 
intergration of 1H at 7.69 ppm also indicating the presence of the (CH3)2NCHC moiety. The 
1
H NMR spectrum also shows a quartet at 4.23 ppm and a triplet at 1.32 ppm indicating the 
presence of the ethyl group. A singlet at 2.33 ppm indicated the presence of the C(O)CH3 
moiety. 
 
In step 2, 2 and phenyl hydrazine were refluxed in ethanol for 2 hours generating 3. 
Compound 3 was purified using flash chromatography and its presence was confirmed by a 
singlet in 
1
H NMR spectrum at 8.03 ppm indicating the CH of pyrazole. A multiplet in the 
1
H 
NMR spectrum at 7.52 – 7.39 ppm, with an intergation for 5H, indicated the presence of the 
aromatic ring. A triplet in the 
1
H NMR spectrum at 1.37 ppm and a quartet in the 
1
H NMR at 
4.32 ppm indicated the presence of ethyl group.   
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In step 3, 3 and potassium hydroxide were refluxed in ethanol for 5 hours generating 4. 
Compound 4 was used without further purification and its presence confirmed by the 
disappearance, in the 
1
H NMR spectrum, of the triplet at 1.37 ppm and the quartet at 4.32 
ppm. 
 
Step 4 required that 4 was treated with 1-(5-trifluoromethyl-2-pyridinyl) piperazine and the 
coupling reagent HOBT and TBTU, in dry DMF under nitrogen for 24 hours. The structure 
of the final product 1 was confirmed by a singlet in the 
1
H NMR spectrum at 8.43 ppm 
indicating the presence of CH of pyrazole, a multiplet with integration of 8H at 3.88 – 3.73 
ppm for the piperazine CH2. The 
13
C NMR spectrum CF3 signal at 124.4 ppm showed the 
expected splitting, quartet, and a coupling constant of 268.5 Hz. The CCF3 quartet in the 
13
C 
NMR spectrum appeared at 115.9 ppm with a coupling constant of 33.0 Hz. The structure of 
compound 1 was supported by HRMS and IR spectroscopy, C=O stretch at 1626 cm
-1
. A 
proposed mechanism for the generation of 1 is shown in Figure 2.1.3 (a) and (b). 
 
Step 1: 
Steps 2 & 3: 
Figure 2.1.3 (a) Proposed mechanism for the generation of 1, steps 1-3. 
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Step 4: 
 
 
 
Figure 2.1.3 (b) Proposed mechanism for the generation of 1, step 4 
 
A family of 1 analogues was then synthesized following the same methodology as used for 1, 
Table 1.1. The intermediates synthesized during the synthesis of 1 family were shown in 
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Figure 2.1.4. For example, the 
1
H NMR spectrum of 6 shows a triplet at 1.11 ppm, 
integrating to 3H, and a quartet at 2.89 ppm, integrating to 2H, indicating the presence of an 
ethyl group. The 
13
C NMR spectrum of 6 shows a quartet at 124.5 ppm, with a coupling 
constant of 268.8 Hz, indicating the presence of the CF3 and a quartet at 115.5 ppm, with a 
coupling constant of 32.5 Hz, indicating the presence of CCF3. The 
1
H NMR spectrum of 1 
shows a multiplet at 7.70 – 7.66 ppm, with an integration of 3H, and a multiplet at 7.54 – 
7.42 ppm, with an integration of 5H, indicating the aromatic systems. The 
1
H NMR spectrum 
of 7 (XQ7) shows a multiplet at 7.56 – 7.42 ppm, with an integration of 7H, and a doublet at 
6.96 ppm, with an integration of 2H, indicating the aromatic systems. Overall, aromatic 
proton integration of 1 is 8H while 7 is 9H, indicating the replacement of pyridine ring with 
the phenyl ring. The 
1
H NMR spectrum of 8 shows a singlet at 2.42 ppm, integrating to 3H, 
indicating the presence of CH3 and a singlet at 3.87 ppm, integrating to 3H, indicating the 
presence of the OCH3. The structures of compound 5-9 were supported by HRMS and IR 
spectroscopy.  
 
 
 
Product R1 R2 X Yield (%)* 
1 H CH3 N 78  
5 CF3 CH3 N 54  
6 H CH2CH3 N 33 
7 H CH3 CH 60 
8 OCH3 CH3 N 54 
9 Cl CH3 N 62 
Table 1.1 1-9, * yield of step 4. 
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Figure 2.1.4 intermediates synthesized during the synthesis of 1 family 
 
We then attempted to employ 1 and 7 as ligands in the synthesis of zinc complexes. 1 or 7 
and zinc chloride were dissolved in methanol and refluxed for 2 hours, Figure 2.1.5. To 
determine whether complexation had occurred we compared the 
1
H NMR shifts of the parent 
ligand and the product mixture.  
 
  
Figure 2.1.5 Attempted synthesis of 1 zinc complex 
 
Unfortunately both 1 and 7 failed to coordinate with zinc, as indicated by the lack of a shift in 
the 
1
H NMR spectra. We also attempted the complexation using different reaction times and 
with zinc acetate in place of ZnCl2, Table 1.2. Complexation did not occur for any of the 
reactions attempted.  
Ligand Metal salt Solvent Time (hours) 
1  Zn(Cl)2 Methanol 2 
7  Zn(Cl)2 Methanol 2 
1  Zn(Cl)2 Methanol 5 
1  Zn(Cl)2 Methanol 16 
1  Zn(OOCCH3)2 Methanol 2 
Table 1.2 Attempted complexation reactions 
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We considered two reasons that may have contributed to the failed reactions: 1) complexation 
occurred in solution but the Zn-N bond was too weak to survive work up; 2) steric hindrance 
(ligand too bulky). We designed several experiments to explore these possible explanations. 
 
 
1) We monitored the reaction by 1H NMR in order that we could identify complexation 
if it were occurring in solution but not surviving work up. No evidence for 
complexation was observed. 
 
 
2) We explored the steric effect by designing and synthesizing less hindered pyrazole 
ligands and employed them in complexation reactions with zinc. 
 
 
 
A series of less hindered but related pyrazole ligands were designed and synthesized. 
Compounds 7, 18, 19, 20 and 21 were synthesized using the same methodology as for 1 with 
one change at step 4, Figure 2.1.2. Changing the piperzine/amine in step 4 allowed for the 
synthesis of the new ligands, Table 1.3. Compound 3 had already been prepared during the 
synthesis of 1, Figure 2.1.2. The structures of the ligands were confirmed using NMR, 
HRMS and IR spectroscopy. For example, the 
1
H NMR spectrum of 18 shows two singlets at 
2.35 ppm and 2.25 ppm, each integrating to 3H, indicating the presence of two methyl groups 
and a multiplet at 7.43 – 7.28 ppm indicating the prescence of an aromatic ring. The 1H NMR 
spectrum of 20 shows a singlet at 3.15 ppm integrating to 6H indicating the presence of the 
N(CH3)2 group. The 
1
H NMR spectrum of 21 shows a quartet at 3.51 ppm, with an 
integration of 4H, and a triplet at 1.22 ppm, with the integration of 6H, indicating the 
presence of the two ethyl groups. Additional spectroscopic data can be found in the 
experimental section. These smaller ligands were then employed in complexation reactions 
with zinc. 
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Product R Yield (%)* 
3  
 
64 
7  
 
60 
18  
 
51 
19  
 
52 
20  
 
31 
21  
 
46 
 
Table 1.3 Ligands synthesized for exploring the steric hindrance during complexation.  
* Yield of final step. 
The larger ligands 7, 19 and 21 did not form a zinc complex upon refluxing with ZnCl2 in 
methanol. Replacing the large phenyl group on 7 with the smaller methyl group produced the 
smaller ligand 18 and 20. Both 18 and 20 did form zinc complexes with zinc, upon reaction 
with ZnCl2 and Zn(OAc)2 respectively, Table 1.4. The formation of the zinc complexes 22 
(zinc complex of 18) and 23 (zinc complex of 20) were confirmed by 
1
H NMR and CHN 
microanalysis. 
Ligand Zinc salt Yield(%) 
3  Zn(Cl)2 98 
7  Zn(Cl)2, Zn(OOCCH3)2 0 
18  Zn(Cl)2 99 
19  Zn(Cl)2 0 
20  Zn(OOCCH3)2 77 
21  Zn(Cl)2, Zn(OOCCH3)2 0 
Table 1.4 Complexation reactions 
The smaller pyrazole ester ligand 3 also formed a complex 24 with zinc, Figure 2.1.6. Again, 
the formation of this complex was first confirmed by a shift in 
1
H NMR spectrum, Figure 
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2.1.7. The most obvious shifts are to the CH3 singlet signals at ~2.5 ppm and to the aromatic 
multiplet at ~7.5 ppm. The CH pyrazole singlet at ~8 ppm also shows a shift upon 
complexation. 
 
Figure 2.1.6 Synthesis of 24 and proposed structure of 24 
Structure of the predicted zinc complex is in accordance with the Hard and Soft Acid and 
Base (HSAB) principle, which was reported by Ralph G. Pearson.
47
 The ratio of ligand to 
zinc appears to be determined by the ratio of starting material and is a 2:1, ligand:metal, ratio. 
Similar zinc(II) complexes have been reported. For example, Jacimovic and co-workers 
reported the zinc(II) complexes of 4-acetyl-3-amino-5-methyl-pyrazole (aamp) with the 
molecular formula of Zn(NCS)2(aamp)2. X-ray crystal structure analysis showed the 
coordination atoms to be the nitrogen of the two pyrazoles and the ratio of ligand to zinc is 2 : 
1, Figure 2.1.8.
48
 The molecular formula for the 24 was further confirmed by CHN 
microanalysis, with a calculated result for C26H28Cl2N4O4Zn of C, 52.32; H, 4.73; N, 9.39; 
and a found result of C, 53.13; H, 4.62; N, 9.26. A crystal of the 24 suitable for x-ray crystal 
structure determination could not be obtained. 
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Figure 2.1.7 Comparison of 
1
H NMR of 3 and its zinc complex 24 
 
 
Figure 2.1.8 Structure and x-ray crystal structure of Zn(NCS)2(aamp)2.
48 
 
24 
3 ligand 
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A family of ligands based on 3 were then synthesized Table 1.5. 25 to 29 vary in the R
1
 
substituent and could be accessed using the same synthetic route as used for 3 but with 
different hydrazines, Figure 2.1.2. Compound 29, with R
2
 = nPr, was also accessed using the 
same route but starting from the keto ester 3-oxo-hexanoic acid ethyl ester. The 
1
H NMR of 
28 shows a singlet at 2.50 ppm, with an integration of 3H, indicating the presence of 
pyrazole-CH3 and a singlet at 3.81 ppm, again with an integration of 3H, indicating the 
presence of OCH3 group. HRMS confirmed the presence of 28 with a calculated (M + H
+
) = 
261.1234 and a found (M + H
+
) = 261.1225 (-3.26 ppm difference). For 29 the 
1
H NMR of 
shows a multiplet at 1.64 – 1.51 ppm, integrating to 2H, a triplet at 2.92 ppm, integrating to 
2H and a triplet at 0.85 ppm, with an integration of 3H, indicating the presence of propyl 
group. HRMS confirmed the presence of 29 with a calculated (2M + Na
+
) = 539.2629 and a 
found (2M + Na
+
) = 539.2653 (4.44 ppm difference) The 3 analogues in Table 1.5 were then 
employed in subsequent complexation reactions with zinc chloride. 
 
 
 
 
 
Product R
1
 R
2
 Yield (%)* 
3 H CH3 64 
25 F CH3 47 
26 Cl CH3 94 
27 CF3 CH3 83 
28 OCH3 CH3 76 
29 H CH2CH2CH3 68 
 
Table 1.5 Compound 3 analogues. * Yield of final step. 
 
The complexation reaction was carried out in refluxing methanol using ZnCl2. The successful 
complexation of 3 analogues with zinc, Table 1.6, was confirmed by shifts in the 
1
H NMR 
and by CHN microanalysis. For example, with 26 and its corresponding zinc complex 31 the 
1
H NMR spectra show a triplet at 2.92 ppm (CH2 attached to the pyrazole) shifting to 2.84 
ppm upon complexation; a triplet at 1.36 ppm (OCH2CH3) shifted to 1.40 ppm upon 
complexation and a quartet at 4.32 ppm (OCH2) shifted to 4.35 ppm upon complexation. 31 
was further confirmed by CHN microanalysis with a calculated result for C30H36Cl2N4O4Zn, 
C, 55.18; H, 5.56; N, 8.58; and a found result of C, 54.87; H, 5.33; N, 8.25 (calculated for). 
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Product Ligand Zinc salt Yield (%)* 
24 3 Zn(Cl)2 98 
30 25 Zn(Cl)2 71 
31 26 Zn(Cl)2 100 
32 27 Zn(Cl)2 67 
33 28 Zn(Cl)2 52 
34 29 Zn(Cl)2 80 
 
Table 1.6 Compound 3 analogue zinc complexes. * Isolated yield. 
 
2.3 Synthesis of a pyrazole-thiourea ligand and its zinc(II) complex 
Previous research carried out in our group identified certain thiourea containing molecules as 
having potent antimicrobial activity.
49
 As such we became interested in the antimicrobial 
activity of pyrazole based thiourea compounds and their zinc complexes. A proposed 
synthetic route to our first pyrazole-thiourea is shown in Figure 2.1.9. 
 
Figure 2.1.9 Proposed synthetic route to a thiourea substituted pyrazole. 
 
We first had to synthesise the amino pyrazoles 35 and 36. This was achieved by refluxing 
2-(ethoxymethylene)malononitrile and hydrazine in ethanol for 30 minutes. The final product 
was obtained after recrystallization, Table 1.8.  
 
Product R Yield (%)* 
35 Ph 55 
36 H 52 
 
Table 1.8 Synthesis of XQ35 and XQ36. * Isolated yield. 
 
All subsequent attempts to generate a thiourea substituted pyrazole by reacting these amino 
pyrazoles with phenyl isothiocyanate failed. A complex mixture was obtained in each case, 
Table 1.9. 
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Starting 
material 
Solvent Base Temperature (
o
C) Time 
(hours) 
Yield 
(%) 
35 Toluene Potassium tert-butyloxide 80 15 0 
35 DMF Potassium tert-butyloxide 80 24 0 
35 Dry DCM N/A rt 12 0 
35 Dry THF N/A rt 24 0 
35 Dry DCM TEA rt 15 0 
35 DMF NaOH rt 15 0 
36 DMF N/A rt 15 0 
36 Dry DCM/ 
DMSO 
TEA rt 15 0 
 
Table 1.9 Attempted synthesis of thiourea substituted pyrazole. 
 
An alternative thiourea substituted pyrazole was needed and we turned our attention to 
generating as simple a pyrazole as possible, 39. The successful three step synthetic route to 
39 is shown Figure 2.2.1.  
Figure 2.2.1 Synthesis of 39 
 
In step 1, pyrazole was heated in a mixture of 98 % H2SO4 and 70 % HNO3 to generate the 
desired product 37. The structure of 37 was identified by 
1
H NMR where a singlet at 13.99 
ppm for the NH was observed along with a singlet at 8.58, with an integration of 2H, for two 
CHs of the pyrazole ring. The presence of 37 was confirmed using HRMS (calculated (M + 
Na
+
) = 136.0117, found (M + Na
+
) = 136.0124 (4.56 ppm)).  
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In step 2, compound 37, iron powder and ammonium chloride were heated in an ethanol/H2O 
solution at 80 
o
C to give 38. Compound 38 was confirmed by 
1
H NMR where a singlet at 
8.58 ppm was observed for the pyrazole CH of pyrazole and singlet at 6.99 ppm integrating 
to 2H observed for the NH2.  
 
In step 3, compound 38 and isothiocyanatobenzene were stirred in DMF under nitrogen for 
24 hours generating 39. The singlet at 12.70 ppm on 
1
H NMR is identified as a NH signal, 
and the singlet at 9.57 ppm, with an integration of 2H, is identified as the signal for the two 
pyrazole CHs. A broad singlet at 7.79 ppm is believed to be generated by a second NH. The 
aromatic protons show up as a multiplet with an integration of 5H. The structure of 39 was 
confirmed using HRMS and IR spectroscopy. Compound 39 was subsequently employed in a 
complexation reaction with zinc acetate.  
 
Compound 39 were heated in methanol at 40
o
C and a methanol solution of zinc acetate added. 
A precipitate appeared upon addition of the zinc acetate, which was isolated. We believe that 
complexation has occurred but a sample of sufficient purity could not be obtained and hence 
the structure of the complex could not be identified. A proposed structure for 39 zinc 
complex 40 is shown in Figure 2.2.2. 
 
Figure 2.2.2 Possible structure of 40 
 
Compounds 41 and 42 
 
Compounds 41 and 42 (compound 2 analogues) were also synthesized, as they were requierd 
as starting materials for the synthesis of compounds 11 and 29 respectively. They were 
synthesized using the same reaction conditions as described for the synthesis of compound 2, 
Figure 2.2.3. Similar to compound 2, the generation of compound 42 was confirmed by the 
presence of a singlet, with an intergration of 6H, at 2.83 ppm in the 
1
H NMR spectrum, 
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indicating the presence of the (CH3)2N moiety. In addition, a singlet, with an intergration of 
1H, at 7.45 ppm was also present and indicated the presence of the (CH3)2NCH moiety. The 
1
H NMR spectrum also shows a quartet, with an intergration of 2H, at 4.03 ppm indicating 
the presence of the OCH2CH3 moiety and a triplet, with an intergration of 3H, at 1.13 ppm 
indicating the presence of the OCH2CH3 moiety. A double of triplets, with an intergration of 
2H, at 1.43 ppm indicated the presence of the CH2CH2CH3 group. 
 
 
 
Figure 2.2.3 Synthesis of compound 41 and 42 
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2.4 Biological evaluation 
 
Pyrazole derivatives have been reported to have antimicrobial activity against both 
Gram-positive and Gram-negative bacteria. For example, Rahimizadeh and co-workers 
reported the biological activity of a series of pyrazole derivatives, with somewhat similar 
structures to our pyrazole ligands.
50
 In this paper N-(4-cyano-1-(2,4-dinitrophenyl) 
-1H-pyrazol-5-yl)-4-nitrobenzamide, Figure 2.2.3, shows a minimum inhibition 
concentration (100 %) of 25.1 μg/mL aginst methicillin-resistant S.aureus (Gram-positive 
bacteria, Cloxacillin was used as a standard with a minimum inhibition concentration (100%) 
of 94.0 μg/mL).50  
 
 
 
Figure 2.2.3 N-(4-cyano-1-(2,4-dinitrophenyl)-1H-pyrazol-5-yl)-4-nitrobenzamide 
 
Jain and co-workers described the biological activity of 
1-phenyl-3-(4-nitrophenyl)-5-(4-(2-ethanoloxy)phenyl) 1H-pyrazole, Figure 2.2.4, which 
was active against E.coli (Gram-negative bacteria) with a minimum inhibition concentration 
(100%) of 0.35 μg/mL.51 As a result of such publications, we were hopeful that our pyrazole 
ligands would show inhibition of both Gram-positive and Gram-negative bacteria. 
 
Figure 2.2.4 1-Phenyl-3-(4-nitrophenyl)-5-(4-(2-ethanoloxy)phenyl) 1H-pyrazole 
Zinc complexes have been reported to improve the activity of both organic ligands and zinc 
salts. For example, the zinc complex reported by Johnson and co-workers displayed 
antimicrobial activity against P. aeruginosa.
35
 In this case, the zinc complex shows an MIC100 
of 280 μg/mL while its Schiff-base ligand displayed a higher MIC100 of 483 μg/mL, with zinc 
acetate having an MIC100 of 1120 μg/mL. The zinc-complex has improved the antibacterial 
activity of both the organic ligand and the zinc acetate. Therefore we were again hopeful that 
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an improvement in the antibacterial activity of our pyrazole ligands and the zinc salts would 
be observed upon complextaion.  
 
All the ligands synthesized, as well as their zinc-complexes and zinc salts, were tested against 
S. aureus, a Gram-positive bacterium, and E.coli, a Gram-negative bacterium. 20 mg of the 
testing compounds were weighed and first dissolved in 1 mL DMSO. The solutions were then 
diluted in water. The stock solutions prepared for testing was 20 μg/mL. The susceptibility 
tests were carried out on 96-well flat-bottom tissue culture plates. The plates from column 12 
to column 4 contain test solutions (DMSO/water) of the synthesized compound. The 
concentration of the test solution is different in each column with column 12 having the 
highest concentration and column 4 the lowest concentration. Column 3 contains bacteria and 
media only with column 1 and 2 containing media only. The plates were incubated for 24 
hours at 37 
o
C. The optical density is then read at 540 nm and growth is quantified as a 
percentage of the control. The E.coli and S.aureus strains tested were clinical isolates from 
patients at St.James Hospital, Dublin. All the results presented are an average from 3 plates 
for each compound, with a percentage error lower than 10 %. The abbreviations ZC and ZA 
stands for zinc chloride and zinc acetate, respectively. 
 
 
Figure 2.2.5 96-well flat-bottom tissue culture plate 
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2.4.1 Evaluation of compound 1 and analogues of compound 1 against E.coli 
 
Most of the 1 family members were found not to be active against E.coli, with the exception 
of 19, Figure 2.2.6. In comparison with 1, 19 has replaced the pyridine ring with an 
unsubstituted phenyl ring. 19 inhibited approximately 40 % of the bacterial growth at 100 
μg/mL, 2.89 × 10-4 mmol/mL. The most interesting comparison is between 19 and 7, as the 
only difference between the two is the presence or absence of a CF3 group. 7 has a p-CF3 
group on the phenyl ring, and is inactive, where as 19 does not have a CF3 group and is active, 
Table 2.1. This is a strange phenomenon as many reported antibiotics, like the 
fluoroquinlones, show improved activity when F atom/atoms are present. A CF3 group would 
also increase lipid solubility and hence increase a compounds ability to penetrate the bacterial 
cell wall.
52
  
 
Product R
1
 R
2
 X R
3
 
1 H CH3 N CF3  
5 CF3 CH3 N CF3 
6 H CH2CH3 N CF3 
7 H CH3 CH CF3 
8 OCH3 CH3 N CF3 
9 Cl CH3 N CF3 
19 H CH3 CH H 
 
Table 2.1 Compound 1 family 
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Figure 2.2.6 Compound 1 family against E.coli. 
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2.4.2 Evaluation of 18, 20, 21 and their zinc complexes against E.coli. 
 
18, 20 and 21 are structurally smaller than the 1 family, Table 2.2. As a result, 18 and 20 
were successfully complexed with zinc. 21 did not form a zinc complex and this may be due 
to its slightly larger size. 
 
Product R 
18 
 
20 
 
21 
 
 
Table 2.2 Structure of 18, 20 and 21 
 
Generally, they did not show significant activity against E.coli, with 20 and 18 displaying 
slightly better activity against E.coli compared to 21, Figure 2.2.7. The reason for this 
slightly superior activity is not clear. Perhaps the fact that 18 and 20 could form a zinc 
complex and 21 could not, may hint that a steric effect may also influence their antibacterial 
activity. Similar phenomenon have been reported, for example Jiménez-Pérez and co-workers 
reported the antibacterial activity of N,N
’
-diaryl-o-phenylenediamines, Figure 2.2.8, against 
S. typhimurium. Minimal inhibitory concentration (100%) of compound a1 and a2 against S. 
typhimurium was reached at 0.35 μg/mL with minimal inhibitory concentration (100%) of 
compound a3 reached at 0.75 μg/mL. Jiménez-Pérez suggested that the the steric hindrance 
effect of the N-aryl groups, on o-phenylendiamines, influenced the biological activity.
53
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Figure 2.2.7 Compounds 18, 20 and 21 against E.coli 
 
 
Sample R R’ 
a1 CH3 H 
a2 CH3 CH3 
a3 iPr H 
 
Figure 2.2.8 N,N
’
-diaryl-o-phenylenediamines.
53
 
 
E.coli growth was inhibited by approximately 60-70 % by the 18 zinc chloride complex (22) 
and by the 20 zinc acetate complex (23), at a concentration of 100 μg/mL, Figure 2.2.9. As 
we had hoped, both 22 (100 μg/mL, 1.42 × 10-4 mmol/mL) and 23 (100 μg/mL, 1.56 × 10-4 
mmol/mL) have greatly improved antibacterial activity (about 60-70 % inhibition of E.coli 
growth) compared to the pyrazole ligands 18 (100 μg/mL, 3.52 × 10-4 mmol/mL) and 20 (100 
μg/mL, 4.37 × 10-4 mmol/mL) alone (about 20 % inhibition of E.coli growth). Zinc chloride 
(100 μg/mL, 7.35 × 10-4 mmol/mL) inhibited E.coli growth by approximately 70-80 % and 
zinc acetate (100 μg/mL, 5.46 × 10-4 mmol/mL) by approximately 70 % growth. As such, 22 
and 23 inhibited nearly the same percentage growth of E.coli at much lower concentration 
compared to zinc salts indicating that the addition of the pyrazole ligands also improved the 
activity of the zinc salts.  
  
 
 
 
45 
 
 
 
Figure 2.2.9 Compound 22 and 23 against E.coli 
 
 
2.4.3 Evaluation of 3, 3 analogues and their zinc complexes against E.coli. 
 
The 3 family, Table 2.3, did not show significant activity against E.coli, Figure 2.3.1. As 
previously observed with 18 the zinc complexes of the 3 family have significantly improved 
activity against E.coli when compared to the pyrazole ligands, Figure 2.3.2. The growth of 
E.coli was inhibited by approximately 70 % when the concentration of 24 was 100 μg/mL, 
1.68 × 10
-4
 mmol/mL and this was the most active complex. Zinc chloride itself inhibited 
approximately 70-80 % E. coli growth at 100 μg/mL, 7.35 × 10-4 mmol/mL. Once again this 
zinc complex is nearly as active as zinc chloride at much lower concentration and as such the 
addition of 3 improved the activity of zinc chloride. 32 shows extremely high percentage 
growth at 25 and 50 μg/mL, possibly due to the precipitation of 32. During solution 
preparation 32 was noticeably harder to dissolve than the other complexes. The growth of 
E.coli was inhibited by approximately 20-30% when the concentration of 32 was 100 μg/mL, 
1.37 × 10
-4
 mmol/mL. This inhibition is very low compared to the other 3 family zinc 
complexes. It may due to the presence of CF3 substituted on the phenyl ring which appeared 
to be problematic with previously described pyrazole ligands, in section 2.4.1, or perhaps it is 
due to the reduced solubility of 32.  
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Product R
1
 R
2
 
3 H CH3 
25 F CH3 
26 Cl CH3 
27 CF3 CH3 
28 OCH3 CH3 
29 H CH2CH2CH3 
 
Table 2.3 3 family  
 
 
 
 
Figure 2.3.1 Compound 3 family against E.coli. 
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Figure 2.3.2 Compound 3 family zinc complexes againt E.coli 
 
 
2.4.4 Evaluation of 39 and 40 against E.coli. 
 
39 is a thiourea substituted pyrazole, Figure 2.3.3. Its zinc complex, 40, could not be isolated 
with 100% purity but was evaluated against E. coli in any case (concentration calculated 
based on the proposed structure shown in Figure 2.2.2). Again we saw that 39 does not show 
significant antibacterial activity against E.coli (approximately 20 % inhibition at 100 μg/mL, 
4.59 × 10
-4
 mmol/mL). However, 40 inhibited approximately 75 % E.coli growth at 100 
μg/mL, 1.51 × 10-4 mmol/mL. Once again, the zinc complex displayed significantly improved 
activity against E.coli compared to pyrazole ligand. 40 was also observed to slightly increase 
the activity against E.coli at 100 μg/mL, 1.51 × 10-4 mmol/mL when compared to zinc acetate 
at 100 μg/mL 5.46 × 10-4 mmol/mL, Figure 2.3.4. 40 also inhibited approximately 50 % E. 
coli growth at a concentration of 50 μg/mL, 0.76 × 10-4 mmol/mL, where as zinc acetate only 
inhibited approximately 35 % growth at 50 μg/mL, 2.73 × 10-4 mmol/mL. 
 
         
                                   
Figure 2.3.3 Structure of 39 
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Figure 2.3.4 Compounds 39 and 40 against E.coli 
2.4.5 Evaluation of the 1 family against S.aureus 
 
Generally, the 1 family did not show activity against S.aureus, Figure 2.3.5 and 2.3.6 The 
structures of the XQ4 family can be seen on Table 2.1. XQ14 showed slight activity against 
S.aureus inhibiting growth by approximately 10% at a concentration of 100 μg/mL, 2.89 × 
10
-4 
mmol/mL.  
 
 
Figure 2.3.5 1 family against S.aureus 
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Figure 2.3.6 Compound 1 family against S.aureus 
 
2.4.6 Evaluation of compounds 18, 20, 21 and their zinc complexes against S.aureus. 
 
The activity of 18 and 21 against S.aureus is very low, Figure 2.3.7. The structure of these 
pyrazoles can be found on Table 2.2. 20 inhibited approximately 20 % of S. aureus growth at 
100 μg/mL, 4.37 × 10-4 mmol/mL.  
 
 
Figure 2.3.7 Compounds 18, 20 and 21 against S.aureus 
 
As with E. coli, the zinc complexes 22 and 23 have significantly improved activity against S. 
aureus compared to the pyrazole ligands alone, Figure 2.3.8. 21 did not form a zinc complex. 
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22 (100 μg/mL, 1.42 × 10-4 mmol/mL) inhibited the growth of S. aureus by approximately 
40 % and XQ25(ZA) (100 μg/mL, 1.56 × 10-4 mmol/mL) by approximately 50 %. Again, we 
saw that 22 and 23 were inhibited nearly the same percentage growth of S.aureus at much 
lower concentration compared to Zinc chloride (100 μg/mL, 7.35 × 10-4 mmol/mL) and zinc 
acetate (100 μg/mL, 5.46 × 10-4 mmol/mL) respectively. XQ25(ZA) inhibited the growth of S. 
aureus by approximately 45 % at 50 μg/mL, 0.78 × 10-4 mmol/mL; zinc acetate inhibited 
approximately 30 % S. aureus growth at 50 μg/mL, 2.73 × 10-4 mmol/mL. 
 
 
Figure 2.3.8 Compounds 22 and 23 against S.aureus. 
 
2.4.7 Evaluation of the 3 family and their zinc complexes against S.aureus. 
 
In general the 3 family did not show signification activity against S.aureus, Figure 2.3.9. The 
structures of the 3 family can be found on Table 2.3. 25 inhibited growth of S. aureus by 
approximately 20 % at 100 μg/mL, 4.03 × 10-4 mmol/mL.  
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Figure 2.3.9 Compound 3 family against S.aureus 
 
 
Once again, the zinc complexes of 3 family exhibited higher activity than the pyrazole 
organic ligands. The zinc complex 24 inhibited growth of S. aureus by approximately 50 % at 
a concentration of 100 μg/mL, 1.68 × 10-4 mmol/mL, Figure 2.4.1. 30 (100 μg/mL, 1.58 × 
10
-4
 mmol/mL) and 32 (100 μg/mL, 1.37 × 10-4 mmol/mL) were both found to inhibit the 
growth of S. aureus by approximately 40 %. The growth of S. aureus at 50 μg/mL of 32 was 
much higher than 100 % and this is possibly due to an increase in the optical density caused 
by the precipitation of 32, as previously discussed in section 2.4.3. 33 inhibited the growth of 
S.aureus by approximately 50% at a concentration of 100 μg/mL, 1.52 × 10-4 mmol/mL. Zinc 
chloride inhibited about 60 % growth of S.aureus at 100 μg/mL, 7.35 × 10-4 mmol/mL. 31 
(100 μg/mL, 1.50 × 10-4 mmol/mL) and 34 (100 μg/mL, 1.53 × 10-4 mmol/mL) exhibited 
approximately 60-65 % growth inhibition of S.aureus. 24, 31 and 34 were inhibited nearly the 
same percentage growth of S.aureus at much lower concentration compared to zinc chloride. 
Thus the addition of 3, 26 and 29 to zinc chloride has improved antimicrobial activity. 
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Figure 2.4.1 Compound 3 family zinc complexes against S.aureus 
 
2.4.8 Evaluation of 39 and 40 against S.aureus. 
 
39 inhibited the growth of S. aureus by approximately 10% at a concentration of 100 μg/mL. 
Its zinc complex, 40, was found to be significantly more active and showed 60 % growth 
inhibition at a concentration of 100 μg/mL (1.51 × 10-4 mmol/mL) (concentration calculated 
based on proposed structure in Figure 2.4.2). The activity of 40 against S. aureus was slightly 
superior to zinc acetate at 100 μg/mL and the concentration of 40 (1.51 × 10-4 mmol/mL) is 
much lower than zinc acetate (5.46 × 10
-4
 mmol/mL). 40 inhibited S. aureus growth by 
approximately 40 % at 50 μg/mL where as zinc acetate only showed approximately 30 % 
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inhibition at 50 μg/mL. The addition of 39 to zinc acetate has improved the activity against 
S.aureus. 
 
 
Figure 2.4.2 Compounds 39 and 40 against S.aureus 
 
2.4.9 Conclusion  
 
As previously discussed in section 2.4, we expected the pyrazole ligands and their zinc 
complexes to exhibit antibacterial activity, with the zinc complexes displaying improved 
antibacterial activity when compared to either the pyrazole ligands and zinc salts alone. 
Generally, the susceptibility test results showed that most pyrazole ligands did not exhibit 
potent activity against either E. coli or S. aureus. 19 was one of the more potent ligands 
displaying 40 % inhibition of E. coli at 100 μg/mL. All of the zinc complexes exhibited good 
antibacterial activity against both E. coli and S. aureus at 100 μg/mL. As we had expected the 
zinc complexes greatly improved the antibacterial activity of the pyrazole ligands. However, 
most zinc complexes were as active as the zinc salts alone at 100 μg/mL. But the 
concentrations of zinc complexes were lower than zinc salts alone. For example, 24 inhibited 
E. coli growth by approximately 70 % at 100 μg/mL (1.68 × 10-4 mmol/mL), 3 inhibited E. 
coli growth by approximately 20 % at 100 μg/mL and zinc chloride inhibited E. coli growth 
by approximately 80 % at 100 μg/mL (7.35 × 10-4 mmol/mL). 40 exhibited better activity 
against both E. coli and S. aureus at 50 μg/mL compared to zinc acetate and 39. The origin of 
the antimicrobial activity of the pyrazole zinc complexes was not determined. It could arise 
from the zinc complexes itself, but it may also result from the zinc salt or ion itself after 
disassociation of the complex upon interaction with the bacterial cell. 
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Chapter 3 Experimental for the synthesis of pyrazole ligands and 
their metal complexes 
 
Instrumentation 
Reagents were purchased from Sigma-Aldrich, Alfa Aesar, Acros Organics and used without 
further purification. Anhydrous DMF was purchased from Sigma Aldrich.  
 
All NMR spectra were recorded on a Bruker Avance spectrometer at a probe temperature of 
25 °C, unless otherwise stated, operating at 300 MHz for the 1H nucleus and 75 MHz for the 
13C nucleus. Proton and carbon signals were assigned with the aid of DEPT experiments for 
novel compounds. High temperature NMR spectroscopy experiments were carried out by 
heating the probe. Spectra were recorded in DMSO-d6, CDCl3 or CD3OD with Me4Si used as 
the internal standard. Chemical shifts are given in ppm downfield form the internal standard 
and coupling constants are given in Hz.  
 
Melting point analyses were carried out using a Stewart Scientific SMP1 melting point 
apparatus. 
 
Infrared (IR) spectra were recorded as KBr disks or liquid films between NaCl plates using a 
Perkin Elmer System 2000 FT-IR spectrometer in the region of 4000-370 cm
-1
. High 
resolution mass spectra (HR-MS) were performed on an Agilent-L 1200 Series coupled to a 
6210 Agilent Time-of-Flight (TOF) mass spectrometer equipped with an both a positive and 
negative electronspray source.  
 
Microanalysis was carried out using a Flash EA 1112 Series Elemental Analyser. The sample 
is burned in oxygen and a helium carrier gas at 900 
o
C in a combustion tube. 
 
Flash column chromatography was performed using silica gel 60 (Merck, 0.040-0.063 mm). 
Analytical thin layer chromatography was carried out on aluminium sheets precoated with 
Merck TLC Silica gel 60 F254.  
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3.1  Synthesis of pyrazole ligands of compound 1 family 
3.1.1 Synthesis of (5-methyl-1-phenyl-1H-pyrazol-4-yl)-[4-(5-trifluoromethyl-pyridin 
-2-yl)-piperazin-1-yl]-methanone 1 (XQ4) 
 
 
 
5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 4 (65 mg, 0.32 mmol), HOBt (54 mg, 0.40 
mmol), TBTU (130 mg, 0.40 mmol), anhydrous triethylamine (0.09 mL, 0.65 mmol) and dry 
dimethylformamide (1 mL) were placed in an oven-dried Schlenk tube under a nitrogen 
atmosphere. The resulting solution was stirred at room temperature for 15 minutes. A second 
oven-dried Schlenk tube was prepared containing 1-(5-trifluoromethyl-2-pyridinyl) 
piperazine (92 mg, 0.4 mmol) and dry dimethylformamide (1 mL) under a nitrogen 
atmosphere. The resulting solution was stirred until complete dissolution of the piperazine 
had occurred. The piperazine solution was then transferred, via a cannula, to the first Schlenk 
tube containing the carboxylic acid. The resulting solution was stirred for 24 hours under a 
nitrogen atmosphere, and monitored by TLC. After 24hrs, the dimethylformamide was 
removed under reduced pressure and the resulting oil was acidified using a 0.1 N aqueous 
hydrochloric acid solution. The aqueous mixture was extracted with ethyl acetate (20 mL, 
followed by 4 × 10 mL). The organic extracts were combined and washed with a saturated 
aqueous sodium bicarbonate solution (3 × 20 mL) and brine (3 × 20 mL). The organic layer 
was separated and dried over anhydrous magnesium sulphate and evaporated under reduced 
pressure. The residue was purified using flash chromatography on silica gel eluting with 
dichloromethane/methanol (95:5) to obtain the desired product as a white solid, 78 % yield 
(99 mg). 
 
m.p. 186-190
 o
C; 
1
H NMR (300 MHz, CDCl3) δ 8.43 (s, 1H, CH of pyrazole), 7.70 – 7.66 (m, 
3H, Ar), 7.54 – 7.42 (m, 5H, Ar), 3.88 – 3.73 (m, 8H, CH2), 2.49 (s, 3H, CH3); 
13
C NMR (75 
MHz, CDCl3) δ 164.9 (C=O), 160.1 (C-2 of pyridine), 145.8 (q, J = 4.5 Hz, C-6 of pyridine), 
141.3 (CCH3), 139.0 (ArC), 138.8 (CH of pyrazole), 134.7 (q, J = 3.0 Hz, C-4 of pyridine), 
129.3 (ArCH), 128.5 (ArCH), 125.3 (ArCH), 124.4 (q, J = 268.5 Hz, CF3), 115.9 (q, J = 33.0 
Hz, CCF3), 115.1 (CC=O), 105.8 (C-3 of pyridine), 44.9 (CH2), 11.8 (CH3); IR (KBr) 3443, 
3058, 2868, 1618 (amide), 1556, 1506, 1439, 1316 (tertiary amine), 1273, 1240 (CF3), 1200 
(tertiary amine), 1161, 1108, 1006, 944, 873, 808, 770, 698, 634, 476 cm
-1
; ESI-MS 
C21H20F3N5O Calc. (M + H
+
) = 416.1693, found (M + H
+
) = 416.1705. 
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3.1.2 Synthesis of ethyl 2-((dimethylamino)methylene)-3-oxobutanoate 2 (XQ1)
54
 
 
 
 
Ethyl acetoacetate (0.2 mL, 1.58 mmol) was stirred at room temperature and 
N,N-dimethylformamide dimethylacetal (0.252 mL, 1.58 mmol) was added drop wise. The 
reaction mixture was allowed to stir at room temperature for 16 hours. The resulting solution 
was evaporated under reduced pressure, then azeotroped with toluene three times 
(evaporating under reduced pressure) and purified using flash chromatography on silica gel 
eluting with ethyl acetate/petroleum ether, (80:20) to give a yellow oil, 14.7 % yield (292 
mg). 
 
Rf value 0.22 (ethyl acetate/petroleum ether, 80:20). 
1
H NMR (300 MHz, CDCl3) δ 7.69 (s, 
1H, CH=C) 4.23 (q, J = 7.1 Hz, 2H, CH2), 3.15 (s, 6H, NCH3), 2.33 (s, 3H, C(O)CH3), 1.32 
(t, J = 7.1 Hz, 3H, CH2CH3). Matches known data.
54 
 
3.1.3 Synthesis of ethyl 5-methyl-1-phenyl-1H-pyrazole-4-carboxylate 3 (XQ2)
55
 
 
 
 
Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate 2 (234 mg, 1.27 mmol) and phenyl 
hydrazine (0.13 mL, 1.27 mmol) were dissolved in ethanol (5 mL) and refluxed for 2 hours. 
The mixture was evaporated under reduced pressure and the resulting residue was dissolved 
in ethyl acetate (40 mL), washed with saturated aqueous sodium bicarbonate (40 mL) and 
extracted with ethyl acetate (3 × 10 mL). The organic extracts were combined and dried over 
anhydrous magnesium sulfate, evaporated under reduced pressure and purified using flash 
chromatography on silica gel eluting with dichloromethane/petroleum ether, (80:20) to give a 
brown oil, 64 % yield (187 mg). 
 
1
H NMR (300 MHz, CDCl3) δ 8.03 (s, 1H, CH of pyrazole), 7.52 – 7.39 (m, 5H, Ar), 4.32 (q, 
J = 7.1 Hz, 2H, CH2), 2.56 (s, 3H, CH3), 1.37 (t, J = 7.1 Hz, 3H, CH2CH3); ESI-MS 
C13H14N2O2 Calc. (M + H
+
) = 231.1128, found (M + H
+
) = 231.1141; Matches known data.
55
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3.1.4 Synthesis of 5-methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 4 (XQ3)
56
 
 
 
 
Potassium hydroxide (4.07 mmol, 228 mg) was dissolved in ethanol (2 mL) and added to a 
solution of ethyl 5-methyl-1-phenyl-1H-pyrazole-4-carboxylate 3 (187 mg, 0.813 mmol) in 
ethanol (2 mL) and refluxed for 5 hours. The resulting solution was evaporated under reduced 
pressure and the residue was acidified with a 6 N aqueous hydrochloride solution to a pH of ~ 
1. A brown solid separated, which was extracted with ethyl acetate (3 × 10 mL). The organic 
extracts were combined, dried over anhydrous magnesium sulfate and evaporated under 
reduced pressure to give a brown solid, 40 % yield (65 mg). 
 
1
H NMR (300 MHz, CDCl3) δ 8.13 (s, 1H, CH of pyrazole), 7.55 – 7.41 (m, 5H, Ar), 2.59 (s, 
3H, CH3); ESI-MS C11H10O2N2 Calc. (M + H
+
) = 203.0815, found (M + H
+
) = 203.0806; 
Matches known data.
56
  
 
3.1.5 Synthesis of 
(5-methyl-1-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)(4-(5-(trifluoromethyl)pyridin-
2-yl)piperazin -1-yl) methanone 5 (XQ5) 
 
 
 
5-Methyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid 14 (382 mg, 1.4 
mmol), HOBT (246 mg, 1.8 mmol), TBTU (584 mg, 1.8 mmol), anhydrous triethylamine (0.4 
mL, 2.5 mmol), and dry dimethylformamide (5 mL) were placed in an oven-dried round 
bottom flask under a nitrogen atmosphere. The resulting solution was stirred at room 
temperature for 15 minutes. A second oven-dried round bottom flask was prepared containing 
1- (5-trifluoromethyl-2-pyridinyl) piperazine (414 mg, 1.8 mmol) and dry 
dimethylformamide (5 mL) under a nitrogen atmosphere. The resulting solution was stirred 
until complete dissolution of the piperazine had occurred. The piperazine solution was then 
transferred to the first round bottom flask containing the carboxylic acid via a syringe. The 
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resulting solution was stirred for 24 hours, under a nitrogen atmosphere, and monitored by 
TLC. After 24 hours, the dimethylformamide was removed under reduced pressure and the 
resulting oil was acidified using a 0.1 N aqueous hydrochloric acid solution. The aqueous 
mixture was extracted with ethyl acetate (40 mL, followed by 4 × 20 mL). The organic 
extracts were combined and washed with a saturated aqueous sodium bicarbonate solution (3 
× 20 mL) and brine (3 × 20 mL). The organic layer was separated and dried over anhydrous 
magnesium sulphate and evaporated under reduced pressure. The residue was purified using 
flash chromatograph on silica gel eluting with dichloromethane/methanol (95:5) to obtain the 
desired product as a light brown solid, 54 % yield (363 mg). 
 
m.p. 166-170 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 8.43 (s, 1H, CH of pyrazole), 7.80 – 7.61 
(m, 6H, Ar), 6.70 (d, J = 8.9 Hz, 1H, Ar), 3.88 – 3.74 (m, 8H, CH2), 2.52 (s, 3H, CH3);
 13
C 
NMR (75 MHz, CDCl3) δ 164.5 (C=O), 160.1 (C-2 of pyridine),145.8 (q, J = 12.0 Hz, C-6 of 
pyridine), 141.8 (ArCN), 141.4 (CCH3), 139.5 (CH of pyrazole), 134.8 (q, J = 3 Hz, C-4 of 
pyridine), 130.3 (q, J = 33.0 Hz, CCF3), 126.5 (q, J = 3.7 Hz, ArCH), 125.2 (ArCH), 124.4 (q, 
J = 298.5 Hz, CF3), 123.7 (q, J = 270.5 Hz, CF3), 115.9 (q, J = 33.0 Hz, CCF3), 116.0 
(CC=O), 105.8 (C-3 of pyridine), 44.8 (CH2), 11.9 (CH3); IR (KBr) 3426, 2869, 1613 
(amide), 1559, 1514, 1424, 1325 (tertiary amine), 1242 (CF3), 1170 (tertiary amine), 1130, 
1007, 947, 846, 641 cm
-1
; ESI-MS C22H19F6N5O Calc. (M + H
+
) = 484.1567, found (M + H
+
) 
= 484.1590. 
 
3.1.6 Synthesis of (5-ethyl-1-phenyl-1H-pyrazol-4-yl)-[4-(5-trifluoromethyl-pyridin-2- 
yl)-piperazin-1-yl]-methanone 6 (XQ6) 
  
 
 
5-Ethyl-1-phenyl-1H-pyrazole-4-carboxylic acid 15 (67 mg, 0.31 mmol), HOBt (53 mg, 0.39 
mmol), TBTU (127 mg, 0.39 mmol), anhydrous triethylamine (0.1 ml, 0.72 mmol) and dry 
dimethylformamide (2 mL) were placed in an oven-dried Schlenk tube under a nitrogen 
atmosphere. The resulting solution was stirred at room temperature for 15 minutes. A second 
oven-dried Schlenk tube was prepared containing 1-(5-trifluoromethyl-2-pyridinyl) 
piperazine (90 mg, 0.39 mmol) and dry dimethylformamide (4 mL) under a nitrogen 
atmosphere. The resulting solution was stirred until complete dissolution of the piperazine 
had occurred. The piperazine solution was then transferred, via a cannula, to the first Schlenk 
tube containing the carboxylic acid. The resulting solution was stirred for 24 hours, under a 
nitrogen atmosphere, and monitored by TLC. After 24 hours, the dimethylformamide was 
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removed under reduced pressure and the resulting oil was acidified using a 0.1 N aqueous 
hydrochloric acid solution. The aqueous mixture was extracted with ethyl acetate (40 mL, 
followed by 4 × 10 mL), the organic extracts were combined and washed with a saturated 
aqueous sodium bicarbonate solution (3 × 30 mL) and brine (3 × 20 mL). The organic layer 
was separated, dried over anhydrous magnesium sulphate and evaporated under reduced 
pressure. The residue was purified using flash chromatograph on silica gel eluting with 
dichloromethane/methanol (95:5) to give an off white solid, 33 % yield (442 mg). 
m.p. 147-149 
o
C;
 1
H NMR (300 MHz, CDCl3) δ 8.43 (s, 1H, CH of pyrazole), 7.70 – 7.65 (m, 
3H Ar), 7.55 – 7.41 (m, 5H, Ar), 3.88 – 3.85 (m, 4H, NCH2), 3.76 – 3.72 (m, 4H, NCH2), 
2.89 (q, J = 7.5 Hz, 2H, CH2CH3), 1.11 (t, J = 7.5 Hz, 3H, CH2CH3); 
13
C NMR (75 MHz, 
CDCl3) δ 164.8 (C=O), 160.1 (C-2 of pyridine), 146.9 (ArC), 145.6 (q, J = 4.5 Hz, C-6 of 
pyridine), 139.1 (CCH2CH3), 138.5 (CH of pyrazole), 134.5 (q, J = 3.3 Hz, C-4 of pyridine), 
129.2 (ArCH), 128.7 (ArCH), 125.7 (ArCH), 124.5 (q, J = 268.8 Hz, CF3), 115.5 (q, J = 32.5 
Hz, CCF3), 114.2 (CC=O), 105.8 (C-3 of pyridine), 44.7 (CH2), 18.4 (CH2CH3), 13.7 (CH3); 
IR (KBr) 3454, 2977, 2925, 1610 (amide), 1552, 1505, 1417, 1332 (tertiary amine), 1245 
(CF3), 1163(tertiary amine), 1080, 1010, 968, 835, 766, 695, 493 cm
-1
. ESI-MS C22H22F3N5O 
Calc. (M + H
+
) = 430.1849, found (M + H
+
) = 430.1871. 
 
3.1.7 Synthesis of (5-methyl-1-phenyl-1H-pyrazol-4-yl)-[4-(4-trifluoromethyl-phenyl)- 
piperazin-1-yl]-methanone 7 (XQ7) 
 
 
 
5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 4 (72 mg, 0.36 mmol), HOBT (62 mg, 
0.46 mmol), TBTU (150 mg, 0.46 mmol), triethylamine (0.1 mL, 0.6 mmol), and dry 
dimethylformamide (1 mL) were placed in an oven-heated round bottom flask under a 
nitrogen atmosphere. The resulting solution was stirred at room temperature for 15 minutes. 
A second oven-heated round bottom flask was prepared containing 
(5-methyl-1-phenyl-1H-pyrazol-4-yl)-[4-(4-trifluoromethyl-phenyl)-piperazin-1-yl]-methano
ne (106 mg, 0.46 mmol) and dry dimethylformamide (1 mL) under a nitrogen atmosphere. 
The resulting solution was stirred until complete dissolution of the piperazine had occurred. 
The piperazine solution was then transferred to the first round bottom flask containing the 
carboxylic acid via a syringe. The resulting solution was stirred for 24 hours, under a 
nitrogen atmosphere, and monitored by TLC. After 24 hours, the dimethylformamide was 
removed under reduced pressure and the resulting oil was acidified using a 0.1 N aqueous 
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hydrochloric acid solution. The aqueous mixture was extracted with ethyl acetate (40 mL, 
followed by 4 × 20 mL), the organic extracts were combined and washed with a saturated 
aqueous sodium bicarbonate solution (3 × 20 mL) and brine (3 × 20 mL). The organic layer 
was separated, dried over anhydrous magnesium sulphate and evaporated under reduced 
pressure. The residue was purified using flash chromatograph on silica gel eluting with 
dichloromethane/methanol (95:5) to obtain the desired product as a light yellow solid, 60 % 
yield (89 mg). 
 
m.p. 218-222 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 7.69 (s, 1H, CH of pyrazole), 7.56 – 7.42 
(m, 7H, Ar), 6.96 (d, J = 8.7 Hz, 2H, Ar), 3.90 (dd, J = 6.5, 3.8 Hz, 4H, CH2), 3.35 (dd, J = 
6.5, 3.8 Hz, 4H, CH2), 2.46 (s, 3H, CH3); 
13
C NMR (75 MHz, CDCl3) δ 164.8 (C=O), 153.0 
(ArCN(CH2)2), 141.3 (CCH3), 139.0 (ArCN), 138.9 (CH of pyrazole), 129.3 (ArCH), 128.5 
(ArCH), 126.5 (q, J = 5.8 Hz, CHCCF3), 125.3 (ArCH), 124.6 (q, J = 269.0 Hz, CF3), 121.4 
(q, J = 32.5 Hz, CCF3), 115.1 (ArCH), 48.5 (CH2), 11.8 (CH3); IR (KBr) 3418, 2839, 1626 
(amide), 1560, 1503, 1426, 1332 (tertiary amine), 1232 (CF3), 1160 (tertiary amine), 1100, 
1065, 1004, 872, 766, 695, 641 cm
-1
; ESI-MS C22H21F3N4O Calc. (M + H
+
) = 415.1740, 
found (M + H
+
) = 415.1756. 
 
3.1.8 Synthesis of 
[1-(4-methoxy-phenyl)-5-methyl-1H-pyrazol-4-yl]-[4-(5-trifluoromethyl-pyridin-2-yl)-pi
perazin-1-yl] –methanone 8 (XQ8) 
 
 
 
1-(4-Methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 16 (342 mg, 1.47 mmol), 
HOBT (249 mg, 1.47 mmol), TBTU (597 mg, 1.47 mmol), anhydrous triethylamine (0.5 mL, 
3.1 mmol), and dry dimethylformamide (5 mL) were placed in an oven-heated round bottom 
flask under a nitrogen atmosphere. The resulting solution was stirred at room temperature for 
15 minutes. A second oven-heated round bottom flask was prepared containing 1- 
(5-trifluoromethyl-2-pyridinyl) piperazine (423 mg, 1.8 mmol) and dry dimethylformamide 
(5 mL) under a nitrogen atmosphere. The resulting solution was stirred until complete 
dissolution of the piperazine had occurred. The piperazine solution was then transferred to the 
first round bottom flask containing the carboxylic acid via a syringe. The resulting solution 
was stirred for 24 hours, under nitrogen atmosphere, and monitored by TLC. After 24 hours, 
the dimethylformamide was removed under reduced pressure and the resulting oil was 
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acidified using a 0.1 N aqueous hydrochloric acid solution. The aqueous mixture was 
extracted with ethyl acetate (40 mL, followed by 4 × 20 mL), the organic extracts were 
combined and washed with a saturated aqueous bicarbonate solution (3 × 20 mL) and brine (3 
× 20 mL). The organic layer was separated, dried over magnesium sulphate and evaporated 
under reduced pressure. The resulting residue was purified using flash chromatograph on 
silica gel with dichloromethane/methanol (95:5) to obtain the desired product as a white solid, 
54 % yield (350 mg). 
 
m.p. 184-188 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 8.43 (s, 1H, CH of pyrazole), 7.70 – 7.65 
(m, 2H, Ar), 7.35 (dd, J = 9.5, 2.8 Hz, 2H, Ar), 7.01 (dd, J = 9.5, 2.8 Hz, 2H, Ar), 6.68 (d, J = 
9.0 Hz, 1H, Ar), 3.87 (s, 3H, OCH3), 3.86 – 3.81 (m, 4H, CH2), 3.79 – 3.73 (m, 4H, CH2), 
2.42 (s, 3H, CH3); 
13
C NMR (75 MHz, CDCl3) δ 165.0 (C=O), 160.1 (C), 159.6 (C), 145.8 (q, 
J = 4.5 Hz, C-6 of pyridine), 141.5 (CCH3), 138.5 (CH of pyrazole), 134.8 (q, J = 3.0 Hz, C-4 
of pyridine), 132.0 (ArCN), 126.8 (ArCH), 124.4 (q, J = 273.3 Hz, CF3), 116.2 (q, J = 33.8 
Hz, CCF3), 114.7 (CC=O), 114.4 (ArCH), 105.8 (C-3 of pyridine), 116.2 (C-CF3), 55.6 
(O-CH3), 44.9 (CH2), 11.6 (CH3); IR (KBr) 3482, 3003, 2840, 1606 (amide), 1558, 1519, 
1425, 1329 (tertiary amine), 1244 (CF3), 1172 (OCH3), 1115 (tertiary amine), 1036 (OCH3), 
1001, 994, 834, 761, 633, 541, 478 cm
-1
; ESI-MS C22H22F3N5O2 Calc. (M + H
+
) = 446.1798, 
found (M + H
+
) = 446.1819. 
 
3.1.9 Synthesis of 
[1-(4-chloro-phenyl)-5-methyl-1H-pyrazol-4-yl]-[4-(5-trifluoromethyl-pyridin-2-yl)-pipe
razin-1-yl]- methanone 9 (XQ9) 
 
 
1-(4-Chloro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 17 (542 mg, 2.3 mmol), HOBT 
(394 mg, 3 mmol), TBTU (952 mg, 3 mmol), anhydrous triethylamine (0.7 mL, 4.6 mmol), 
and dry dimethylformamide (7 mL) were placed in an oven-heated round bottom flask under  
a nitrogen atmosphere. The resulting solution was stirred at room temperature for 15 minutes. 
A second oven-heated round bottom flask was prepared containing 1- 
(5-trifluoromethyl-2-pyridinyl) piperazine (673 mg, 3 mmol) and dry dimethylformamide (7 
mL) under a nitrogen atmosphere. The resulting solution was stirred until complete 
dissolution of the piperazine had occurred. The piperazine solution was then transferred to the 
first round bottom flask containing the carboxylic acid via a syringe. The resulting solution 
was stirred for 24 hours, under a nitrogen atmosphere, and monitored by TLC. After 24 hours, 
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the dimethylformamide was removed under reduced pressure and the resulting oil was 
acidified using a 0.1 N aqueous hydrochloric acid solution. The aqueous mixture was 
extracted with ethyl acetate (40 mL, followed by 4 × 20 mL), the organic extracts were 
combined and washed with a saturated aqueous bicarbonate solution (3 × 20 mL) and brine (3 
× 20 mL). The organic layer was separated, dried over anhydrous magnesium sulphate and 
evaporated under reduced pressure. The resulting residue was purified using flash 
chromatograph on silica gel with dichloromethane/methanol (95:5) to obtain the desired 
product as a white solid, 62 % yield (643 mg). 
 
m.p. 186-190 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 8.42 (s, 1H, CH of pyrazole), 7.70 – 7.66 
(m, 2H, Ar), 7.50 – 7.38 (m, 4H, Ar), 6.69 (d, J = 9.0 Hz, 1H, Ar), 3.88 – 3.83 (m, 4H, CH2), 
3.77 – 3.73 (m, 4H, CH2), 2.46 (s, 3H, CH3); 
13
C NMR (75 MHz, CDCl3) δ 164.7 (C=O), 
160.1 (C-2 of pyridine), 145.6 (q, J = 17 Hz, C-6 of pyridine), 141.4 (CCH3), 139.1 (CH of 
pyrazole), 137.5 (ArCN), 134.8 (q, J = 3.3 Hz, C-4 of pyridine), 134.4 (CCl), 129.5 (ArCH), 
126.5 (ArCH), 115.5 (CC=O), 105.8 (C-3 of pyridine), 124.4 (q, J = 268.8 Hz, CF3), 115.9 (q, 
J = 32.8 Hz, CCF3), 44.8 (CH2), 11.8 (CH3); IR (KBr) 3506, 3059, 2912, 1618 (amide), 1558, 
1504, 1470, 1422, 1333 (tertiary amine), 1246 (CF3), 1168, 1119 (tertiary amine), 1081, 1003, 
947, 814, 749 (Cl), 665, 629, 529, 478 cm
-1
; ESI-MS C21H19ClF3N5O Calc. (M + H
+
) = 
450.1303, found (M + H
+
) = 450.1326 
 
3.1.10 Synthesis of ethyl 
5-methyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester 10 
(XQ5b)
57
 
 
 
 
Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate 2 (600 mg, 3.24 mmol) and 
4-trifluoromethylphenylhydrazine (570 mg, 3.24 mg) were dissolved in ethanol (20 mL) and 
refluxed for 2 hours. The mixture was evaporated under reduced pressure and the resulting 
residue was dissolved in ethyl acetate (20 mL), washed with saturated aqueous sodium 
bicarbonate solution (20 mL) and extracted with ethyl acetate (3 × 15 mL). The organic 
extracts were combined, dried over anhydrous magnesium sulfate and evaporated under 
reduced pressure. The resulting residue was purified using flash chromatography on silica gel 
eluting with ethyl acetate/petroleum ether (80:20) to obtain the desired product as a brown 
solid, 32 % yield (309 mg). 
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m.p. 54-58 
o
C;
 1
H NMR (300 MHz CDCl3) δ 8.06 (s, 1H, CH of pyrazole), 7.79 (d, J = 9.0 
Hz, 2H, Ar), 7.61 (d, J = 9.0 Hz, 2H, Ar), 4.34 (q, J = 7.1 Hz, 2H, CH2CH3), 2.63 (s, 3H, 
CH3), 1.39 (t, J = 7.1 Hz, 3H, CH2CH3); ESI-MS C14H13N2O2F3 Calc. (M + H
+
) = 299.1002, 
found (M + H
+
) = 299.1013. Matches known data.
57
 
 
3.1.11 Synthesis of ethyl 5-ethyl-1-phenyl-1H-pyrazole-4-carboxylate 11 (XQ6b) 
58
 
 
 
 
Ethyl 2-((dimethylamino)methylene)-3-oxopentanoate 41 (375 mg, 1.88 mmol), and phenyl 
hydrazine (0.185 mL, 1.88 mmol) were dissolved in ethanol (10 mL) and refluxed for 2 hours. 
The mixture was evaporated under reduced pressure and the resulting residue was dissolved 
in ethyl acetate (20 mL), washed with saturated aqueous sodium bicarbonate solution (20 mL) 
and extracted with ethyl acetate (3 × 20 mL). The organic extracts were combined and dried 
over anhydrous magnesium sulfate and evaporated under reduced pressure to give a red oil, 
85 % yield (390 mg). 
 
1
H NMR (300 MHz, CDCl3) δ 8.03 (s, 1H, CH of pyrazole), 7.49 – 7.38 (m, 5H, Ar), 4.33 (q, 
J = 7.1 Hz, 2H, OCH2CH3), 2.95 (q, J = 7.5 Hz, 2H, CH2CH3), 1.37 (t, J = 7.1 Hz, 3H, 
OCH2CH3), 1.17 (t, J = 7.5 Hz, 3H, CH2CH3). Matches know data.
58
  
 
3.1.12 Synthesis of ethyl 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-4-carboxylate 12 
(XQ8b)
55
 
 
 
 
Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate 2 (608 mg, 3.3 mmol) and 
(4-methoxy-phenyl)-hydrazine (456 mg, 3.3 mmol) were dissolved in ethanol (15 mL) and 
refluxed for 2 hours. The mixture was evaporated under reduced pressure and the resulting 
residue was dissolved in ethyl acetate (10 mL), washed with a saturated aqueous sodium 
bicarbonate solution and extracted with ethyl acetate (3 × 20 mL). The organic extracts were 
combined, dried over anhydrous magnesium sulfate and evaporated under reduced pressure to 
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give a yellow oil, 76 % yield (1.1 g). 
 
1
H NMR (300 MHz, CDCl3) δ 7.99 (s, 1H, CH of pyrazole), 7.30 (d, J = 8.9 Hz, 2H, Ar), 
6.96 (d, J = 8.9 Hz, 2H, Ar), 4.30 (q, J = 7.1 Hz, 2H, CH2CH3), 3.81 (s, 3H, OCH3), 2.50 (s, 
3H, CH3), 1.35 (t, J = 7.1 Hz, 3H, CH2CH3); ESI-MS C14H16N2O3 Calc. (M + H
+
) = 
261.1234, found (M + H
+
) = 261.1225; Matches know data.
55 
 
3.1.13 Synthesis of ethyl 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylate 13 
(XQ9b)
55
 
 
 
 
Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate 2 (473 mg, 2.6 mmol) and 
(4-chloro-phenyl)-hydrazine (465 mg, 2.6 mmol) were dissolved in ethanol (20 mL) and 
refluxed for 2.5 hours. The resulting solution was evaporated under reduced pressure and the 
resulting residue was dissolved in ethyl acetate (15 mL), washed with a saturated aqueous 
sodium bicarbonate solution (3 × 20 mL) and extracted with ethyl acetate (3 × 15 mL). The 
organic extracts were combined, dried over anhydrous sodium sulfate and evaporated under 
reduced pressure to give a yellow solid, 94 % yield (647 mg). 
 
m.p. 38-40 
o
C;
 1
H NMR (300 MHz, CDCl3) δ 8.02 (s, 1H, CH of pyrazole), 7.47 (d, J = 8.8 
Hz, 2H, Ar), 7.38 (d, J = 8.8 Hz, 2H, Ar), 4.33 (q, J = 7.1 Hz, 2H, CH2), 2.57 (s, 3H, CH3), 
1.37 (t, J = 7.1 Hz, 3H, CH2CH3); ESI-MS C13H13N2O2Cl Calc. (M + H
+
) = 265.0738, found 
(M + H
+
) = 265.0750. Matches known data.
55
 
 
3.1.14 Synthesis of 5-methyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid 
14 (XQ5c) 
57
 
 
 
 
Potassium hydroxide (952 mg, 17 mmol) was dissolved in ethanol (15 mL) and added to a 
solution of 5-methyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylic acid ethyl ester 
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10 (1.016 g, 3.4 mmol) in ethanol (10 mL) and refluxed for 5 hours. The resulting solution 
was evaporated under reduced pressure and the residue was acidified with a 6 N aqueous 
hydrochloride solution to a pH of ~ 1. A brown solid separated, which was extracted by ethyl 
acetate (3 × 20 mL). The organic extracts were combined, dried over anhydrous magnesium 
sulfate and evaporated under reduced pressure to give a brown solid, 42 % yield (382 mg). 
 
1
H NMR (300 MHz, CDCl3) δ 8.15 (s, 1H, CH of pyrazole), 7.80 (d, J = 8.2 Hz, 2H, Ar), 
7.61 (d, J = 8.2 Hz, 2H, Ar), 2.65 (s, 3H, CH3). Matches known data.
57
 
 
3.1.15 Synthesis of 5-ethyl-1-phenyl-1H-pyrazole-4-carboxylic acid 15 (XQ6c) 
56
 
 
 
 
Potassium hydroxide (448 mg, 8 mmol) was dissolved in ethanol (15 mL) and added to a 
solution of ethyl 5-ethyl-1-phenyl-1H-pyrazole-4-carboxylate 11 (390 mg, 1.6 mmol) in 
ethanol (5 mL), and refluxed for 5 hours. The resulting solution was evaporated under 
reduced pressure and the residue was acidified with a 6 N aqueous hydrochloride solution to 
a pH ~ 1. A brown solid separated, which was extracted with ethyl acetate (3 × 20 mL). The 
organic extracts were combined, dried over anhydrous magnesium sulfate and evaporated 
under reduced pressure to give a brown solid, 81 % yield (289 mg). 
 
1
H NMR (300 MHz, CDCl3) δ 8.13 (s, 1H, CH of pyrazole), 7.55 – 7.40 (m, 5H, Ar), 2.97 (q, 
J = 7.4 Hz, 2H, CH2CH3), 1.19 (t, J = 7.4 Hz, 3H, CH2CH3). Matches known data.
56
 
 
 
3.1.16 Synthesis of 1-(4-methoxy-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 16 
(XQ8c)
59
 
 
 
 
Potassium hydroxide (1.1 g, 20 mmol) was dissolved in ethanol (20 mL) and added to a 
solution of ethyl 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-4-carboxylate 12 (1.1 g, 2.5 
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mmol) in ethanol (5 mL) and refluxed for 5 hours. The resulting solution was evaporated 
under reduced pressure and the resulting residue was acidified with a 6 N aqueous 
hydrochloride solution to a pH of ~ 1. A brown solid separated, which was extracted with 
ethyl acetate (3 × 20 mL). The organic extracts were combined, dried over anhydrous sodium 
sulfate and evaporated under reduced pressure to give a brown solid, 59 % yield (342 mg). 
 
1
H NMR (300 MHz, CDCl3)
 δ 8.09 (s, 1H, CH of pyrazole), 7.34 (d, J = 8.9 Hz, 2H, Ar), 
7.01 (d, J = 8.9 Hz, 2H, Ar), 3.87 (s, 3H, OCH3), 2.55 (s, 3H, CH3). Matches known data.
59
 
 
 
3.1.17 Synthesis of 1-(4-chloro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid 17 
(XQ9c)
60
 
 
Potassium hydroxide (1.1 g, 19.6 mol) was dissolved in ethanol (15mL) and added to a 
solution of ethyl 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-4-carboxylate 13 (647 mg, 2.45 
mmol) in ethanol (10 mL), and refluxed for 5 hours. The resulting solution was evaporated 
under reduced pressure and the resulting residue was acidified with a 6 N aqueous 
hydrochloride solution to a pH of ~ 1. A brown solid separated, which was extracted with 
ethyl acetate (3 × 20 mL). The organic extracts were combined, dried over anhydrous sodium 
sulfate and evaporated under reduced pressure to give a brown solid, 94 % yield (542 mg). 
 
1
H NMR (300 MHz, CDCl3) δ 8.11 (s, 1H, CH of pyrazole), 7.44 (dd, J = 7.8 Hz, 23.9 Hz, 
4H, Ar), 2.59 (s, 3H, CH3). Matches known data.
60
 
3.1.18 Synthesis of 
(5-methyl-1-phenyl-1H-pyrazol-4-yl)-(4-methyl-piperazin-1-yl)-methanone 18 (XQ13) 
 
 
 
5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 4 (156 mg, 0.8 mmol), HOBT (132 mg, 
1.0 mmol), TBTU (316 mg, 1.0 mmol), anhydrous triethylamine (0.22 mL, 1.4 mmol), and 
dry dimethylformamide (3 mL) were placed in an oven-heated round bottom flask under a 
nitrogen atmosphere. The resulting solution was stirred at room temperature for 15 minutes. 
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A second oven-heated round bottom flask was prepared containing 1-methyl-piperazine (0.11 
mL, 1.0 mmol) and dry dimethylformamide (2 mL) under a nitrogen atmosphere. The 
resulting solution was stirred until complete dissolution of the piperazine had occurred. The 
piperazine solution was then transferred to the first round bottom flask containing the 
carboxylic acid via a syringe. The resulting solution was stirred for 24 hours, under a nitrogen 
atmosphere, and monitored by TLC. After 24 hours, the dimethylformamide was removed 
under reduced pressure and the resulting oil was acidified using a 0.1 N aqueous hydrochloric 
acid solution. The aqueous mixture was extracted with ethyl acetate (40 mL, followed by 4 × 
20 mL), the organic extracts were combined and washed with a saturated aqueous 
bicarbonate solution (3 × 20 mL) and brine (3 × 20 mL). The organic layer was separated, 
dried over anhydrous magnesium sulphate and evaporated under reduced pressure. The 
resulting residue was purified using flash chromatograph on silica gel with 
dichloromethane/methanol (95:5) to obtain the desired product as a brown solid, 51 % yield 
(112 mg). 
m.p. 132-134 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 7.65 (s, 1H, CH of pyrazole), 7.43 – 7.28 
(m, 5H, Ar), 3.67 – 3.64 (m, 4H, CH2), 2.39 – 2.36 (m, 4H, CH2), 2.35 (s, 3H, CH3) 2.25 (s, 
3H, CH3). 
13
C NMR (75 MHz, CDCl3) δ 164.6 (C=O), 140.8 (CCH3), 139.1 (ArC), 138.9 
(CH of pyrazole), 129.2 (ArCH), 128.4 (ArCH), 125.3 (ArCH), 115.6 (CC=O), 55.2 (CH2), 
46.1 (NCH3), 11.7 (CH3); IR (KBr) 3433, 2936, 2790, 1599 (amide), 1558, 1439, 1265, 1200 
(tertiary amine), 1149 (tertiary amine), 1008, 939, 899, 878, 767, 696, 658, 600, 511 cm
-1
; 
ESI-MS C16H20N4O Calc. (M + H
+
) = 285.1710, found (M + H
+
) = 285.1711. 
 
3.1.19 Synthesis of 
(5-methyl-1-phenyl-1H-pyrazol-4-yl)-(4-phenyl-piperazin-1-yl)-methanone 19 (XQ14) 
 
 
 
5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 4 (331 mg, 1.4 mmol), HOBT (246 mg, 
1.9 mmol), TBTU (591 mg, 1.9 mmol), triethylamine (0.45 mL, 2.8 mmol),  dry 
dimethylformamide (5 mL) were placed in an oven-heated round bottom flask under a 
nitrogen atmosphere. The resulting solution was stirred at room temperature for 15 minutes. 
A second oven-heated round bottom flask was prepared containing 1-phenyl-piperazine (0.3 
mL, 1.9 mmol) and dry dimethylformamide (2 mL) under a nitrogen atmosphere. The 
resulting solution was stirred until complete dissolution of the piperazine had occurred. The 
piperazine solution was then transferred to the first round bottom flask containing the 
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carboxylic acid via a syringe. The resulting solution was stirred for 24 hours, under a nitrogen 
atmosphere, and monitored by TLC. After 24 hours, the dimethylformamide was removed 
under reduced pressure and the resulting oil was acidified using a 0.1 N aqueous hydrochloric 
acid solution. The aqueous mixture was extracted with ethyl acetate (40 mL, followed by 4 × 
20 mL), the organic extracts were combined and washed with a saturated aqueous sodium 
bicarbonate solution (3 × 20 mL) and brine (3 × 20 mL). The organic layer was separated, 
dried over anhydrous magnesium sulphate and evaporated under reduced pressure. The 
resulting residue was purified using flash chromatograph on silica gel with 
dichloromethane/methanol (95:5) to obtain the desired product as a yellow solid, 52 % yield 
(259 mg). 
 
m.p. 140-144 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 7.70 (s, 1H, CH of pyrazole), 7.54 – 7.41 
(m, 5H, Ar), 7.33 – 7.27 (m, 2H, Ar), 6.98 – 6.90 (m, 3H, Ar), 3.91 – 3.88 (m, 4H, CH2), 3.26 
– 3.23 (m, 4H, CH2), 2.45 (s, 3H, CH3); 
13
C NMR (75 MHz, CDCl3) δ 150.96, 139.0 (CH of 
pyrazole), 129.3 (ArCH), 128.6 (ArC), 125.5 (ArCH), 120.6 (ArCH), 116.7 (ArCH), 115.4 
(CC=O), 49.9 (CH2), 11.7 (CH3); IR (KBr) 3414, 2836, 1726, 1613  (amide), 1503, 1438, 
1228 (tertiary amine), 1156, 1007, 871, 757, 695, 523 cm
-1
; ESI-MS C21H23N4O (M + H
+
) = 
347.1866, found (M + H
+
) = 347.1875. 
 
3.1.20 Synthesis of 5-methyl-1-phenyl-1H-pyrazole-4-carboxylic acid dimethylamide 20 
(XQ25) 
 
 
 
5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 4 (963 mg, 4.8 mmol), HOBT (851 mg, 
6.3 mmol), TBTU (2 g, 6.3 mmol), anhydrous triethylamine (0.9 mL, 6.3 mmol), and dry 
dimethylformamide (10 mL) were placed in an oven-heated round bottom flask under a 
nitrogen atmosphere. The resulting solution was stirred at room temperature for 15 minutes. 
Dimethylamine (0.8 mL, 6.3 mmol) was added to the solution via a syringe. The resulting 
solution was stirred for 24 hours under a nitrogen atmosphere, and monitored by TLC. After 
24 hours, the dimethylformamide was removed under reduced pressure and the resulting oil 
was acidified using a 0.1 N aqueous hydrochloric acid solution. The aqueous mixture was 
extracted with ethylacetate (40 mL, followed by 4 × 20 mL), the organic extracts were 
combined and washed with a saturated aqueous sodium bicarbonate solution (3 × 20 mL) and 
brine (3 × 20 mL). The organic layer was separated, dried over anhydrous magnesium 
sulphate and evaporated under reduced pressure. The residue was purified using flash 
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chromatograph on silica gel with ethyl acetate/petroleum ether (80:20) to obtain the desired 
product as a white solid, 31 % yield (240 mg). 
 
m.p. 144-148 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 7.70 (s, 1H, CH of pyrazole), 7.53 – 7.39 
(m, 5H, Ar), 3.15 (s, 6H, NCH3), 2.45 (s, 3H, CH3); 
13
C NMR (75 MHz, CDCl3) δ 165.9 
(C=O), 141.0 (CCH3), 139.2 (ArC), 139.1 (CH of pyrazole), 129.2 (ArCH), 128.4 (ArCH), 
125.3 (ArCH), 77.2 (N(CH3)2), 115.9 (CC=O), 11.8 (CH3); IR (KBr) 3449, 2936, 1563 
(amide), 1507, 1496, 1441, 1385, 1264, 1185, 1069, 948, 904, 761, 696, 657, 576, 515 cm
-1
; 
ESI-MS C13H15ON3 Calc. (M + H
+
) = 230.1288, found (M + H
+
) = 230.1301.  
 
3.1.21 Synthesis of 5-methyl-1-phenyl-1H-pyrazole-4-carboxylic acid diethylamide 21 
(XQ27) 
 
 
 
5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid 4 (868 mg, 4.3 mmol), HOBT (702 mg, 
5.2 mmol), TBTU (1650 mg, 5.2 mmol), anhydrous triethylamine (0.74 mL, 5.2 mmol), and 
dry dimethylformamide (7 mL) were placed in an oven-dried round bottom flask under a 
nitrogen atmosphere. The resulting solution was stirred at room temperature for 15 minutes. 
Diethylamine (0.55 mL, 5.2 mmol) was added to the solution via a syringe. The resulting 
solution was stirred for 24 hours under a nitrogen atmosphere, and monitored by TLC. After 
24 hours, the dimethylformamide was removed under reduced pressure and the resulting oil 
was acidified using a 0.1 N aqueous hydrochloric acid solution. The aqueous mixture was 
extracted with ethyl acetate (40 mL, followed by 4 × 20 mL), the organic extracts were 
combined and washed with a saturated aqueous sodium bicarbonate solution (3 × 20 mL) and 
brine (3 × 20 mL). The organic layer was separated, dried over anhydrous magnesium 
sulphate and evaporated under reduced pressure. The resulting residue was purified using 
flash chromatograph on silica gel with ethyl acetate/petroleum ether (80:20) to obtain the 
desired product as a yellow oil, 46 % yield (503 mg). 
 
Rf : 0.45 (ethyl acetate/petroleum ether, 80:20); 
1
H NMR (300 MHz, , CDCl3) δ 7.66 (s, 1H, 
CH of pyrazole), 7.52 – 7.35 (m, 5H, Ar), 3.51 (q, J = 7.1 Hz, 4H, CH2), 2.42 (s, 3H, CH3), 
1.22 (t, J = 7.1 Hz, 6H, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 165.0 (C=O), 140.3 (CCH3), 
139.1 (ArC), 137.8 (CH of pyarzole), 129.0 (ArCH), 128.1 (ArCH), 125.1 (ArCH), 116.5 
(CC=O), 42.9 (CH2), 39.8 (CH2), 13.8 (CH2CH3), 11.6 (CH3); Liquid IR (dichloromethane) 
3441, 2979, 1616 (amide), 1561, 1477, 1432, 1383, 1265, 1084, 736, 448 cm
-1
; ESI-MS 
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C15H19ON3 Calc. (M + H
+
) = 258.1601, found (M + H
+
) = 258.1622. 
 
3.2 Synthesis of zinc complexes of compound 3, 18 and 20 
3.2.1 Synthesis of 22 (zinc complex of 18 (XQ13)) 
 
(5-Methyl-1-phenyl-1H-pyrazol-4-yl)-(4-methyl-piperazin-1-yl)-methanone 18 (111 mg, 0.39 
mmol) was dissolved in methanol (20 mL). Zinc chloride (28 mg 0.2 mmol) was added and 
the solution refluxed for 2 hours. The resulting solution was evaporated under reduced 
pressure, and the resulting residue was dissolved in chloroform. The resulting solution was 
filtered through a filter paper and the filtrate was evaporated under reduced pressure to give a 
yellow solid, 99 % yield (137 mg). 
 
m.p. 150-154 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 7.65 (s, 2H, CH of pyrazole), 7.53 – 7.42 
(m, 10H, Ar), 3.84 – 3.81 (m, 8H, CH2), 2.47-2.44 (m, 8H, CH2), 2.43 (s, 6H, CH3) 2.35 (s, 
6H, CH3); 
13
C NMR (75 MHz, CDCl3) δ 164.6 (C=O), 141.2 (CCH3), 139.0 (CH of 
pyrazole), 138.8 (ArC), 129.3 (ArCH), 128.6 (ArCH), 125.4 (ArCH), 115.1 (CC=O), 55.2 
(CH2), 46.2 (NCH3), 11.7 (CH3); IR (KBr) 3450, 2937, 2794, 1598 (amide), 1558, 1504, 
1452, 1396, 1290, 1255, 1233 (tertiary amine), 1142, 1009 (tertiary amine), 938, 877, 765, 
698, 658; Anal. calcd for C32H40Cl2N8O2Zn, C, 54.51; H, 5.72; N, 15.90; found C, 54.39; H, 
6.07; N, 15.52. 
3.2.2 Synthesis of 23 (zinc complex of 20(XQ25)) 
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5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid dimethylamide 20 (115 mg, 0.5 mmol) 
was dissolved in methanol (10 mL). Zinc acetate (66 mg, 0.3 mmol) in methanol (5 mL) was 
added drop wise and the solution was refluxed for 2 hours. The resulting solution was 
evaporated under reduced pressure and residue recrystallized from methanol to give a white 
solid, 77 % yield (140 mg). 
 
m.p. 152-154 
o
C (methanol); 
1
H NMR (300 MHz, CDCl3) δ 7.71 (s, 2H, CH of pyrazole), 
7.54 – 7.41 (m, 10H, Ar), 3.47 (s, 6H, C(O)CH3), 3.17 (s, 12H, NCH3), 2.18 (s, 6H, CH3); 
13
C NMR (75 MHz, CDCl3) δ 207.5 (C(O)CH3), 165.9 (C=O), 141.2 (CCH3), 139.1 (CH of 
pyrazole), 138.9 (ArC), 129.3 (ArCH), 128.5 (ArCH), 125.4 (ArCH), 115.7 (CC=O), 50.6 
(NCH3), 31.0 (C(O)CH3), 11.8 (CH3); IR (KBr) 3424, 3053, 2936, 2805, 1609 (amide), 1598, 
1563, 1507, 1496, 1453, 1392, 1263, 1215, 1185, 1174, 1068, 948, 904, 761, 696, 657, 576, 
515 cm
-1
; Anal. calcd for C30H36N6O6Zn·2H2O,  C, 53.14; H, 5.95; N, 12.39; found C, 53.49; 
H, 5.49; N, 11.88. 
 
3.2.3 Synthesis of 24 (zinc complex of 3 (XQ2)) 
 
 
 
5-Methyl-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester 3 (484 mg, 2.10 mmol) was 
dissolved in methanol (20 mL). Zinc chloride (143 mg 1.05 mmol) was added and the 
solution refluxed for 2 hours. The resulting solution was evaporated under reduced pressure 
and the residue recrystallized from chloroform. The desired product was obtained as a brown 
solid, 98 % yield (607 mg). 
 
m.p. 228-232 
o
C (chloroform); 
1
H NMR (300 MHz, CDCl3) δ 8.08 (s, 2H, CH of pyrazole), 
7.44 – 7.54 (m, 6H, Ar), 7.34 – 7.29 (m, 4H, Ar), 4.38-4.31 (q, J = 7.1 Hz, 4H, CH2), 2.42 (s, 
6H, CH3), 1.42-1.37 (t, J = 7.1 Hz, 6H, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 162.4 
(C=O), 146.8 (CCH3), 143.5 (CH of pyrazole), 135.5 (ArC), 130.7 (ArCH), 129.6 (ArCH), 
127.4 (ArCH), 113.1 (CC=O), 60.6 (CH2), 14.5 (CH3), 11.6 (CH2CH3); IR (KBr) 3423, 2977, 
1716 (ester), 1562, 1504, 1401, 1289, 1238 (ester), 1096 (ester), 963, 771, 699, 658, 500 cm
-1
; 
Anal. calcd for C26H28Cl2N4O4Zn, C, 52.32; H, 4.73; N, 9.39; found C, 53.13; H, 4.62; N, 
9.26. 
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3.3 Synthesis of pyrazole ligands 25, 29 
3.3.1 Synthesis of ethyl 1-(4-fluorophenyl)-5-methyl-1H-pyrazole-4-carboxylate 25 
(XQ16)
61
 
 
 
Ethyl 2-((dimethylamino)methylene)-3-oxobutanoate 2 (515 mg, 2.8 mmol) and 
4-fluoro-phenyl hydrazine (455 mg, 2.8 mmol) were dissolved in ethanol (20 mL) and 
refluxed for 2.5 hours. The resulting solution was evaporated under reduced pressure, and the 
resulting residue was dissolved in ethyl acetate (20 mL), washed with a saturated aqueous 
sodium bicarbonate solution (3 × 20 mL) and extracted with ethyl acetate (3 ×10 mL). The 
organic extracts were combined, dried over anhydrous magnesium sulfate and evaporated 
under reduced pressure to give a brown oil, 47 % yield (353 mg). 
 
1
H NMR (300 MHz, CDCl3) δ 8.02 (s, 1H, CH of pyrazole), 7.43 – 7.38 (m, 2H, Ar), 7.24 – 
7.16 (m, 2H, Ar), 4.33 (q, J = 7.1 Hz, 2H, CH2), 2.55 (s, 3H, CH3), 1,38 (t, J = 7.1 Hz, 3H, 
CH2CH3); ESI-MS C13H13O2N2F Calc. (M + H
+
) = 249.1034, found (M + H
+
) = 249.1046. 
Matches known data.
61
 
 
 
3.3.2 Synthesis of ethyl 1-phenyl-5-propyl-1H-pyrazole-4-carboxylate 29 (XQ23)
56
 
 
 
 
Ethyl 2-((dimethylamino)methylene)-3-oxohexanoate 42 (617 mg, 2.9 mmol) and phenyl 
hydrazine (0.3 mL, 2.9 mmol) were dissolved in ethanol (20 mL) and refluxed for 2.5 hours. 
The resulting solution was evaporated under reduced pressure, and the residue was dissolved 
in ethyl acetate (20 mL), washed with a saturated aqueous sodium bicarbonate solution (3 × 
20 mL), and extracted with ethyl acetate (3 × 20 mL). The organic extracts were combined, 
dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give a 
light yellow oil, 68 % yield (310 mg). 
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1
H NMR (300 MHz, CDCl3) δ 8.04 (s, 1H, CH of pyrazole), 7.51 – 7.35 (m, 5H, Ar), 4.32 (q, 
J = 7.1 Hz, 2H, OCH2), 2.92 (t, J = 7,8 Hz, 2H, CH2CH2CH3), 1.64 – 1.51 (m, 2H, 
CH2CH2CH3), 1.36 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.85 (t, J = 7.4 Hz, 3H, CH2CH2CH3); 
ESI-MS C15H18N2O2 Calc. (2M + Na
+
) = 539.2629, found (2M + Na
+
) = 539.2653. Matches 
known data.
56
 
3.4 Synthesis of zinc complexes of compound 3 family 
3.4.1 Synthesis of 30 (zinc complex of 25 (XQ16)) 
 
1-(4-Fluoro-phenyl)-5-methyl-1H-pyrazole-4-carboxylic acid ethyl ester 25 (267 mg, 1.07 
mmol) was dissolved in methanol (20 mL). Zinc chloride (74 mg, 0.54 mmol) was added and 
the solution refluxed for 2 hours. The resulting solution was evaporated under reduced 
pressure and the residue recrystallized from methanol to give a brown solid, 71 % yield (242 
mg). 
 
m.p. 58-60 
o
C (methanol);
 1
H NMR (300 MHz, CDCl3) δ 8.06 (s, 2H, CH of pyrazole), 7.33 
– 7.27 (m, 4H, Ar), 7.19 – 7.13 (m, 4H, Ar), 4.35 (q, J = 7.2 Hz, 4H, CH2), 2.43 (s, 6H, CH3), 
1.39 (t, J = 7.1 Hz, 6H, CH3CH2); 
13
C NMR (75 MHz, CDCl3) δ 163.4 (d, J = 250.3 Hz, CF), 
162.3 (C=O), 146.9 (CCH3), 143.2 (CH of pyrazole), 131.7 (d, J = 3.0 Hz, ArC), 129.5 (d, J 
= 9.0 Hz, ArCH), 116.7 (d, J = 25.3 Hz, ArCH), 113.2 (CC=O), 60.7 (CH2CH3), 14.3 
(CH2CH3), 11.6 (CH3); IR (KBr) 3419, 2984, 1721 (ester), 1563, 1515, 1382, 1293, 1232 (F), 
1224 (ester), 1099 (ester), 1011, 845, 777, 629, 579, 514 cm
-1
; Anal. calcd for 
C26H26Cl2F2N4O4Zn, C, 49.35; H, 4.14; N, 8.86; found C, 48.56; H, 4.06; N, 8.40. 
3.4.2 Synthesis of 31 (zinc complex of 26 (XQ17)) 
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1-(4-Chloro-phenyl)-5-methyl-1H-pyrazole-4-carboxylate 26 (see 13) (265 mg, 1.1 mmol) 
was dissolved in methanol (20 mL). Zinc chloride (75 mg, 0.55 mmol) was added and the 
solution refluxed for 2 hours. The resulting solution was evaporated under reduced pressure 
to give a pale yellow solid, 100 % yield (340 mg). 
 
m.p. 182-186 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 8.10 (s, 2H, CH of pyrazole), 7.47 – 7.42 
(m, 4H, Ar), 7.30 – 7.23 (m, 4H, Ar), 4.35 (q, J = 7.1 Hz, 4H, CH2CH3), 2.46 (s, 6H, CH3), 
1.39 (t, J = 7.1 Hz, 6H, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 162.4 (C=O), 146.5 (CCH3), 
143.4 (CH of pyrazole), 136.6 (ArC), 134.3 (CCl), 129.8 (ArCH), 128.4 (ArCH), 113.4 
(CC=O), 60.7 (CH2), 14.4 (CH2CH3), 11.6 (CH3); IR (KBr) 3412, 3126, 2978, 1717 (ester), 
1556, 1501, 1411, 1236 (ester), 1101 (ester), 1010, 963, 836, 777 (Cl), 661, 620, 507; Anal. 
calcd for C26H26Cl4N4O4Zn, C, 46.91; H, 3.94; N, 8.42; found C, 47.73; H, 3.91; N, 8.34. 
 
3.4.3 Synthesis of 32 (zinc complex of 27 (XQ18))  
 
 
 
5-Methyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazole-4-carboxylate 27 (see 10) (201 mg, 0.56 
mmol) was dissolved in methanol (20 mL). Zinc chloride (38 mg, 0.28 mmol) was added and 
the solution refluxed for 2 hours. The resulting solution was evaporated under reduced 
pressure and the residue recrystallized from methanol to give a brown solid, 67 % yield (160 
mg). 
 
m.p. 150-154 
o
C (methanol); 
1
H NMR (300 MHz, CDCl3) δ 8.16 (s, 2H, CH of pyrazole), 
7.78 (d, J = 8.2 Hz, 4H, Ar), 7.54 (d, J = 8.2 Hz, 4H, Ar), 4.35 (q, J = 7.1 Hz, 4H, CH2), 2.54 
(s, 6H, CH3), 1.39 (t, J = 7.1 Hz, 6H, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 162.1 (C=O), 
146.7 (ArC), 143.5 (CH of pyrazole), 138.6 (CCH3), 132.1 (q, J = 33.0 Hz, CCF3), 127.7 
(ArCH), 126.7 (q, J = 3.7 Hz, ArCH), 123.3 (q, J = 270.8 Hz, CF3), 113.7 (CC=O), 60.7 
(CH2), 14.1 (CH2CH3), 11.6 (CH3), IR (KBr) 3429, 2986, 1722 (ester), 1617, 1561, 1400, 
1326 (CF3), 1246 (ester), 1132, 1100 (ester), 1067, 1010, 961, 851, 777, 663, 613, 515 cm
-1
; 
Anal. calcd for C28H26Cl2F6N4O4Zn, C, 45.89; H, 3.58; N, 7.65; found C, 46.42; H, 3.79; N, 
7.37. 
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3.4.4 Synthesis of 33 (zinc complex of 28(XQ19)) 
 
 
 
Ethyl 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-4-carboxylate 28 (see 12) (213 mg, 0.82 
mmol) was dissolved in methanol (20 mL). Zinc chloride (56 mg, 0.41 mmol) was added and 
the solution refluxed for 2 hours. The resulting solution was evaporated under reduced 
pressure and the residue recrystallized from chloroform to give a pale brown solid, 52 % 
yield (140mg). 
 
m.p. 210-214 
o
C (chloroform); 
1
H NMR (300 MHz, CDCl3) δ 8.09 (s, 2H, CH of pyrazole), 
7.20 – 7.15 (m, 4H, Ar), 6,94 – 6.89 (m, 4H, Ar), 4.33 (q, J = 7.1 Hz, 4H, CH2), 3.85 (s, 6H, 
OCH3), 2.39 (s, 6H, CH3), 1.38 (t, J = 7.1 Hz, 6H, CH2CH3); 
13
C NMR (75 MHz, CDCl3) δ 
162.4 (C=O), 161.1 (COCH3), 147.1 (CCH3), 143.2 (CH of pyrazole), 128.8 (ArC), 127.9 
(CC=O), 114.5 (ArCH), 112.8 (ArCH), 60.6 (CH2), 55.6 (OCH3), 14.4 (CH3CH2), 11.6 (CH3); 
IR (KBr) 3415, 2984, 1724 (ester), 1514, 1382, 1258 (ester), 1229 (ether), 1105 (ester), 1019, 
963, 836, 772, 637, 590, 526; Anal. calcd for C28H32Cl2N4O6Zn·2H2O, C, 48.54; H, 5.24; N, 
8.09; found C, 48.84; H, 4.30; N, 8.21. 
3.4.5 Synthesis of 34 (zinc complex of 29 (XQ23)) 
 
1-Phenyl-5-propyl-1H-pyrazole-4-carboxylate 29 (310 mg, 1.20 mmol) was dissolved in 
methanol (20 mL). Zinc chloride (83 mg, 0.6 mmol) was added and the solution refluxed for 
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2 hours. The resulting solution was evaporated under reduced pressure and the residue 
recrystallized from chloroform to give a white solid, 80 % yield (314 mg). 
 
m.p. 200-204 
o
C (chloroform); 
1
H NMR (300 MHz, CDCl3) δ 8.05 (s, 2H, CH of pyrazole), 
7.56 – 7.42 (m, 6H, Ar), 7.31 – 7.23 (m, 4H, Ar), 4.35 (q, J = 7.1 Hz, 4H, OCH2CH3), 2.84 (t, 
J = 7.8 Hz, 4H, CH2CH2CH3), 1.56 – 1.46 (m, 4H, CH2CH2CH3), 1.40 (t, J = 7.1 Hz, 6H, 
OCH2CH3), 0.84 (t, J = 7.4 Hz, 6H, CH3CH2CH2); 
13
C NMR (75 MHz, CDCl3) δ 162.1 
(C=O), 150.9 (ArC), 143.6 (CH of pyrazole), 135.6 (CCH2CH3), 130.7 (ArCH), 129.5 
(ArCH), 127.7 (ArCH), 112.5 (CC=O), 60.5 (OCH2CH3), 26.7 (CH2CH2CH3), 22.3 
(CH2CH2CH3), 14.4 (OCH2CH3), 13.8 (CH2CH2CH3); IR (KBr) 3427, 2971, 1725 (ester), 
1555, 1502, 1455, 1380, 1297, 1253 (ester), 1215, 1101 (ester), 979, 765, 694, 646, 510 cm
-1
; 
Anal. calcd for C30H36Cl2N4O4Zn, C, 55.18; H, 5.56; N, 8.58; found C, 54.87; H, 5.33; N, 
8.25. 
3.5  Synthesis of a thiourea substituted pyrazole and its zinc complex 
3.5.1 Synthesis of 4-nitro-1H-pyrazole 37 (XQ43)
62
 
 
Pyrazole (533 mg, 7.83 mmol) was added in portions to concentrated sulfuric acid (4 mL) 
while keeping the temperature below 40 
o
C using an ice bath. Nitric acid (70 % aqueous 
solution, 0.55 mL) was added dropwise while maintaining the temperature below 55 
o
C, the 
mixture was then heated at 55 
o
C for 5 hours. The resulting solution was slowly poured onto 
ice and neutralized with 50 % aqueous sodium hydroxide. The resulting slurry was diluted 
with ethyl acetate (30 mL) and the mixture filtered. The filtrate was washed with distilled 
water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate, and evaporated under 
reduced pressure to give a white solid, 60 % yield (534 mg). 
  
1
H NMR (300 MHz, DMSO-d6) δ 13.99 (s, 1H, NH), 8.58 (s, 2H, CHC); 
13
C NMR (75 MHz, 
DMSO-d6) δ 135.32 (CNO2), 132.32 (CHC); ESI-MS C3H3N3O2 Calc. (M + Na
+
) = 136.0117, 
found (M + Na
+
) = 136.0124. Matches known data.
62
 
3.5.2 Synthesis of 1H-pyrazol-4-ylamine 38 (XQ44)
62
 
 
A stirred mixture of iron (773 mg, 13.8 mmol), ammonium chloride (247 mg, 4.6 mmol), 
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water (1.5 mL) and ethanol (7 mL) was heated to 80 
o
C. 4-Nitro-1H-pyrazole 37 (520 mg, 4.6 
mmol) was added in portions. The mixture was stirred at 80 
o
C for 2 hours after which it was 
allowed to cool to room temperature. The reaction mixture was diluted with ethyl acetate (30 
× 3mL), the resultant mixture was filtered through a pad of celite and the filtrate was 
evaporated under reduced pressure. In order to remove residual water, the residue was diluted 
with ethyl acetate (30 mL), dried over anhydrous sodium sulfate, and evaporated under 
reduced pressure to give a purple red oil, 41 % yield (155 mg). 
 
1
H NMR (300 MHz, DMSO-d6) δ 8.58 (s, 2H, CH), 6.99 (s, 2H, NH); Matches known data.
62
 
3.5.3 Synthesis of 1-phenyl-3-(1H-pyrazol-4-yl)-thiourea 39 (XQ45) 
 
To a solution of 1H-pyrazol-4-ylamine 38 (196 mg, 2.4 mmol) in anhydrous 
dimethylformamide (8 mL), isothiocyanatobenzene (0.36 mL, 3 mmol) was added under a 
nitrogen atmosphere. The resulting solution was stirred for 24 hours under a nitrogen 
atmosphere and then evaporated under reduced pressure and diluted with ethyl acetate (30 
mL). The mixture was filtered and the solid obtained was dried to give a grey solid, 16 % 
yield (82 mg). 
m.p. 174-176 
o
C; 
1
H NMR (300 MHz, DMSO-d6) δ 12.70 (s, 1H, NH-N), 9.57 (s, 2H, CH of 
pyrazole), 7.79 (br, 2H, NHC=S), 7.47 – 7.44 (m, 2H, Ar), 7.34 – 7.29 (m, 2H, Ar), 7.14 – 
7.09 (m, 1H, Ar); 
13
C NMR (75 MHz, DMSO-d6) δ 179.1 (C=S), 139.5 (ArC), 128.3 (C of 
pyrazole), 124.3 (ArCH), 123.7 (ArCH), 79.1 (CH of pyrazole); IR (KBr) 3448, 3325 
(secondary amine), 3225, 2977, 1589, 1549, 1496 (secondary amine), 1370 (C=S), 1309 
(secondary amine), 1279 (secondary amine), 1011, 953, 698, 608 cm
-1
; ESI-MS C10H10N4S 
Calc. (M + H
+
) = 219.0699, found 219.0706. 
3.5.4 Synthesis of 40 (zinc complex of 39 (XQ45)) 
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1-Phenyl-3-(1H-pyrazol-4-yl)-thiourea 39 (97 mg, 0.445 mmol) was dissolved in methanol 
(10 mL) and the solution was heated to 40 
o
C to give a clear solution. Zinc acetate (49 mg, 
0.223 mmol) was dissolved in methanol (5 mL) and this solution was added drop wise to the 
thiourea solution. A solid precipitated was generated, which was filtered and dried to give a 
grey solid, 54 % yield (40 mg). 
 
m.p. > 300 
o
C; 
1
H NMR (300 MHz, DMSO-d6) δ 9.97 (br, 2H, NNH), 7.80 (s, 4H, CH of 
pyrazole), 7.57 – 7.46 (m, 4H, Ar), 7.36 – 7.27 (m, 4H, Ar), 7.11 – 7.06 (m, 2H, Ar), 1.87 (s, 
6H, OCH3); 
13
C NMR (75 MHz, DMSO-d6) δ 139.86 (ArC), 128.20 (C of pyrazole), 123.90 
(ArCH), 123.38 (ArCH), 79.12 (CH of pyrazole), 22.80 (OCH3); IR (KBr) 3252 (secondary 
amine), 1592, 1537, 1496 (secondary amine), 1389 (C=S), 1337 (secondary amine), 1198, 
1144 (secondary amine), 1071, 1013, 924, 886, 847, 754, 693, 623, 546, 489 cm
-1
. Anal. 
calcd for C22H28N8O4S2Zn2, C, 39.83; H, 4.25; N, 16.89; found C, 39.81; H, 2.86; N, 17.80. 
 
3.6.1 Synthesis of ethyl 2-((dimethylamino)methylene)-3-oxopentanoate 41 (XQ6a)
56
 
 
 
 
3-Oxo-pentanoic acid ethyl ester (0.6 mL, 4.74 mmol) was stirred at room temperature and 
dimethoxymethyl-dimethyl-amine (0.76 mL, 4.74 mmol) was added drop wise. The resulting 
solution was allowed to stir at room temperature for 16 hours. The resulting solution was 
evaporated under reduced pressure and azetroped with toluene three times (evaporating under 
reduced pressure) to give a yellow oil, 51 % yield (471 mg). The crude product was used 
without further purification. 
 
1
H NMR (300 MHz, CDCl3) δ 7.57 (s, 1H, C=CH), 4.14 (q, J = 7.1 Hz, 2H, OCH2), 2.95 (s, 
6H, NCH3), 2.59 (q, J =7.4 Hz, 2H, C(O)CH2), 1.24 (t, 3H, J = 7.1 Hz, OCH2CH3), 1.01 (t, 
3H, J = 7.4 Hz, CH2CH3). Matches known data.
56
 
3.6.2 Synthesis of ethyl 2-((dimethylamino)methylene)-3-oxohexanoate 42 (XQ22)
54
 
 
  
 
 
 
79 
 
3-Oxo-hexanoic acid ethyl ester (0.4 mL, 2.5 mmol) was stirred at room temperature and 
dimethoxymethyl–dimethyl–amine (0.42 mL, 3.12 mmol) was added drop wise. The reaction 
mixture was allowed to stir at room temperature for 16 hours. The resulting solution was 
evaporated under reduced pressure and then azotroped with toluene three times (evaporating 
under reduced pressure) to give a yellow oil, 80 % yield (427 mg). The crude product was 
used without further purification. 
 
Rf value: 0.42 (ethyl acetate/petroleum ether, 80 : 20); 
1
H NMR (300 MHz, CDCl3) δ 7.45 (s, 
1H, CH=C), 4.03 (q, J = 7.1 Hz, 2H, OCH2CH3), 2.83 (s, 6H, NCH3), 2.44 (t, J = 7.5 Hz, 2H, 
CH2CH2CH3), 1.43 (dt, J = 7.4 Hz, 2H, C(O)CH2CH2CH3), 1.13 (t, J = 7.1 Hz, 3H, 
OCH2CH3), 0.73 (t, J = 7.4 Hz, 3H, C(O)CH2CH2CH3). Matches know data.
54 
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Chapter 4: Introduction to the synthesis of biphenyl sulfones and 
their fluorescent properties 
4.1 Fluorescence 
 
Fluorescence is a particular case of luminescence. Energy is supplied in the form of 
electromagnetic radiation resulting in excitation of the molecule from a lower energy state 
into a higher energy state. We then see decay back to a lower energy state with the release of 
the energy in the form of light.  
 
In 1819 Edward D. Clarke described fluorescence in fluorites (a halide mineral composed of 
calcium fluoride).
63
 Sir David Brewster described the fluorescence of chlorophyll (a green 
pigment found in cyanobacteria and the chloroplasts of algae and plants) in 1833
64
 and Sir 
John Herschel described fluorescence of quinine sulfate in 1845.
65
 In 1852, George Gabriel 
Stokes described the ability of fluorites and uranium glass to change invisible light beyond 
the violet end of the visible light into blue light. “Fluorescence” was named in his seminal 
paper on the wavelength change of light.
66
 Since then fluorescence spectroscopy was 
developed significantly and been applied to many areas e.g. biochemistry, medicine and 
analytical chemistry.
70,71
 An interesting case is that of the fluorescence reported by Nicolás 
Monardes in 1565.
67
 This fluorescence was observed in an infusion from a medicinal wood 
called lignum nephriticum. Monardes did not know the chemical compound responsible for 
the fluorescence at that time. It was subsequently found to be matlaline, but this only 
reported by A. Ulises Acuña in 2009, Figure 4.1.1.
68
 
 
 
Figure 4.1.1 Structure of matlaline 
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4.2 Fluorophores 
 
As discussed on previous page, fluorescence has been applied to various areas including 
biochemistry, medicine and analytical chemistry. Some organic fluorescent dyes have proved 
to be efficient fluorescent probes and sensors in photochemistry and photobiology. For 
example, the photo-induced intramolecular charge transfer in donor-acceptor biphenyls was 
shown to be very useful in sensing hydrogen bonds as well as pH.
69
 Fluorescence probes 
represent the most important area of fluorescence spectroscopy. Organic fluorescent markers 
for the labeling of amino acids, peptides, proteins, DNA, and other biomolecules are 
common.
70
 They are more generally covalently bonded to macromolecules as markers for 
bioactive reagents. There are two major classes of fluorophores, intrinsic and extrinsic. 
Intrinsic fluorophores are natural occurring fluorophores which including NADH 
(Nicotinamide adenine dinucleotide), flavins, aromatic amino acids, derivatives of pyridoxyl 
and chlorophyll. Extrinsic fluorophores either provide fluorescence activity to the sample 
when none exists or change the spectral properties of the sample after its addition.
71
 
4.2.1 Intrinsic fluorophores 
 
NADH (Nicotinamide adenine dinucleotide) is an enzyme cofactor found in all living cells. 
NADH is highly fluorescent, where as in its oxidized form NAD
+
 is non-fluorescent, Figure 
4.1.2. NADH has a maximum absorption at 340 nm, and a maximum emission at 460 nm. It 
partially quenches (decreases in intensity of fluorescence) in solution due to the collision and 
stacking of the adenine moiety. Once bound to a protein, the fluorescence activity of NADH 
will change, and depending on the protein, the fluorescence will either increase or decrease. 
The lifetime of NADH is increased in aqueous buffer,
71
 lifetimes as long as 5 ns have been 
reported for NADH bound to horse liver alcohol dehydrogenase
72
 and octopine 
dehydrogenase.
73
 
 
Flavins including riboflavin, FMN (flavin mononucleotide), and FAD (flavin adenine 
dinucleotide) have fluorescent activity in their oxidized form, whereas their reduced forms 
are non-fluorescent. This is in contrast to NADH. The fluorescent activity of FAD is 
quenched due to complex formation between the flavin and the adenosine units, Figure 
4.1.2.
74
 The typical lifetime for FAD is 2.3 ns. Flavins have maximum absorption around 
425 nm (visible range), and maximum emission around 525 nm. Once bound to proteins, 
flavins are generally weakly fluorescent or non-fluorescent.
71
 
 
Aromatic amino acids including tryptophan, tyrosine and phenylalanine, Figure 4.1.2, are the 
origin of intrinsic fluorescence in proteins.
75
 Here tryptophan is taken as an example. 
Tryptophan is often used as a reporter group for protein conformational changes, because its 
emission is highly sensitive to its environment. Tryptophan has a maximum absorption 
around 295 nm, and a maximum emission around 353 nm. The indole groups of tryptophan 
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residues are the dominant sources of emission in proteins. They can be quenched by a nearby 
electron deficient group, such as a carboxylic acids and protonated histidine residues, 
amongst others.
71
 
 
 
 
         
 
 
         
 
Figure 4.1.2 Structures of some intrinsic fluorophores 
4.2.2 Extrinsic fluorophores 
 
Numerous extrinsic fluorophores have been developed during the past decade due to the 
inadequacy of intrinsic fluorophores for certain purposes. For example, extrinsic 
fluorophores with a longer wavelength of emission and excitation were developed for 
labeling proteins. Extrinsic fluorophores have also been developed for the labeling of lipids 
and DNA.
69
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4.2.3 Protein labeling fluorophores 
 
Fluorophores used for the labeling of proteins can be attached via covalent bonds or via 
non-covalent interactions. 
 
There are a number of fluorophores used to covalently label proteins, e.g. dansyl chloride, 
fluorescein and rhodamine. These fluorophores are some of the most widely used. Dansyl 
chloride, Figure 4.1.3, was originally described by Gregorio Weber,
76
 and it is widely used 
to label proteins. Its emission wavelength is highly sensitive to the solvent polarity. Dansyl 
chloride has a maximum emission around 520 nm and a maximum absorption at 350 nm, a 
wavelength at which intrinsic fluorophores in proteins cannot be excited. Fluoresceins and 
rhodamines, Figure 4.1.3, have maximum emission from 510 to 615 nm and have maximum 
absorption around 480 and 600 nm, respectively. Unlike dansyl chloride, fluoresceins and 
rhodamines are not sensitive to solvent polarity; but they have high molar extinction 
coefficients. As well as the labeling of proteins they have also been used for the labeling of 
antibodies.
71
 
 
 
          
 
Figure 4.1.3 Structures of some fluorophores used to covalently label proteins 
 
There are a number of fluorophores used for non-covalent protein labeling. ANS 
(1-anilinonaphthalene-6-sulfonic acid) and TNS (2-(p-toluidinyl)naphthalene-6-sulfonic acid) 
are the commonly used fluorophores. They belong to the family of non-covalent protein 
labeling fluorophores, naphthylamine sulfonic acids, Figure 4.1.4. Here ANS is taken as an 
example. Emission from ANS is insignificant when dissolved in buffer, but it is highly 
fluorescence when bound to proteins.
77
 For example, when ANS is added to BSA (bovine 
serum albumin), the ANS emission increases and tryptophan emission from BSA decreases. 
The maximum emission of ANS bound to BSA occurs at ≈ 470 nm (280 nm excitation).71 
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Figure 4.1.4 Structures of fluorophores used for the non-covalent labeling of proteins 
 
4.2.4 Membrane labeling fluorophores 
 
Membranes have been labeled by the covalent attachment of fluorophores to lipids. For 
example, pyrene has been attached to lipids (pyrene-lipid) to estimate the diffusive process in 
membranes by the extent of excimer formation, Figure 4.1.5. The maximum emission of 
pyrene-PC (pyrene-phosphatidylcholine) is at ≈ 470 nm and its intensity is highly dependent 
on the temperature. The unstructured emission at higher temperatures is due to excimer 
formation between the pyrene groups.
78
 
 
 
Figure 4.1.5 Structure of pyrenyl-PC 
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4.2.5 DNA labeling flourophores 
 
DNA can be made fluorescent through the use of fluorescent DNA base analogues. For 
example, IXP (isoxanthopterin), an analogue of guanine, Figure 4.1.6, has a maximum 
emission at around 420 nm when part of a dinucleotide or oligonucleotide. IXP fluorescence 
quenches when part of a double-helical DNA oligonucleotide, but it is more fluorescent when 
part of a dinucleotide.
79
 IXP has found use in an assay for the HIV integrase protein, due to 
its dependence on the DNA structure.
80
 
 
           
 
Figure 4.1.6 Structures of guanine and IXP 
4.3 Fluorescence spectroscopy 
 
Fluorescence spectroscopy is concerned with measuring/detecting transitions between 
electronic states and vibrational states of a given molecule. Molecules being examined have a 
ground electronic state of low energy and an excited electronic state of higher energy. Each 
of these electronic states has various vibrational states.  
 
Fluorescent molecules are able to absorb and emit photons of lights, which contain energy 
proportional to their frequency. The higher the frequency of the light then the higher energy 
the photons carry.  
 
In fluorescence spectroscopy, a molecule is excited by absorbing a photon and moves from 
its ground electronic state to one of the various vibrational states of its excited electronic 
state. The molecule will reach its lowest vibrational state by collision with other molecules, 
losing vibrational energy through these collisions, and then emit a photon and returning to its 
ground electronic state. As the molecules could drop down to any one of the various 
vibrational states of its ground electronic state, the photons emitted could be of different 
amounts of energy. Therefore the light emitted could have different frequencies. 
Fluorescence spectroscopy analyses the different frequencies of light emitted to determine 
the nature/energies of the different energy levels. The fluorometer measures different 
frequencies of fluorescent light emitted from the sample with the excitation light held 
constant, giving an emission spectrum. For an excitation spectrum, the excitation lights were 
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scanned through different wavelengths using monochrometer and recorded with the emission 
light held a constant wavelength.
81
 
4.4 Electrocyclic reaction  
 
An electrocyclic reaction is an intramolecular reaction in which a new ζ bond is formed 
between the ends of conjugated π system. There are two kinds of electrocyclic reactions and 
they differ in terms of their reaction conditions, thermal and photochemical conditions, which 
give opposite configurations. 
 
 
 
Figure 4.1.7 Examples of electrocyclic reactions 
 
To form the new ζ bond, the p orbital at the end of the conjugate system must rotate. There 
are two ways of this can occur. If the HOMO (highest occupied molecular orbital) is 
asymmetric, then the conrotatory ring-closure is symmetry allowed. If the HOMO is 
symmetric, then the disrotatory ring-closure is symmetry allowed.                                              
 
                
HOMO is asymmetric                                       HOMO is symmetric 
 
Figure 4.1.8 Conrotatory and disrotatory ring closures 
4.4.1 Woodward-Hoffmann rules  
 
The Woodward-Hoffmann rules are a set of rules in organic chemistry predicting the energy 
barrier heights of pericyclic reactions and are based on the conservation of orbital symmetry. 
Hoffmann was awarded the Nobel Prize in chemistry in 1981. 
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Number of conjugated π 
bonds 
Reaction conditions Allowed mode of ring 
closure 
Even number Thermal Conrotatory 
 Photochemical Disrotatroy 
Odd number Thermal Disrotatory 
 Photochemical Conrotatory 
Figure 4.1.9 Summary of Woodward-Hoffmann rules for electrocyclic Reaction 
 
Looking at the ring closure of (2E,4Z,6E)-octatriene as an example of a three conjugated π 
bonds system:  
 
The ground-state HOMO of a compound with three conjugated π bonds is symmetric, and 
hence under thermal condition, the ring closure of (2E,4Z,6E)-octatriene is disrotatory, 
Figure 4.2.1, and the cis conformation of the product is obtained. 
 
 
       
 
 
Figure 4.2.1 Thermal ring closure of (2E, 4E, 6E)-octatriene 
 
 
Under photochemical conditions, the excited state HOMO must be considered. The new 
HOMO prodcued of the triene, under the photochemical conditions, is asymmetric, therefore 
the ring closure of (2E,4Z,6E)-octatriene is conrotatory, Figure 4.2.2, and the trans 
conformation of the product is obtained. 
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Figure 4.2.2 Photochemical ring closure of (2E, 4E, 6E)-octatriene 
4.4.2 Some typical examples of electrocyclic reaction 
 
Electrocyclic reactions have been frequently found in biological system, e.g. biosynthesis of 
natural products. Classical examples of an electrocyclic reaction in biosynthesis include the 
biosynthesis of endiandric acid or vitamin D. Here the biosynthesis of vitamin D3 is taken as 
an example. The first step is a conrotatory ring opening of 7-dehydrocholesterol under 
photochemical conditions, to form pre vitamin D3. A [1,7]-hydride shift then followed to form 
vitamin D3, Figure 4.2.3.
82
 Another example of an electrocyclic reaction in a biological 
system was the thermal rearrangement of benzonorcaradiene diterpenoid to the 
benzocycloheptatriene diterpenoid isosalvipuberlin, Figure 4.2.4.
83
 This transformation can 
be considered as a thermal disrotatory electrocyclic reaction. 
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Figure 4.2.3 Vitamin D3 formation 
 
 
Figure 4.2.4 Benzocycloheptatriene diterpenoid isosalvipuberlin formation 
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Electrocyclic reactions are also often found in organic synthesis. One well studied example is 
the conrotatory thermal ring-opening of benzocyclobutane. The resulting product is a very 
unstable ortho-quinodimethene, which can be trapped in an endo Diels Alder addition with a 
strong dienophile such as maleic anhydride, Figure 4.2.5.
84
  
 
 
Figure 4.2.5 An electrocyclic ring opening and subsequent Diels Alder cycloaddition. 
 
4.5 Project aims for biphenyl sulfone section 
 
This project, in part, aims to 1) synthesize and characterize a family of bis-sulfonyl trienes 
that are potential substrates for electrocyclisation reactions, 2) use the trienes to generate, and 
characterize, a family of biphenyl sulfones via an electrocyclisation reaction, 3) the biphenyl 
sulfones are expected to be fluorescent in nature and as such their fluorescence will be 
evaluated and characterized.  
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Chapter 5 Results and discussion of the synthesis of biphenyl 
sulfones and their fluorescent properties 
Preliminary research carried out by the Stephens group discovered that a bissulfonyl triene 
can undergo a thermally driven rearrangement to give a biphenyl sulfone, albeit in a low yield, 
Figure 5.1.1.
87
 This was an intriguing result and one we decided to investigate further. We 
were also curious to see if a fluorescent biphenyl would result, particularly if we added an 
electron donating group, e.g. dimethylamino, on the biphenyl and para to the sulfone.
93
 
 
Figure 5.1.1 Thermal generation of 4-(phenylsulfonyl)-1,1'-biphenyl 43 
 
A traditional method for preparing 4-(phenylsulfonyl)-1,1'-biphenyl is using a 
Suzuki-Miyaura coupling
85
 or Friedel-Crafts reaction.
86
 For example, Su-Dong Cho 
reported a synthetic route using Suzuki-Miyaura coupling. Here Su-Dong employed 
phenylboronic acid and 1-chloro-4-(phenylsulfonyl)benzene as starting materials with 2 
equivalents of Cs2CO3 as base, 10 mol% of a bulky electron-rich monoaryl phosphine ligand, 
Figure 5.1.2, and 1 mol% Pd2(dba)3. The reaction mixture was refluxed in 1,4-dioxane for 12 
hours to afford the bisphenyl sulfone product in a 97 % yield.
85
 
 
Figure 5.1.2 Phosphine ligand used in the Suzuki-Miyaura coupling
85 
 
Tongshou Jin and co-workers reported a Friedel-Crafts synthetic route for synthesizing 
4-(phenylsulfonyl)-1,1'-biphenyl, Figure 5.1.3. The reaction was catalyzed using Fe(OH)3 
and stirred at 140 
o
C to give the bisphenyl sulfone in 80% yield.
86
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Figure 5.1.3 Friedel-Crafts generation of 4-(phenylsulfonyl)-1,1'-biphenyl 43
86
 
5.1 Synthesis of bissulfonyl trienes 
 
In order to optimize the thermal generation of the bisphenyl sulfones we first had to generate 
the corresponding bissulfonyl trienes. The trienes in question could be prepared using the 
previous developed methodology of the Stephens group. Triene 44 was synthesised in one 
step from the commercial available trans-cinnamaldehyde and bis-phenylsulfonyl propene, a 
stock of which was previously made by Stephens group, with aluminium oxide as the catalyst 
Figure 5.1.4. The bis-phenylsulfonyl propene was made by treating allyl phenylsulfone with 
elemental bromine and TEA. The resulting bromo-phenylsulfonyl propene was treated with 
benzenesulfinic acid sodium salt to generate the desired product.
87
  
 
 
Figure 5.1.4 Triene 44 synthesis 
 
A family of novel trienes were synthesized using this methodology, Table 5.1. The triene 
derivatives were choosen to synthesis with the aim of exploring the effect of adding the 
electron donating or electron withdrawing groups to the biphenyl sulfones. The trienes were 
characterized using NMR, IR, HRMS and CHN microanalysis. For example, the 
1
H and 
13
C 
NMR spectra for triene 44 generated the expected multitude of signals in the aromatic 
reagion. Seventeen distinct signals were found in the 
13
C NMR spectrum, four of which were 
identified as tertiary carbons using a DEPT 135 spectrum (as expected). CHN microanalysis 
and HRMS for triene 44 confirmed its identity, calculated for [C24H20O4S2] C, 66.03; H, 4.62; 
found C, 66.19; H, 4.66 and HRMS calc. (M + H
+
) = 437.0876, found (M + H
+
) = 437.0871 
(-1.17 ppm). The IR spectrum also showed the SO2 group with bands at 1310 and 1145 cm
-1
. 
1
H NMR of triene 50 shows a singlet at 3.87 ppm with an integration of 3H indicating the 
presence of OCH3 group. 
1
H NMR of triene 53 shows a singlet at 2.41 ppm indicating the 
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presence of CH3 group. 
13
C NMR of triene 3 exhibited twenty one distinct signals due to the 
unsymmetrical of the ortho substituted phenyl ring. CHN microanalysis of the triene 46 
confirmed its identity, calculated for [C25H22O5S] C, 64.36; H, 4.75; found C, 64.56; H, 4.55. 
1
H NMR of triene 48 shows a singlet at 3.08 ppm with an integration of 6H indicating the 
presence of N(CH3)2 group. 
1
H NMR of triene 52 shows a singlet at 3.95 ppm with an 
integration of 3H indicating the presence of C(O)OCH3 group. CHN microanalysis of the 
triene 52 confirmed its identity, calculated for [2(C26H22O6S2)H2O] C, 62.01; H, 4.60; found 
C, 62.20; H, 5.08. The 
1
H NMR spectrum of triene 44 is shown in Figure 5.1.5. 
 
Product R
1
 R
2
 Yield (%) 
Triene 44 H H 57 
4-Nitro triene 45 NO2 H 57 
2-OMe triene 46 H OCH3 62 
2-Nitro triene 47 H NO2 46 
4-Dimethylamino triene 
48 
N(CH3)2 H 77 
4-Chloro triene 49 Cl H 43 
4-OMe triene 50 OCH3 H 37 
4-Cyano triene 51 CN H 29 
4-MeO2C triene 52 C(O)OCH3 H 32 
4-Methyl triene 53 CH3 H 26 
Table 5.1 Triene synthesis 
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Figure 5.1.5 
1
H NMR of triene 44 
 
X-ray crystal structures of triene 45 and triene 50 were obtained with our collaborator Prof 
Pat McArdle (NUI Galway), Figure 5.1.6 and 5.1.7. (for X-ray data, see Appendix table 
0.1-0.2) 
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Figure 5.1.6 X-ray crystal structure of 
1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-nitrobenzene 45 
 
 
Figure 5.1.7 X-ray crystal structure of 
((1E,3E,5E)-6-(4-methoxyphenyl)hexa-1,3,5-triene-1,3diyldisulfonyl)dibenzene 50 
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The starting cinnamaldehydes for some trienes were not commercially available and had to 
be synthesized as a result. The triene 51 is taken as an example. 4-Cyano cinnamaldehyde 54 
was prepared by refluxing 4-formylbenzonitrile in THF with (triphenylphosphoranylidene) 
acetaldehyde for 24 hours, Figure 5.1.8. The final product was purified using flash 
chromatography. The product obtained was a mixture of trans and cis isomers (trans 
predominately), and used without further purification.
99
 The product was confirmed by 
1
H 
NMR, with a doublet doublet at 6.8 ppm for CH=CHC(O)H, and HRMS,  C10H7NO calc. 
(M + H
+
) = 158.0600, found (M + H
+
) = 158.0604 (2.17 ppm). The mechanism of this 
reaction is shown in Figure 5.1.9. 
 
 
Figure 5.1.8 Synthesis of 4-cyano cinnamaldehyde 54 
 
 
 
Figure 5.1.9 Proposed mechanism for synthesis of 4-cyano cinnamaldehyde 54 
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5.2 Synthesis of the biphenyl sulfone family 
A number of different reaction conditions were explored in order to develop an effective 
methodology for the synthesis of bisphenyl sulfones, Table 5.2. The synthesis of 
4-(phenylsulfonyl)-1,1'-biphenyl 43 was used as the test reaction. The first conditions we 
explored used microwave irradiation. Microwaves would be able to heat the triene directly 
and as a result we thought tha this method may produce a fast and high yielding 
transformation. We dissolved triene 44 in different solvents e.g. toluene, NMP, and heated 
the solution at various temperature under microwave irradiation. The microwave reaction 
conditions found to work best employed NMP as the solvent and heated at 170 
o
C for 1 hour 
under microwave. However, the isolated yield was only 45 % yield for this reaction. We were 
keen to try a solvent free reaction but were concerned about generating super heated hot spots 
(due directly heating solids) under microwave conditions. As a result we explored heating the 
neat compound in an oil bath. This proved to be an excellent approach and after some 
optimization the 4-(phenylsulfonyl) -1,1'-biphenyl 43
 
was obtained in a 96 % yield after 
heating for 1 hour at 170 
o
C. All the reactions attempted are shown in Table 5.2. The 
structure of desired products was confirmed 
1
H and 
13
C NMR, HRMS and CHN 
microanalysis, Figure 5.2.1.  
 
 
 
Concentration 
/amount 
Solvent Temperature 
 (
o
C) 
Time microwave Yield 
(%) 
14 mg neat 115
 
 5 hours No small 
10mg/3mL Toluene 110
 
 15 mins yes N/A 
10mg/3mL Toluene 130
 
 15 min yes N/A 
10mg/3mL DMF 120
 
 15 mins yes N/A 
14mg neat 115
 
 10 hours no small 
15mg/1mL Toluene 133
 
 15 mins yes N/A 
15mg/1mL NMP 200
 
 15 mins yes small 
14mg/0.5mL NMP 200
 
 1 hours yes small 
62mg neat 170
 
 1 hours no 96 
58mg neat 150
 
 1 hours no 61 
71mg neat 130
 
 1 hours no N/A 
59mg/2mL NMP 170
 
 1 hours yes 45 
57mg neat 170
 
 45 mins no 78 
Table 5.2 Attempted reactions for the synthesis of 4-(phenylsulfonyl)-1,1'-biphenyl 43 
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Figure 5.2.1 
1
H NMR of 4-(phenylsulfonyl)-1,1'-biphenyl 43 
 
An x-ray crystal structure of the biphenyl 43 was obtained with our collaborator Prof Pat 
McArdle (NUI Galway), Figure 5.2.2.
87
 
 
 
Figure 5.2.2 X-ray crystal structure of 4-(phenylsulfonyl)-1,1'-biphenyl 43
87
 
 
We consider the thermal generation of the biphenyl sulfones to be a thermal electrocyclic 
reaction, whose proposed mechanism is shown in Figure 5.2.3. A disrotatory overlap of the 
HOMO orbitals was assigned, Figure 5.2.4, based on the analysis of frontier molecular 
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orbitals of triene 44. This predicts the syn-diastereomer of intermediate diene according to the 
Woodward-Hoffman rules (see introduction on electrocyclic reactions). 
 
 
 
                                 
Figure 5.2.3 Proposed reaction mechanism for the generation of the bisphenyl sulfones. 
 
 
Figure 5.2.4 Analysis of molecular orbitals of the thermal electrocyclic reaction. 
 
A family of biphenyls was synthesized using this methodology. Their structures and yields 
are given in Table 5.3. The structure of the biphenyl derivatives were confirmed by 
1
H and 
13
C NMR, HRMS and CHN microanalysis. The 
1
H NMR spectrum of 4-dimethylamino 
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biphenyl 55 showed a singlet at 3.01 ppm, with an integration of 6H, indicating the presence 
of N(CH3)2 group. Its HRMS analysis generated a found (M + H
+
) = 338.1210 (calculated for 
C20H19NO2S (M + H
+
) = 338.1209, 0.16 ppm difference). CHN microanalysis calculated for 
[3(C20H19NO2S) · H2O] C, 69.94; H, 5.77; N, 4.08; found C, 70.19; H, 6.28; N, 3.39. The 
calibration of H2O is based on the 
1
H NMR of dimethylamino biphenyl, Figure 5.2.5, which 
shows a 3:1 ratio of biphenyl:H2O.  
 
Product R
1
 R
2
 Yield (%) 
Biphenyl 43 H H 96 
4-Dimethylamino biphenyl 
55 
N(CH3)2 H 42 
4-Methyl biphenyl 56 NO2 H 35 
4-MeO2C biphenyl 57 Cl H 60 
4-OMe biphenyl 58 C(O)OCH3 H 62 
4-Chloro biphenyl 59 CN H 50 
4-Cyano biphenyl 60 OCH3 H 31 
2-OMe biphenyl 61 H OCH3 39  
2-Nitro biphenyl 62 H NO2 31 
4-Nitrobiphenyl 63 CH3 H 40 
Table 5.3 Biphenyl compounds synthesized  
 
 
 
 
  
 
 
 
101 
 
 
Figure 5.2.5 
1
H NMR of dimethylamino biphenyl 55 
 
An x-ray crystal structure of the biphenyl 63 and biphenyl 58 were obtained with our 
collaborator Prof Pat McArdle (NUI Galway), Figure 5.2.6 and 5.2.7. (for X-ray data, see 
Appendix table 0.1-0.2) 
  
Figure 5.2.6 X-ray crystal structure of 4-nitro-4'-(phenylsulfonyl)-1,1'-biphenyl 63 
 
  
 
 
 
102 
 
 
Figure 5.2.7 X-ray crystal structure of 4-methoxy-4'-(phenylsulfonyl)-1,1'-biphenyl 58 
 
 
The
 1
H NMR spectrum of biphenyl 61 showed two poorly separated singlets at 3.78 ppm that 
together integrated to 3H, Figure 5.2.8. This suggested that two isomers or perhaps two 
rotamers for biphenyl 61 were formed.   
 
 
Figure 5.2.8 
1
H NMR of biphenyl 61 
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HRMS analysis generated a found (M + H
+
) = 325.0905 for biphenyl 61 (calculated for 
C19H16O3S, (M + H
+
) = 325.0893, 3.6 ppm difference). CHN microanalysis found C, 69.58; 
H, 5.48; calculated for [4(C19H16O3S) ·H2O] C, 69.38; H, 5.06. In order to investigate if two 
rotamers were present, which might be expected to interconvert rapidly at higher 
temperatures, we recorded the 
1
H NMR in CDCl3 at 25 
o
C and 50 
o
C and in DMSO-d6 at 25 
o
C and 111 
o
C. In all cases the two singlets did not change and did not turn into single singlet 
(i.e. an average signal of two rapidly interconverting rotamers). The 
13
C NMR and DEPT 135 
spectra revealed ten tertiary carbons. The structure of biphenyl 61 contains five tertiary 
carbons, furthermore two signals at 55.78 and 55.54 ppm were obtained indicating two OCH3 
groups. As such, the 
13
C NMR data supported our two isomers theory. DFT calculations 
carried out by our colaborator Dr Elisa Fadda, NUI Maynooth (details are described in 
section 5.3.9) found two isomers of equal stablity in the gas phase, Figure 5.2.9 and 5.3.1, 
which again supported our theory. 
  
Figure 5.2.9 Molecular orbital plots of the two biphenyl 61 isomers (HOMO) 
 
 
  
Figure 5.3.1 Molecular orbital plots of the two biphenyl 61 isomers (LUMO) 
 
 
We believe that the existence of a partial double bond between the biphenyl aromatic rings 
stops the rotation of the biphenyl system resulting in two stable isomers, see Figure 5.3.2. 
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The related biphenyl 62 exists as single isomer as the NO2 substituent on the phenyl ring is 
strongly electron withdrawing (as opposed to electron donating) and therefore does not 
generate a partial double bond in the biphenyl system. The general synthesis of triene and 
biphenyl compounds were shown in Figure 5.3.3. 
 
 
Figure 5.3.2 Partial double bond in biphenyl system of biphenyl 61  
 
 
Figure 5.3.3 The general synthesis of triene and biphenyl compounds 
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5.3 Fluorescent properties of the biphenyl sulfone family 
The substituted biphenyls were found exhibiting fluorescent properties, and as a result they 
underwent a fluorescence study. The substituted biphenyl compounds 55-63 Table 5.4, were 
examined for fluorescent activity. The procedure for fluorescent study were described in 
experimental section. Compound 55 was of particular interest to us as we believed that a 
“push-pull” effect would exist due to the presence of the electron donating dimethylamino 
group and the electron withdrawing sulfone group. This, we believed, would manifest itself 
through a twisted intramolecular charge transfer (TICT) mechanism of fluorescence.
91
 As 
such, compound 55 was employed in the generation of a UV-absorption spectrum, emission 
spectrum and excitation spectrum in several solvents (chloroform, methanol, toluene, 
ethylene glycol, acetic acid, n-hexane, dichloromethane and acetonitrile). Compounds 56-63 
were also studied and their UV-absorption spectrum, emission spectrum, and excitation 
spectrum generated in two solvents (chloroform and methanol). UV-absorption spectrums 
were recorded using a Unicam UV 500 spectrometer, emission and excitation spectrums were 
recorded using a JASCO FP-6300 spectrofluorometer. 
 
Product R
1
 R
2
 
Biphenyl 55 N(CH3)2 H 
Biphenyl 56 CH3 H 
Biphenyl 57 C(O)OCH3 H 
Biphenyl 58 OCH3 H 
Biphenyl 59 Cl H 
Biphenyl 60 CN H 
Biphenyl 61 H OCH3 
Biphenyl 62 H NO2 
Biphenyl 63 NO2 H 
Table 5.4 Biphenyl compounds 
 
5.3.1 Absorption spectrum of 55 
 
Compound 55 was studied in eight solvents and summary of its UV-absorption spectra is 
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given in Table 5.5. The UV-absorption spectra shown in Figure 5.3.4, Figure 5.3.5 and 
Figure 5.3.6 were recorded at a higher concentration (This was only for present the bands 
clearly, not for calculating quantum yield). The UV-absorption spectra were also recorded at a 
lower concentration (0.712 × 10
-3
 mM) as this was required for quantum yield calculation, 
see in appendix (Figure 0.1-0.6). 
 
 
Solvent abs
a
 
Chloroform 343 
Methanol 339 
Toluene 340 
Acetic acid 277
b
 
Ethylene glycol 348 
Dichloromethane 348 
n-Hexane 336 
Acetonitrile 344 
Table 5.5 UV absorption maxima for compound 55. 
a
 abs are reported at the maximum 
absorbance wavelength in nm (concentration of sample, 0.712 × 10
-3
 mM). 
b
 Shoulder at 324 
nm. 
 
Figure 5.3.4 Absorption spectrum of 55 (in CHCl3, MeOH and acetic acid) 
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Figure 5.3.5 Absorption spectrum of 55 (in toluene) 
 
Figure 5.3.6 Absorption spectrum of 55 (in ethylene glycol and MeCN) 
 
 
5.3.2 Emission spectrum of 55 
 
The absorption maximum from the UV spectrum was used as an excitation parameter to 
generate the emission spectra. After excitation at 340 nm, a single emission band for 
compound 55 was found in all solvents (except n-hexane), Table 5.6. The emission spectra 
are show in Figure 5.3.7 and Figure 5.3.8. 
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Solvent em
a
 
Chloroform 433 
Methanol 483 
Toluene 412 
Acetic acid 463 
Ethylene glycol 486 
Dichloromethane 450 
n-Hexane 374
b
 
Acetonitrile 475 
 
Table 5.6 Maximum emission bands for compound 55 after excitation at 340 nm. 
a
 em in nm. 
b
 A second emission band was observed at 390 nm (concentration of sample, 0.712 × 10
-3
 
mM). 
 
 
 
Figure 5.3.7 Emission spectra of 55 in different solvents (concentration of sample, 0.712 × 
10
-3
 mM) 
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Figure 5.3.8 Zoomed in emission spectra of 55 in acetic acid and ethylene glycol 
(concentration of sample, 0.712 × 10
-3
 mM) 
 
In order to better understand the nature of the emission our colleague, Dean St. Mart, fitted 
the emission band of 55 in chloroform using a Gaussian calculation, Figure 5.3.9. Two single 
bands were obtained indicating two possible deactivation pathways/processes. The intensity 
ratio of the two bands was 1.3: 1. We propose that the major band could be from the 
deactivation of S1 (1
st
 excited state) to S0 (ground state), as it requires less energy for the 
molecule to be excited to S1, and the minor band was from the deactivation from S2 (2
nd
 
excited state) to S1. 
16000 18000 20000 22000 24000 26000 28000 30000
0.0
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0.4
0.6
0.8
1.0
Data: fluoresce_normCHCl3
Model: Gauss 
Equation: y=y0 + (A/(w*sqrt(PI/2)))*exp(-2*((x-xc)/w)^2) 
Weighting:
y No weighting
  
Chi^2/DoF = 0.00003
R^2 =  0.99971
  
y0 0 ±0
xc1 22391.35333 ±76.14949
w1 2545.39522 ±35.68031
A1 1716.37283 ±135.73588
xc2 23388.58877 ±10.63839
w2 1847.04077 ±35.51398
A2 1323.7513 ±134.56587N
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Chi^2/DoF 3.16951E-5 
R^2 0.99971 
Peak Area Center Width Height 
--------------------------------------------------------------------------- 
1 1716.4 22391 2545.4 0.53802                                  
2 1323.8 23389 1847.0 0.57183                                  
--------------------------------------------------------------------------- 
Yoffset = 0 
Figure 5.3.9 Gaussian normalised fit for compound 55 in chloroform 
 
5.3.3 Excitation spectrum of 55 
 
Emission maximum values were used as an emission parameter to generate the excitation 
spectra for compound 55. Excitation bands for compound 55 are summarized in Table 5.7. 
The excitation spectra are show in Figure 5.4.1, Figure 5.4.2 and Figure 5.4.3. 
 
Solvent em
a
 ex
b
 
Chloroform 433 346 
Methanol 483 345 
Toluene 412 346 
Acetic acid 463 327 
Ethylene glycol 486 347 
Dichloromethane 450 346 
n-Hexane 374 336 
Acetonitrile 475 342 
 
Table 5.7 Excitation bands for compound 55. 
a
 em in nm. 
b
 ex in nm (concentration of 
sample, 0.712 × 10
-3
 mM). 
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Figure 5.4.1 Excitation spectrum of 55 in different solvents (concentration of sample, 0.712 
× 10
-3
 mM). 
 
 
Figure 5.4.2 Excitation spectrum of 55 in different solvents (concentration of sample, 0.712 
× 10
-3
 mM). 
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Figure 5.4.3 Zoomed in excitation spectrum of 55 in acetic acid and ethylene glycol 
(concentration of sample, 0.712 × 10
-3
 mM). 
 
5.3.4 Absorption spectra of compounds 56-61 
 
The biphenyl sulfones 56-61 were studied in chloroform and methanol and a summary of 
their UV-absorption spectra is given in Table 5.8. The UV-absorption spectra are shown in 
Figure 5.4.4, Figure 5.4.5 and Figure 5.4.6. 
 
 
 
Compound abs in 
CHCl3
a
 
abs in 
MeOH
a
 
56 291 284 
57 280 281 
58 295 299 
59 281 279 
60 280 276 
61 285 284 
 
Table 5.8 UV absorption maxima for compounds 56-61. 
a
 abs are reported at the maximum 
absorbance wavelength in nm (56 at 1.1 × 10
-3
 mM; 57 at 0.60 × 10
-3
 mM; 58 at 0.88 × 10
-3
 
mM; 59 at 0.96 × 10
-3
 mM; 60 at 0.35 × 10
-3
 mM; 61 at 0.86 × 10
-3
 mM) 
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Figure 5.4.4 Absorption spectrum of 56-57 in chloroform and methanol (56 at 1.1 × 10
-3
 
mM;  
57 at 0.60 × 10
-3
 mM). 
 
 
Figure 5.4.5 Absorption spectrum of 58-59 in chloroform and methanol (58 at 0.88 × 10
-3
 
mM; 59 at 0.96 × 10
-3
 mM). 
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Figure 5.4.6 Absorption spectrum of 60-61 in chloroform and methanol (60 at 0.35 × 10
-3
 
mM; 61 at 0.86 × 10
-3
 mM). 
 
5.3.5 Emission spectra of 56-61 
 
The absorption maximum from the UV spectrum was used as an excitation parameter to 
generate the emission spectra. Compounds 56-61 were excitated at 285 nm and a summary of 
their emission bands are given in Table 5.9. The emission spectra are show in Figure 5.4.7, 
5.4.8 and Figure 5.4.9. 
 
 
Compound em in 
CHCl3
a
 
em in 
MeOH
a
 
56 340 348 
57 332
b
 332
c
 
58 359 389 
59 335 345 
60 329
d
 327
e
 
61 362
f
 406
g
 
 
Table 5.9 Maximum emission bands for compounds 56-61 after excitation at 285 nm. 
a
 em in 
nm. 
b
 two shoulders at 320 nm and 347 nm. 
c
 two shoulders at 319 nm and 342 nm. 
d
 two 
shoulders at 316 nm and 341 nm. 
e
 two shoulders at 315 nm and 339 nm. 
f
 one shoulder at  
418 nm. 
g
 an unsymmetrical emission band. 
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Figure 5.4.7 Emission spectra of compounds 56-58 in chloroform and methanol (56 at 1.1 × 
10
-3
 mM; 57 at 0.60 × 10
-3
 mM; 58 at 0.88 × 10
-3
 mM). 
 
 
 
Figure 5.4.8 Emission spectrum of 59-61 in chloroform and methanol (59 at 0.96 × 10
-3
 mM; 
60 at 0.35 × 10
-3
 mM; 61 at 0.86 × 10
-3
 mM). 
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Figure 5.4.9 Zoomed in emission spectrum of 57 in chloroform and methanol 
 
5.3.6 Excitation spectrum of 56-61 
 
Emission maximum values were used as an emission parameter to generate the excitation 
spectra for compounds 56-61. Excitation bands for compound 56-61 are summarized in Table 
5.10. The excitation spectra are show in Figure 5.4.10 and Figure 5.5.1. 
 
 
Compound em in 
CHCl3
a
 
ex in 
CHCl3
a
 
em in 
MeOH
a
 
ex in 
MeOH
a
 
56 340 288 348 287 
57 332 286 332 286 
58 359 299 389 299 
59 335 284 345 284 
60 329 284 327 283 
61 362 301
b
 406 301
b
 
Table 5.10 Excitation bands for compound 56-61. 
a
 em and ex in nm. 
b
 Shoulder observed at 
273 nm. 
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Figure 5.4.10 Excitation spectra of 56-58 in chloroform and methanol (56 at 1.1 × 10
-3
 mM; 
57 at 0.60 × 10
-3
 mM; 58 at 0.88 × 10
-3
 mM). 
 
 
Figure 5.5.1 Excitation spectra of 59-61 in chloroform and methanol (59 at 0.96 × 10
-3
 mM; 
60 at 0.35 × 10
-3
 mM; 61 at 0.86 × 10
-3
 mM). 
 
Compound 62 and 63 did not exhibit any fluorescent properties, Figure 5.5.2. This is 
possibly due to the strong electron-withdrawing nature of NO2 group, the resultant existence 
of a low-lying n to π* transition and an efficient intersystem crossing process.88 Thus most 
NO2 substituted aromatic compounds are not fluorescent. The absence of detectable 
fluorescence is possibly due to a high rate of S1 (1
st
 excited state) to S0 (ground state) internal 
conversion, non-radiative decay.
88
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Figure 5.5.2 Structure of (a) 62 and (b) 63 
 
5.3.7 Photophysics of 55-61 
 
The absorption, emission and excitation spectra of compounds 55-61 were analyzed, and their 
corresponding photophysical data listed in Table 5.11.  
 
Table 5.11 Photophysical data for the biphenyl sulfones 
 
The Stokes shifts were calculated using Stokes shift = λem - λabs, where λem is the wavelength 
Compound Solvent λabs λem Stokes 
(nm) 
ε (×104 
M
-1
cm
-1
) 
Φ  
55 Chloroform 284/343 433 90 2.47 0.71 
 Methanol 339 483 144 2.89 0.18 
 Toluene 340 412 72 4.18 0.88 
 Acetic acid 277/324 463 139 4.72 0.02 
 Ethylene glycol 348 486 138 8.43 0.23 
 Dichloromethane 348 450 102 3.16 0.88 
 n-Hexane 336 374/390 38/54 3.51 0.70 
 Acetonitrile 344 475 131 2.67 0.12 
56 Chloroform 291 340 49 4.00 0.31 
 Methanol 284 348 64 3.57 0.39 
57 Chloroform 280 332 52 5.08 0.09 
 Methanol 281 332 51 3.29 0.07 
58 Chloroform 295 359 64 5.83 0.25 
 Methanol 299 389 90 7.00 0.57 
59 Chloroform 281 335 54 4.99 0.55 
 Methanol 279 345 66 4.71 0.48 
60 Chloroform 280 329 49 15.6 0.71 
 Methanol 276 327 51 7.14 0.40 
61 Chloroform 285 362/418 77/133 6.14 0.20 
 Methanol 284 406 122 3.25 0.16 
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of maximum emission from the emission spectrum and λabs is the wavelength of absorbance, 
which corresponding to the maximum emission, in UV-absorption spectrum.  
Molar extinction coefficient e was obtained from the Beer Lamber law and calculated using e 
= 1 /  l * c, where c is the concentration of the examed solution, l is the path length of the 
cuvette and 1 is the corrected maximum absorbance.  
 
Quantum yields Q were calculated using Q = QR(I/IR)(ODR/OD)(n
2
/n
2
R)
71
 where the “Q” is 
quantum yield; “I” is the integrated intensity of emission spectrum; “OD” is the optical 
density i.e. the corrected absorbance which corresponds to the maximum emission in 
UV-absorption spectrum (base line corrected using “origin” software before being applied to 
the quantum yield calculation.); “n” is the refractive index of the solvent; subscript “R” refers 
to the reference fluorophore of known quantum yield. Quinine sulfate in 0.1 M H2SO4 was 
chosen as the standard for calculating quantum yield of compound 55 and was prepared at the 
same concentration as compound 55. UV-absorption spectrum of quinine sulfate in 0.1 M 
H2SO4 was obtained along with the emission spectrum after excitation at 340 nm (same 
wavelength as used for compound 55). 2-Aminopyridine in 0.1 N H2SO4 was chosen as the 
standard for calculating the quantum yields of compounds 56-61 and was prepared at 
different concentrations (1.1 × 10
-6
 M; 0.88 × 10
-6 
M; 0.66 × 10
-6
 M; 0.35 × 10
-6
 M) to match 
the concentrations of compounds 56-61. UV-absorption spectrum of 2-aminopyridine in 0.1 
N H2SO4 was obtained; emission spectrum was obtained after excitation at 285 nm (same 
wavelength as used for compounds 56-61). 
 
Compound 55 was found to have a Stokes shift in all solvents (from 90 nm in chloroform to 
144 nm in methanol). Compound 55 had a very high quantum yield in toluene and 
dichloroform (Φ close to 0.9), a high quantum yield in chloroform and n-hexane (Φ > 0.7) 
and a high molar extinction coefficient in ethylene glycol (ε > 80 000 M-1cm-1). Compound 
56-61 all generated relatively large Stokes shifts (from 49 nm for compound 56 in chloroform 
to 122 nm for compound 61 in methanol). The quantum yield varied across compounds 56-61 
(from a low of Φ = 0.07 for compound 57 in methanol to Φ = 0.71 for compound 60 in 
chloroform). As we previously discussed on page 101, compound 61 was a mixture of two 
isomers and may explain the two large Stokes shifts obtained in chloroform (77 nm and 133 
nm). A single large Stokes shift was obtained for compound 61 in methanol (122 nm).  
5.3.8 Solvatochromic analysis, compound 55 
Solvatochromism was termed by Hantzschlater. It is a phenomenon that UV/vis/near-IR 
absorption spectra of chemical coumpounds may be influenced by the surrounding medium 
and that solvents can bring about a change in the position, intensity and shape of absorption 
bands.
89
 An initial observation of compound 55 in two solvents, chloroform and methanol, 
suggested that compound 55 may be highly solvatochromic. Subsequent quantum yield 
calculations confirmed what we had observed, namely a marked difference in quantum yield 
for compound 55 in the two solvents (Φ = 0.71 in chloroform and Φ = 0.18 in methanol).  
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As a result compound 55 underwent a solvatochromic study where it’s UV-absorption and 
fluorescence was examined in eight solvents. Photophysical data for compound 55 (Stokes 
shifts, quantum yield and extinction coefficient, Table 5.11) in different solvents were plotted 
against solvent polarity, Table 5.12.  
 
Solvent ET
30
(kcal mol
-1
)错
误！未定义书签。 
Chloroform 39.1 
Methanol 55.4 
Toluene 33.9 
Acetic acid 55.2 
Ethylene glycol 56.3 
Dichloromethane 40.7 
n-Hexane 31.0 
Acetonitrile 45.6 
Table 5.12 Solvent polarity, ET
30
 
The maximum absorbance for compound 55 was found to be insensitive to solvent polarity, 
(ET
30
).
89
  
 
The Stokes shifts were plotted against Reichardt’s solvent polarity parameter (ET
30
)
89
 to give 
an excellent linear correlation (R
2
 = 0.8941, Figure 5.5.3). The Stokes shifts were found to be 
highly solvatochromic, to solvent polarity, generating a large slope of 3.35 nm/kcal mol
-1
. 
The changes in Stokes shift resulted from changes of its emission wavelength in the different 
solvents. For example, the Stokes shift of 55 increased from 72 nm in toluene (λem = 412 nm) 
to 144 nm in methanol (λem = 483 nm).  
 
  
 
 
 
121 
 
Figure 5.5.3 Plot of Stokes shift versus ET
30 
value for compound 55 
 
The quantum yields of 55, in different solvents, were plotted against Reichardt’s solvent 
polarity parameter (ET
30
) to give a relatively linear correlation (R
2
 = 0.7121, Figure 5.5.4). 
The quantum yield was found to be highly sensitive to solvent polarity with a slope of -0.033 
mol kcal
-1
 and ranging from from Φ = 0.88 in toluene to Φ = 0.18 in methanol. The quantum 
yield of 55 was very low (Φ = 0.02) in acetic acid, even when compared to the protic solvent 
methanol (Φ = 0.18). This is probably due to the acetic acid (pKa = 4.7) protonating the 
dimethylamino group (pKaH ~ 10) which inhibits the intramolecular charge transfer (ICT) and 
hence quenches the fluorescence. The result in acetic acid is in fact supportive of an 
intramolecular charge transfer mechanism for fluorescence.  
 
 
Quantum yield vs. ET
30 
of 55 
 
Figure 5.5.4 Plot of quantum yield versus ET
30 
value for compound 55 
 
5.3.9 Mechanism of fluorescence 
 
The mechanism of fluorescence for these biphenyls is most likely via a twisted 
intramolecular charge transfer (TICT) process. Lippert and co-workers reported that 
p-(dimethylamino)-benzonitrile (DMABN) showed one emission band at around 360 nm in 
non-polar solvent and two emission bands in polar solvent with an extra band at around 
450-500 nm.
90
 This phenomenon was explained by the concept of TICT.
91
 TICT suggests 
that the donor dialkylamino transfers an electron to the acceptor cyanobenzene, and the donor 
undergoes a twist simultaneously. The donor orbital become orthogonal to the acceptor 
orbital which ensures complete electron transfer due to this twist process, Figure 5.5.5. The 
resulting state is polar and known as TICT state.
91
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Figure 5.5.5 TICT process of DMABN91 
 
 
2,4-Dichloro-6-[p-(N,N-diethylamino)biphenylyl]-1,3,5-triazine, Figure 5.5.6, is a 
fluorescent dye reported by Yan Ma and co-workers. It has a diethyl amino (electron donor) 
and triazine (electron acceptor) joined by the twistable aromatic chain and as a result exhibits 
intramolecular charge transfer character.
92
  
 
 
Figue 5.5.6 Structure of 2,4-Dichloro-6-[p-(N,N-diethylamino)biphenylyl]-1,3,5-triazine
92
 
 
Michael Maus and co-workers reported a series of biphenyls with dimethylamino (electron 
donor) and cyano group (electron acceptor) joined by the twistable biphenyl chain, Figure 
5.5.7.
93
 These compounds are similar in structure to our biphenyl sulfones where we have a 
dimethylamino donor and a sulfone acceptor linked by a biphenyl, compound 55.  
 
Figure 5.5.7 Structure of biphenyls as reported by Michael Maus
93
 
 
DFT calculations of compounds 55-63 were performed on request by our colleague Dr Elisa 
Fadda using the following method: All molecules were built with version 9.4 of Maestro 
(Academic License);
94
 their geometry was optimized with version 6.5 of TURBOMOLE
95
 at 
the b97d//def2-SVP level of theory
96
, within the resolution of the identity approximation and 
in redundant internal coordinates. b97d represents the b97 GGA functional
97
 augmented with 
Grimme dispersion contribution.
96
 The molecular orbitals images have been produced with 
version 4.5.0 of the MOLEKEL software package.
98
 These DFT calculations generated 
HOMO and LUMO energies for compounds 55-63.  
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The DFT calculations of compound 55 indicate charge transfer from the dimethylamino 
group to the phenylsulfone group upon going from HOMO to LUMO, Figure 5.5.8. DFT 
calculations of compound 56-63 were shown in the appendix. These results suggest the 
existing of a push-pull system where the dimethylamino group acts as an electron donor and 
phenylsulfone group acts as an electron acceptor in the excited state. The calculated 
HOMO-LUMO gaps (55 < 58 < 59 < 57 < 60 < 56) were inversely correlated with the Stokes 
shifts (in chloroform), Table 5.13.  
 
Figure 5.5.8 Molecular orbital plot of compound 55 
 
Compound HOMO-LUMO gaps (au) Stokes shifts (nm)
a
 
55 0.094 90 
58 0.112 64 
59 0.120 54 
57 0.121 52 
60 0.122 49 
56 0.123 49 
Table 5.13 Comparison of HOMO-LUMO gap and Stokes shift. 
a
 In chloroform. 
 
Increasing the electron donating ability of the electron donor was accompanied by a decrease 
in the HOMO-LUMO gap. These results are consistent with our prediction that these 
biphenyl compounds exhibit fluorescence via a twisted intramolecular charge transfer (TICT). 
Compound 55 is taken as an example, the donor (dimethylamino) group transfers an electron 
to the acceptor (phenylsulfone) and undergoes a twist simultaneously. The donor 
(dimethylamino) group orbital becomes orthogonal to the acceptor (phenylsulfone) orbital 
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which ensures complete electron transfer due to this twist process, Figure 5.5.9. 
Figure 5.5.9 Proposed TICT mechanism for compound 55 
 
As previously mentioned in section 5.3.9, the calculated HOMO-LUMO gaps for 55-60 were 
inversely correlation to their Stokes shift. The HOMO-LUMO gaps of compound 55-60 were 
plotted against their Stokes shifts (in chloroform) giving an excellent linear correlation (R
2
 = 
0.9978, Figure 5.6.1). These results suggested that the underlying photophysical processes 
are similar for 55-60, where stronger electron donating groups generate smaller 
HOMO-LUMO gaps and red-shifted emissions, as compared to weaker electron donating 
groups. Therefore, it may be possible for us to tailor the biphenyl system so as to further 
decrease the HOMO-LUMO gap with the aim of causing a red-shift in emission. 
 
Figure 5.6.1 Plot of Stokes shifts (in chloroform) versus HOMO-LUMO gaps 
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5.4.1 Conclusion 
 
We have developed a novel solvent-free methodology for synthesizing fluorescent biphenyl 
sulfones with a relatively short reaction time and in good yields. This methodology exploits 
an interesting electrocyclisation of bissulfonyl trienes. A new family of substituted biphenyl 
sulfones resulted. UV-absorption, emission and excitation spectra were generated for the 
family of biphenyl sulfones and their photophysical characterisitics studied (e.g. Stokes shift, 
quantum yield, molar extinction coefficients). The biphenyl sulfones with NO2 substituents 
did not exhibit fluorescence due to the strong electron withdrawing nature of the NO2 group. 
Other substituted biphenyl sulfones exhibited highly solvatochromic emissions from twisted 
intramolecular charge transfer (TICT) states. Of these substituted biphenyls, compound 55 
was found to show a very high quantum yield in toluene and dichloromethane (Φ close to 0.9) 
and high quantum yield in chloroform and n-hexane (Φ > 0.7). Compound 55 also exhibited 
large Stokes shifts (90 nm in chloroform; 144 nm in methanol; 139 nm in acetic acid; 138 nm 
in ethylene glycol; 102 nm in dichloromethane; 131 nm in acetonitrile) and high molar 
extinction coefficient in ethylene glycol (ε > 80 000 M-1cm-1). The HOMO-LUMO gaps of 
the biphenyl sulfones (compounds 55-60) were plotted against their Stokes shifts (in 
chloroform) giving an excellent linear correlation (R
2
 = 0.9978). These results suggested that 
the underlying photophysical processes are similar for 55-60, where stronger electron 
donating groups generate smaller HOMO-LUMO gaps and red-shifted emissions, as 
compared to weaker electron donating groups. In future work, it may be possible to tailor the 
electronics of this biphenyl system to further decrease the HOMO-LUMO gap with the aim 
of causing a red-shift in emission. These biphenyl systems also have potential as probes for 
reporting changes in microenvironmental polarity. 
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Chapter 6 Experimental for the synthesis of biphenyl sulfones 
 
Instrumentation 
Reagents were purchased from Sigma-Aldrich, Alfa Aesar, Acros Organics and used without 
further purification. Anhydrous DMF was purchased from Sigma Aldrich.  
 
All NMR spectra were recorded on a Bruker Avance spectrometer at a probe temperature of 
25 °C, unless otherwise stated, operating at 300 MHz for the 1H nucleus and 75 MHz for the 
13C nucleus. Proton and carbon signals were assigned with the aid of DEPT experiments for 
novel compounds. High temperature NMR spectroscopy experiments were carried out by 
heating the probe. Spectra were recorded in DMSO-d6, CDCl3 or CD3OD with Me4Si used as 
the internal standard. Chemical shifts are given in ppm downfield form the internal standard 
and coupling constants are given in Hz.  
 
Melting point analyses were carried out using a Stewart Scientific SMP1 melting point 
apparatus. 
 
Infrared (IR) spectra were recorded as KBr disks or liquid films between NaCl plates using a 
Perkin Elmer System 2000 FT-IR spectrometer in the region of 4000-370 cm
-1
. High 
resolution mass spectra (HR-MS) were performed on an Agilent-L 1200 Series coupled to a 
6210 Agilent Time-of-Flight (TOF) mass spectrometer equipped with an both a positive and 
negative electronspray source.  
 
Microanalysis was carried out using a Flash EA 1112 Series Elemental Analyser. The sample 
is burned in oxygen and a helium carrier gas at 900 
o
C in a combustion tube. 
 
Flash column chromatography was performed using silica gel 60 (Merck, 0.040-0.063 mm). 
Analytical thin layer chromatography was carried out on aluminium sheets precoated with 
Merck TLC Silica gel 60 F254.  
 
UV-vis spectra were recorded using a Unicam UV 540 spectrometer. Excitation and emission 
spectra were recorded on a JASCO FP-6300 spectrofluorometer. 
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6.1 Attempted procedures for the synthesis of 4-(phenylsulfonyl)-1,1'-biphenyl 43 
(Biphenyl 11) 
 
 
1-[(1E,3E,5E)-4,6-Bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (10 mg, 0.023 
mmol) was dissolved in toluene (3 mL). The solution was heated under microwave conditions 
at 110 
o
C for 15 minutes. The resulting solution was purified using flash chromatograph on 
silica gel with ethyl acetate/petroleum ether (50 : 50). The 
1
H NMR of the elutent showed no 
reaction. 
 
1-[(1E,3E,5E)-4,6-Bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (10 mg, 0.023 
mmol) was dissolved in toluene (3 mL). The solution was heated under microwave conditions 
at 130 
o
C for 15 minutes. The resulting solution was purified using flash chromatograph on 
silica gel with ethyl acetate/petroleum ether (50 : 50). The 
1
H NMR of the elutent showed no 
reaction. 
 
1-[(1E,3E,5E)-4,6-Bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (15 mg, 0.034 
mmol) was dissolved in toluene (1 mL). The solution was heated under microwave conditions 
at 130 
o
C for 15 minutes. The resulting solution was purified using flash chromatograph on 
silica gel with ethyl acetate/petroleum ether (50 : 50). The 
1
H NMR of the elutent showed no 
reaction. 
 
1-[(1E,3E,5E)-4,6-Bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (10 mg, 0.023 
mmol) was dissolved in dimethylformamide (3 mL). The solution was heated under 
microwave conditions at 120 
o
C for 15 minutes. The resulting solution was purified using 
flash chromatograph on silica gel with ethyl acetate/petroleum ether (50 : 50). The 
1
H NMR 
of the elutent showed no reaction. 
 
1-[(1E,3E,5E)-4,6-Bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (15 mg, 0.034 
mmol) was dissolved in NMP (1 mL). The solution was heated under microwave conditions 
at 200 
o
C for 15 minutes. The resulting solution was purified using flash chromatograph on 
silica gel with ethyl acetate/petroleum ether (50 : 50) to give a pale yellow solid. The yield 
was too low to be isolated. 
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1-[(1E,3E,5E)-4,6-Bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (14 mg, 0.032 
mmol) was dissolved in NMP (0.5 mL). The solution was heated under microwave conditions 
at 200 
o
C for 1 hour. The resulting solution was purified using flash chromatograph on silica 
gel with ethyl acetate/petroleum ether (50 : 50) to give a pale yellow solid. The yield was too 
low to be isolated. 
 
Neat 1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (14 mg, 
0.032 mmol) was heated at 115 
o
C for 5 hours and purified using flash chromatograph on 
silica gel with ethyl acetate/petroleum ether (50:50) to give a pale yellow solid. The yield was 
too low to be isolated. 
 
Neat 1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (14 mg, 
0.032 mmol) was heated 115 
o
C for 10 hours and purified using flash chromatograph on silica 
gel with ethyl acetate/petroleum ether (50:50) to give a pale yellow solid. The yield was too 
low to be isolated. 
 
Neat 1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (62 mg, 
0.142 mmol) was heated at 170 
o
C for 1 hour and purified using flash chromatograph on 
silica gel with ethyl acetate/petroleum ether (50:50) to give a pale yellow solid, 96 % yield 
(40 mg). 
 
Neat 1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (58 mg, 
0.133 mmol) was heated at 150 
o
C for 1 hour and purified using flash chromatograph on 
silica gel with ethyl acetate/petroleum ether (50:50) to give a pale yellow solid, 61 % yield 
(24 mg). 
 
Neat 1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (71 mg, 
0.163 mmol) was heated at 130 
o
C for 1 hour and purified using flash chromatograph on 
silica gel with ethyl acetate/petroleum ether (50:50). The 
1
H NMR of elutent showed no 
reaction. 
 
1-[(1E,3E,5E)-4,6-Bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (59 mg, 0.135 
mmol) was dissolved in NMP (2 mL). The solution was heated under microwave at 170 
o
C 
for 1 hour. The resulting solution was purified using flash chromatograph on silica gel with 
ethyl acetate/petroleum ether (50 : 50) to give a pale yellow solid, 45 % yield (18 mg). 
 
Neat 1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (57 mg, 
0.131 mmol) was heated at 170 
o
C for 45 minutes and purified using flash chromatograph on 
silica gel with ethyl acetate/petroleum ether (50:50) to give a pale yellow solid, 78 % yield 
(30 mg). 
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6.1.1 Synthesis of 4-(phenylsulfonyl)-1,1'-biphenyl under microwave conditions 43 
(Biphenyl 11) 
 
 
1-[(1E,3E,5E)-4,6-Bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (59 mg, 0.2 mmol) 
was dissolved in NMP, and heated under microwave conditions at 170 
o
C for 1 hour. The 
resulting solution was purified using flash chromatograph on silica gel with ethyl 
acetate/petroleum ether (50:50) to give a pale yellow solid, 45 % yield (18 mg). 
 
m.p. 150-154 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 8.03 – 7.97 (m, 4H), 7.72 – 7.68 (m, 2H), 
7.61 – 7.38 (m, 8H); 13C NMR (75 MHz, CDCl3) δ 146.2 (C), 141.7 (SO2C), 140.1 (SO2C), 
139.2 (C), 133.2 , 129.4, 129.1, 128.6, 128.2, 128.0, 127.7, 127.4; IR (KBr) 3430, 3059, 
2917, 1726, 1446, 1395, 1308 (SO2), 1155 (SO2), 1108, 1072, 843, 724, 595, 567 (SO2) cm
-1
; 
ESI-MS C18H14O2S Calc. (M + H
+
) = 295.0787, found (M + H
+
) = 295.0792; Anal. calcd for 
[C18H14O2S] C,73.44; H, 4.79; found C, 73.49; H, 4.68. 
 
6.1.2 Synthesis of 4-(phenylsulfonyl)-1,1'-biphenyl under neat condition 43 (Biphenyl 
11) 
 
 
Neat 1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 44 (62 mg, 0.14 
mmol) was heated at 170 
o
C for 1 hour. The resulting brown oil was cooled to room 
temperature and purified using flash chromatography on silica gel with ethyl 
acetate/petroleum ether (50:50) to give a pale yellow solid, 96 % yield (40 mg). 
 
m.p. 150-154 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 8.03 – 7.97 (m, 4H), 7.72 – 7.68 (m, 2H), 
7.61 – 7.38 (m, 8H); 13C NMR (75 MHz, CDCl3) δ 146.2 (C), 141.7 (SO2C), 140.1 (SO2C), 
139.2 (C), 133.2 , 129.4, 129.1, 128.6, 128.2, 128.0, 127.7, 127.4; IR (KBr) 3430, 3059, 
2917, 1726, 1446, 1395, 1308 (SO2), 1155 (SO2), 1108, 1072, 843, 724, 595, 567 (SO2) cm
-1
; 
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ESI-MS C18H14O2S Calc. (M + H
+
) = 295.0787, found (M + H
+
) = 295.0792; Anal. calcd for 
[C18H14O2S] C,73.44; H, 4.79; found C, 73.49; H, 4.68. 
 
6.2 Synthesis of Trienes 
6.2.1 Synthesis of 1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-benzene 
44 (Triene 1) 
 
 
1,3-Bisphenylsulfonyl propene (644 mg, 2 mmol), trans-cinnamaldehyde (0.25 mL, 2 mmol) 
and aluminium oxide (6.732 g, 66 mmol) were stirred in dichloromethane (5 mL) for 4 hours 
at room temperature. The resulting suspension was filtered through a pad of celite and 
extracted with dichloromethane (40 mL). The resulting solution was evaporated under 
reduced pressure and purified using flash chromatograph on silica gel with ethyl 
acetate/petroleum ether (50:50) to give a green solid, 57 % yield (495 mg). 
 
m.p.164-166 
o
C; 
1
H NMR (300 MHz, CDCl3) δ 7.78 – 7.88 (m, 3H), 7.71 – 7.78 (m, 2H), 
7.61 – 7.70 (m, 1H), 7.50 – 7.61 (m, 6H), 7.36 – 7.48 (m, 5H), 7.08 – 7.24 (m, 3H); 13C 
NMR (75 MHz, CDCl3) δ 147.8, 145.5, 139.9 (SO2ArC), 139.7 (SO2ArC), 135.0 (ArC), 
133.7, 133.6, 132.9, 132.2 (C), 130.8, 129.4, 129.3, 129.1, 128.3, 127.7, 127.5, 120.3; IR 
(KBr) 3077, 3057, 3031, 1590, 1446, 1310 (SO2), 1213, 1178, 1145 (SO2), 1072, 976, 848, 
719, 545 cm
-1
; ESI-MS Calc. (M + H
+
) = 437.0876, found (M + H
+
) = 437.0871; Anal. calcd 
for [C24H20O4S2] C, 66.03; H, 4.62; found C, 66.19; H, 4.66. 
6.2.2 Synthesis of 1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4- 
nitrobenzene 45 (Triene 2) 
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1,3-Bisphenylsulfonyl propene (96 mg, 0.3 mmol), 4-nitrocinnamaldehyde (54 mg, 0.3 mmol) 
and aluminium oxide (1009 mg, 9.9 mmol) were stirred in dichloromethane (1 mL) for 4 
hours at room temperature. The resulting suspension was filtered through a pad of celite and 
extracted with dichloromethane (40 mL). The resulting solution was evaporated under 
reduced pressure and purified using flash chromatograph on silica gel with ethyl 
acetate/petroleum ether (50:50) to give a green solid, 57 % yield (82 mg). 
 
m.p. 166-170
 o
C; 
1
H NMR (300 MHz, CDCl3) δ 8.29 – 8.25 (m, 2H), 7.84 – 7.80 (m, 3H), 
7.75 – 7.64 (m, 6H), 7.61 – 7.50 (m, 4H), 7.44 – 7.39 (m, 2H), 7.26 – 7.18 (m, 2H); 13C 
NMR (75 MHz, CDCl3) δ 148.4 (NO2ArC), 143.9, 143.5, 140.8 (ArC), 139.5 (SO2ArC), 
139.1 (SO2ArC), 135.1 (C), 134.4, 133.9, 133.9, 129.5, 129.4, 128.6, 128.5, 127.8, 127.7, 
124.4, 124.1; IR (KBr) 3429, 3068, 1602, 1517 (NO2), 1446, 1342 (NO2), 1306 (SO2), 1144 
(SO2), 1086, 989, 831, 746, 686, 601, 585 (NO2), 548 (SO2) cm
-1
; ESI-MS C24H19NO6S2 
Calc. (M + H
+
) = 482.0727, found 482.0730. 
 
6.2.3 Synthesis of 
((1E,3E,5E)-6-(2-methoxyphenyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 46 
(Triene 3) 
 
 
1,3-Bisphenylsulfonyl propene (96 mg, 0.3 mmol), 2-methoxy cinnamaldehyde (49 mg, 0.3 
mmol), and aluminium oxide (1009 mg, 9.9 mmol) were stirred in dichloromethane (1 mL) 
for 4 hours at room temperature. The resulting suspension was filtered through a pad of celite 
and extracted with dichloromethane (40 mL). The resulting solution was evaporated under 
reduced pressure and recrystallized from dichloromethane and petroleum ether, to give a 
yellow solid, 62 % yield (87 mg). 
 
m.p.162-166
 o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 7.88 – 
7.80 (m, 3H), 7.76 – 7.73 (m, 2H), 7.65 – 7.51 (m, 7H), 7.43 – 7.36 (m, 3H), 7.33 – 7.28 (m, 
1H), 7.24 – 7.09 (m, 1H), 7.04 – 6.93 (m, 2H), 3.93 (s, 3H, OCH3). 
13
C NMR (75 MHz, 
CDCl3) δ 158.4 (COCH3), 147.0, 143.5, 140.0 (SO2ArC), 139.9 (SO2ArC), 133.6, 133.5, 
132.3, 132.1, 131.0 (C), 129.6, 129.4, 129.2, 128.8, 127.7, 127.5, 123.9 (ArC), 121.0, 121.0, 
111.3, 55.7 (CH3); IR (KBr) 3436, 3008, 1585, 1481, 1309 (SO2), 1149 (SO2), 1185 (OCH3), 
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1085 (OCH3), 985, 844, 753, 687, 597, 544 (SO2) cm
-1
; ESI-MS C25H22O5S2 Calc. (M + H
+
) 
= 467.0981, found (M + H
+
) = 467.0978; Anal. calcd for [C25H22O5S] C, 64.36; H, 4.75; 
found C, 64.56; H, 4.55. 
6.2.4 Synthesis of 
((1E,3E,5E)-6-(2-nitrophenyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 47 (Triene 
4) 
 
1,3-Bisphenylsulfonyl propene (96 mg, 0.3 mmol), 2-nitro cinnamaldehyde (54 mg, 0.3 
mmol), and aluminium oxide (1009 mg, 9.9 mmol) were stirred in dichloromethane (1 mL) 
for 4 hours at room temperature. The resulting suspension was filtered through a pad of celite 
and extracted with dichloromethane (40 mL). The resulting solution was evaporated under 
reduced pressure and recrystallized from dichloromethane and petroleum ether to give a 
yellow solid, 46 % yield (67 mg). 
 
m.p. 170-174
 o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 8.09 – 
8.06 (m, 1H), 7.86 – 7.78 (m, 4H), 7.76 – 7.64 (m, 5H), 7.62 – 7.49 (m, 5H), 7.46 – 7.39 (m, 
2H), 7.22 – 7.03 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 148.0 (NO2ArC), 143.9, 141.8, 
139.5 (SO2ArC), 139.2 (SO2ArC), 134.9 (ArC), 134.2, 133.9, 133.8, 133.8, 130.8 (C), 130.6, 
129.5, 129.4, 129.1, 128.7, 127.8, 127.7, 125.3, 124.8; IR (KBr) 3429, 3062, 1608, 1523 
(NO2), 1446, 1349 (NO2), 1304 (SO2), 1147 (SO2), 1082, 952, 746, 595 (NO2), 542 (SO2) 
cm
-1
; ESI-MS C24H19NO6S2 Calc. (M + H
+
) = 482.0727, found (M + H
+
) = 482.0718. 
6.2.5 Synthesis of 
4-((1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl)-N,N-dimethylaniline 48 
(Triene 5) 
 
 
  
 
 
 
133 
 
1,3-Bisphenylsulfonyl propene (96 mg, 0.3 mmol), 4-dimethylamino cinnamaldehyde (54 mg, 
0.3 mmol), and aluminium oxide (1009 mg, 9.9 mmol) were stirred in dichloromethane (1 
mL) for 4 hours at room temperature. The resulting suspension was filtered through a pad of 
celite and extracted with dichloromethane (40 mL). The resulting solution was evaporated 
under reduced pressure and recrystallized from dichloromethane and petroleum ether to give 
a red solid, 77 % yield (111 mg). 
 
m.p. 168-172
 o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 7.85 – 
7.79 (m, 3H), 7.76 – 7.72 (m, 2H), 7.65 – 7.46 (m, 8H), 7.41 – 7.36 (m, 2H), 7.21 – 7.16 (m, 
1H), 7.03 – 6.93 (m, 2H), 6.71 – 6.67 (m, 2H), 3.08 (s, 6H, NCH3); 
13
C NMR (75 MHz, 
CDCl3) δ 152.2 (CN), 149.6, 147.9, 140.4 (SO2ArC), 140.4 (C), 133.4, 133.2, 130.6, 129.9, 
129.7, 129.3, 129.1, 127.6, 127.2, 122.8 (ArC), 115.1, 111.9, 40.1 (NCH3); IR (KBr) 3430, 
2914, 1572, 1446, 1372 (N(CH3)2), 1306 (SO2), 1166 (SO2) 1147 (N(CH3)2), 1084, 978, 841, 
752, 601 (SO2) cm
-1
; ESI-MS C26H25NO4S2 Calc. (M + H
+
) = 480.1298, found (M + H
+
) = 
480.1322. 
6.2.6 Synthesis of 
((1E,3E,5E)-6-(4-chlorophenyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 49 (Triene 
6) 
 
1,3-Bisphenylsulfonyl propene (96 mg, 0.3 mmol), 4-chlorocinnamaldehyde (50 mg, 0.3 
mmol), and aluminium oxide (1009 mg, 9.9 mmol) were stirred in dichloromethane (1 mL) 
for 4 hours at room temperature. The resulting suspension was filtered through a pad of celite 
and extracted with dichloromethane (40 mL). The resulting solution was evaporated under 
reduced pressure and recrystallized from dichloromethane and petroleum ether to give a 
green/yellow solid, 43 % yield (61 mg). 
 
m.p. 128-132 
o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 7.83 – 
7.79 (m, 3H), 7.74 – 7.64 (m, 3H), 7.61 – 7.48 (m, 6H), 7.44 – 7.39 (m, 4H), 7.22 – 7.07 (m, 
3H); 
13
C NMR (75 MHz, CDCl3) δ 146.2, 145.1, 139.8 (SO2ArC), 139.5 (SO2ArC), 136.8 
(CCl,), 133.8, 133.6, 133.4 (ArC), 133.1, 132.6 (C), 129.5, 129.5, 129.4, 129.3, 128.9, 127.7, 
127.5, 120.7; IR (KBr) 3426, 1602, 1308 (SO2), 1145 (SO2), 1085, 843, 752 (Cl), 601 (SO2) 
cm
-1
; ESI-MS C24H19ClO4S2 Calc. (M + H
+
) = 471.0486, found (M + H
+
) = 471.0490; Anal. 
calcd for [2(C24H19ClO4S2) · H2O] C, 60.05; H, 4.20; found C, 60.08; H, 3.65. Calibration of 
H2O is based on the 
1
H NMR. 
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6.2.7 Synthesis of 
((1E,3E,5E)-6-(4-methoxyphenyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 50 
(Triene 7) 
 
1,3-Bisphenylsulfonyl propene (96 mg, 0.3 mmol), 4-methoxycinnamaldehyde (49 mg, 0.3 
mmol), and aluminium oxide (1009 mg, 9.9 mmol) were stirred in dichloromethane (1 mL) 
for 4 hours at room temperature. The resulting suspension was filtered through a pad of celite 
and extracted with dichloromethane (40 mL). The resulting solution was evaporated under 
reduced pressure and recrystallized from dichloromethane and petroleum ether to give a 
yellow/green solid, 37 % yield (52 mg). 
 
m.p. 166-170 
o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 7.87 – 
7.80 (m, 3H), 7.76 – 7.72 (m, 2H), 7.68 – 7.51 (m, 7H), 7.44 – 7.37 (m, 2H), 7.24 – 7.15 (m, 
2H), 7.10 – 7.04 (m, 1H), 7.00 – 6.92 (m, 2H), 3.87 (s, 3H, OCH3); 
13
C NMR (75 MHz, 
CDCl3) δ 162.0 (COCH3), 148.0, 146.5, 140.0 (SO2ArC), 139.9 (SO2ArC), 133.6, 133.5, 
131.7, 130.3 (C), 130.2, 129.4, 129.3, 129.2, 127.8 (ArC), 127.7, 127.4, 118.0, 114.7; IR 
(KBr) 3438, 3066, 1588, 1307 (SO2), 1257 (OCH3), 1149 (SO2), 1085 (OCH3), 851, 740, 602 
(SO2) cm
-1
; ESI-MS C25H22O5S2 Calc. (M + H
+
) = 467.0981, found (M + H
+
) = 467.0987; 
Anal. calcd for [3(C25H22O5S2) · H2O] C, 63.54; H, 4.83; found C, 63.09; H, 4.37. 
Calibration of H2O is based on the 
1
H NMR. 
6.2.8 Synthesis of 
4-((1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl)benzonitrile 51 (Triene 8) 
 
1,3-Bisphenylsulfonyl propene (139 mg, 0.43 mmol), 4-cyanocinnamaldehyde 54 (68 mg, 
0.43 mmol), and aluminium oxide (1458 mg, 14.3 mmol) were stirred in dichloromethane (2 
mL) for 4 hours at room temperature. The resulting suspension was filtered through a pad of 
celite and extracted with dichloromethane (40 mL). The resulting solution was evaporated 
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under reduced pressure and recrystallized from dichloromethane and petroleum ether to give 
a pale green solid, 29 % yield (58 mg). 
 
m.p. 156-160 
o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 7.88 – 
7.79 (m, 3H), 7.74 – 7.68 (m, 5H), 7.66 – 7.62 (m, 2H), 7.60 – 7.50 (m, 4H), 7.44 – 7.39 (m, 
2H), 7.22 – 7.16 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 144.5, 143.7, 139.5 (SO2ArC), 
139.2 (SO2ArC), 139.0 (ArC), 134.7 (C), 134.2, 133.9 , 133.9, 132.8, 129.5, 129.4, 128.6, 
128.4, 127.8, 127.7, 123.5, 118.3 (CN), 113.6 (CCN); IR (KBr) 3414, 3069, 2223 (CN), 
1605, 1445 1307 (SO2), 1287, 1145 (SO2), 1085, 972, 846, 718, 684, 585, 545 (SO2) cm
-1
; 
ESI-MS C25H19NO4S2 Calc. (M + H
+
) = 462.0828, found (M + H
+
) = 462.0832. 
 
6.2.9 Synthesis of methyl 
4-((1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl)benzoate 52 (Triene 9) 
 
 
1,3-Bisphenylsulfonyl propene (96 mg, 0.3 mmol), 4-(3-oxo-propenyl)-benzoic acid methyl 
ester 64 (57 mg, 0.3 mmol), and aluminium oxide (1009 mg, 9.9 mmol) were stirred in 
dichloromethane (2 mL) for 4 hours at room temperature. The resulting suspension was 
filtered through a pad of celite and extracted with dichloromethane (40 mL). The resulting 
solution was evaporated under reduced pressure and recrystallized from dichloromethane and 
petroleum ether to give a yellow/green solid, 32 % yield (48 mg). 
 
m.p. 168-172
 o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 8.11 – 
8.07 (m, 2H), 7.85 – 7.81 (m, 3H), 7.76 – 7.72 (m, 2H), 7.70 – 7.53 (m, 7H), 7.67 – 7.39 (m, 
2H), 7.25 – 7.15 (m, 3H), 3.95 (s, 3H, OCH3); 
13
C NMR (75 MHz, CDCl3) δ 166.3 (C=O), 
145.9, 144.5, 139.7 (SO2ArC), 139.4 (SO2ArC), 139.0 (CC(O)OCH3), 133.8, 133.7, 133.6 
(C), 133.6, 131.6 (ArC), 130.3, 129.5, 129.3, 128.8, 128.0, 127.8, 127.6, 122.4, 52.4 (CH3); 
IR (KBr) 3430, 3004, 2813, 1718 (C(O)OCH3), 1683, 1425, 1316 (SO2), 1288 (C(O)OCH3), 
1128 (SO2), 1107 (C(O)OCH3), 982, 760, 691, 584 (SO2) cm
-1
; ESI-MS C26H22O6S2 Calc. 
(M + H
+
) = 495.0931, found (M + H
+
) = 495.0920; Anal. calcd for [2(C26H22O6S2) · H2O] C, 
62.01; H, 4.60; found C, 62.20; H, 5.08. The calibration of H2O is based on the 
1
H NMR. 
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6.2.10 Synthesis of ((1E,3E,5E)-6-(p-tolyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 
53 (Triene 10) 
 
 
3-p-Tolyl-propenal 65 (72 mg, 0.49 mmol), 1,3-bisphenylsulfonyl propene (128 mg, 0.4 
mmol) and aluminium oxide (1346 mg, 13.2 mmol) were stirred in dichloromethane (3 mL) 
for 4 hours at room temperature. The resulting suspension was filtered through a pad of celite 
and extracted with dichloromethane (40 mL). The resulting solution was evaporated under 
reduced pressure and recrystallized from dichloromethane and petroleum ether to give a 
yellow solid, 26 % yield (47 mg). 
 
m.p. 148-152
 o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 7.84 – 
7.80 (m, 3H), 7.74 – 7.72 (m, 2H), 7.67 – 7.63 (m, 2H), 7.61 – 7.51 (m, 4H), 7.47 – 7.38 (m, 
4H), 7.25 – 7.20 (m, 2H), 7.15 – 7.07 (m, 2H), 2.41 (s, 3H, CH3); 
13
C NMR (75 MHz, CDCl3) 
δ 148.2, 146.2, 141.7 (C), 139.9 (SO2ArC), 139.7 (SO2ArC), 133.7, 133.5, 132.3, 131.3 
(ArC), 129.9, 129.5, 129.3, 129.2, 128.4, 127.7, 127.5, 119.3, 21.7 (CH3); IR (KBr) 3425, 
3067, 1591, 1446 (CH3), 1308 (SO2), 1143 (SO2), 1084, 988, 846, 740, 687, 602, 566 (SO2) 
cm
-1
; ESI-MS C25H22O4S2 Calc. (M + H
+
) = 451.1032, found (M + H
+
) = 451.1022. 
 
6.2.11 Synthesis of 4-cyanocinnamaldehyde 54 
99
 
 
 
A solution of 4-formylbenzonitrile (255 mg, 1.95 mmol) and (triphenylphosphoranylidene) 
acetaldehyde (550 mg, 1.73 mmol) in tetrahydrofuran (10 mL) was refluxed for 24 hours. 
The resulting solution was evaporated under reduced pressure and purified using flash 
chromatograph on silica gel eluting with ethyl acetate/petroleum ether (10:90–30:70) to give 
a white solid, 47 % yield (128 mg). 
 
1
H NMR (300 MHz, CDCl3) δ 9.78 (d, J = 7.5 Hz, 1H, C(O)H), 7.77 – 7.70 (m, 4H, Ar), 
7.54 (d, J = 16.1 Hz, 1H, PhCH=CH), 6.80 (dd, J = 16.1, 7.5 Hz, 1H, CH=CHC(O)H); 
ESI-MS C10H7NO Calc. (M + H
+
) = 158.0600, found (M + H
+
) = 158.0604. Matches known 
data.
99
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6.3 Synthesis of biphenyl sulfones 
6.3.1 Synthesis of N,N-dimethyl-4'-(phenylsulfonyl)-[1,1'-biphenyl]-4-amine 55 
(Biphenyl 12) 
 
 
Neat 4-((1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl)-N,N-dimethylaniline 48 
(61 mg, 0.13 mmol) was stirred at 170 
o
C for 1 hour. The resulting brown oil was cooled to 
room temperature and purified using flash chromatography on silica gel with ethyl 
acetate/petroleum ether (50:50) and recrystallized from dichloromethane and petroleum ether 
to give a pale yellow solid, 42 % yield (18 mg). 
 
m.p. 204-208
 o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 7.99 – 
7.92 (m, 4H), 7.68 – 7.64 (m, 2H), 7.59 – 7.43 (m, 5H), 6.83 – 6.76 (m, 2H), 3.01 (s, 6H, 
NCH3); 
13
C NMR (75 MHz, CDCl3) δ 150.7 (CH3NC), 146.2 (SO2ArC), 142.1 (SO2ArC), 
138.2 (ArC), 133.0, 129.3, 128.2, 128.0, 127.5, 126.5, 112.5, 40.4 (CH3); IR (KBr) 3415, 
2922, 1612, 1588, 1446, 1369 (N(CH3)2), 1307 (SO2), 1261 (N(CH3)2), 1153 (SO2), 807, 739, 
621, 576 (SO2) cm
-1
; ESI-MS C20H19NO2S Calc. (M + H
+
) = 338.1209, found 338.1210. 
6.3.2 Synthesis of 4-methyl-4'-(phenylsulfonyl)-1,1'-biphenyl 56 (Biphenyl 13) 
 
 
Neat ((1E,3E,5E)-6-(p-tolyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 53 (34 mg, 0.075 
mmol) was stirred at 170 
o
C for 1 hour. The resulting brown oil was cooled to room 
temperature and purified using flash chromatography on silica gel with dichloromethane and 
recrystallized from dichloromethane and petroleum ether to give a white solid 35 % (8 mg). 
 
m.p. 154-158
 o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 8.04 – 
7.97 (m, 3H), 7.73 – 7.66 (m, 2H), 7.61 – 7.45 (m, 5H), 7.28 – 7.25 (m, 3H), 2.40 (s, 3H, 
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CH3 ); 
13
C NMR (75 MHz, CDCl3) δ 146.1 (C), 141.8 (SO2C), 139.7 (SO2C), 138.7 (C), 
136.2 (CH3C), 133.2, 129.8, 129.3, 128.2, 127.7, 127.6, 127.2, 21.2 (CH3); IR (KBr) 3431, 
3025, 1594, 1448 (CH3), 1393 (CH3), 1321, 1308 (SO2), 1155 (SO2), 1108, 805, 749, 630, 
580, 562 (SO2) cm
-1
; ESI-MS C19H16O2S Calc. (M + H
+
) = 309.0944, found (M + H
+
) = 
309.0945 Anal. calcd for [3(C19H16O2S) · H2O] C, 72.58; H, 5.34; found C, 73.05; H, 4.94. 
The calibration of H2O is based on the 
1
H NMR. 
6.3.3 Synthesis of methyl 4'-(phenylsulfonyl)-[1,1'-biphenyl]-4-carboxylate 57 (Biphenyl 
14) 
 
Neat methyl 4-((1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl)benzoate 52 (42 mg, 
0.085 mmol) was stirred at 170 
o
C for 1 hour. The resulting brown oil was cooled to room 
temperature and purified using flash chromatography on silica gel with dichloromethane and 
recrystallized from dichloromethane and petroleum ether to give a white solid 60 % yield (14 
mg). 
 
m.p. 204-208
 o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 8.14 – 
8.11 (m, 2H), 8.06 – 7.97 (m, 4H), 7.75 – 7.72 (m, 2H), 7.65 – 7.50 (m, 5H), 3.95 (s, 3H, 
OCH3); 
13
C NMR (75 MHz, CDCl3) δ 165.6 (C=O), 143.9 (ArC), 142.4 (ArC), 140.5 
(SO2ArC), 134.0 (SO2ArC), 132.3, 129.3, 129.1 (CC=O), 128.4, 127.3, 127.1, 126.7, 126.3, 
52.3 (CH3); IR (KBr) 3433, 3065, 1714 (C(O)OCH3), 1609, 1431, 1321 (SO2), 1280 
(C(O)OCH3), 1157 (SO2), 1108 (C(O)OCH3), 1073, 834, 771, 732, 603, 544 (SO2) cm
-1
; 
ESI-MS C20H16O4S Calc. (M + H
+
) = 353.0842, found (M + H
+
) = 353.0825; Anal. calcd for 
[2(C20H16O4S) ·3H2O] C, 63.31; H, 5.05; found C, 62.81; H, 4.66. Calibration of H2O is base 
on the 
1
H NMR. 
6.3.4 Synthesis of 4-methoxy-4'-(phenylsulfonyl)-1,1'-biphenyl 58 (Biphenyl 15) 
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Neat ((1E,3E,5E)-6-(4-methoxyphenyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 50 (46 
mg, 0.099 mmol) was stirred at 170 
o
C for 1 hour. The resulting brown oil was cooled to 
room temperature and purified using flash chromatography on silica gel with 
dichloromethane and recrystallized from dichloromethane and petroleum ether to give a 
white solid 62 % (20 mg). 
 
m.p. 170-174
 o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 8.00 – 
7.95 (m, 4H), 7.68 – 7.64 (m, 2H), 7.60 – 7.48 (m, 5H), 7.01 – 6.96 (m, 2H), 3.86 (s, 3H, 
OCH3); 
13
C NMR (75 MHz, CDCl3) δ 160.2 (CH3OC), 145.8 (C), 141.8 (C), 139.3 (C), 
133.2, 131.5 (C), 129.3, 128.5, 128.2, 127.6, 127.3, 114.5, 55.4 (CH3); IR (KBr) 3425, 3066, 
1605, 1589, 1485, 1448, 1392, 1307 (SO2), 1255 (OCH3), 1152 (SO2), 1107, 1033 (OCH3), 
825, 747, 629, 583, 563 (SO2) cm
-1
; ESI-MS C19H16O3S Calc. (M + H
+
) = 325.0893, found 
(M + H
+
) = 325.0896; Anal. calcd for [2(C19H16O3S) ·H2O] C, 68.45; H, 5.08; found C, 
68.11; H, 4.94. The calibration of H2O is based on 
1
H NMR. 
 
 
6.3.5 Synthesis of 4-chloro-4'-(phenylsulfonyl)-1,1'-biphenyl 59 (Biphenyl 16) 
 
 
Neat ((1E,3E,5E)-6-(4-chlorophenyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 49 (53 
mg, 0.11 mmol) was stirred at 170 
o
C for 1 hour. The resulting brown oil was cooled to room 
temperature and purified using flash chromatography on silica gel with ethyl 
acetate/petroleum ether (50:50) and recrystallized from dichloromethane and petroleum ether 
to give a pale yellow solid, 50 % yield (18 mg). 
 
m.p. 162-166
 o
C (dichloromethane/petroleum); 
1
H NMR (300 MHz, CDCl3) δ 8.04 – 7.97 (m, 
4H), 7.74 – 7.64 (m, 2H), 7.61 – 7.40 (m, 7H); 13C NMR (75 MHz, CDCl3) δ 144.9 (ClC), 
141.6 (SO2ArC), 140.5 (SO2ArC), 137.6 (ArC), 134.9 (ArC), 133.3, 129.4, 129.3, 128.6, 
128.3, 127.8, 127.7; IR (KBr) 3429, 3063, 1593, 1477, 1389, 1318 (SO2), 1158 (SO2), 1107, 
1002, 816, 781, 718 (Cl), 604, 572 (SO2) cm
-1
; ESI-MS C18H13ClO2S Calc. (M + H
+
) = 
329.0398, found  (M + H
+
) = 329.0395. 
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6.3.6 Synthesis of 4'-(phenylsulfonyl)-[1,1'-biphenyl]-4-carbonitrile 60 (Biphenyl 17) 
 
 
Neat 4-((1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl)benzonitrile 51 (60 mg, 0.13 
mmol) was stirred at 170 
o
C for 1 hour. The resulting brown oil was cooled to room 
temperature and purified using flash chromatography on silica gel with dichloromethane and 
recrystallized from dichloromethane and petroleum ether to give a white solid 31 % yield (13 
mg). 
 
m.p. 186-190
 o
C (dichloromethane/petroleum ether), 
1
H NMR (300 MHz, CDCl3) δ 8.08 – 
7.97 (m, 3H), 7.78 – 7.45 (m, 9H), 7.19 – 7.08 (m, 1H); 13C NMR (75 MHz, CDCl3) δ 144.0 
(ArC), 143.6 (ArC), 141.6 (SO2ArC), 141.3 (SO2ArC), 133.5, 132.9, 129.5, 128.5, 128.2, 
128.1, 127.8, 118.5 (CN), 112.3 (NCC); IR (KBr) 3429, 2227 (CN), 1592, 1391, 1308 (SO2), 
1156 (SO2), 823, 745, 616, 562 (SO2) cm
-1
; ESI-MS C19H13NO2S Calc. (M + Na
+
) = 
342.0559, found (M + Na
+
) = 342.0570. 
 
6.3.7 Synthesis of 2-methoxy-4'-(phenylsulfonyl)-1,1'-biphenyl 61 (Biphenyl 18) 
 
 
Neat ((1E,3E,5E)-6-(2-methoxyphenyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 46 (77 
mg, 0.165 mmol), was stirred at 170 
o
C for 1 hour. The resulting brown oil was cooled to 
room temperature and purified using flash chromatography on silica gel with ethyl 
acetate/petroleum ether (30:70) to give a white solid, 39 % yield (21 mg).  
 
m.p. 22-26
 o
C; 
1
H NMR (300 MHz, CDCl3) δ 8.01 – 7.93 (m, 4H), 7.67 – 7.44 (m, 5H), 7.40 
– 7.38 (m, 1H), 7.25 – 7.15 (m, 2H), 7.05 – 6.95 (m, 1H), 3.78 (s, 3H, OCH3).
13
C NMR (75 
MHz, CDCl3) δ 156.4 (COCH3), 156.3 (COCH3), 143.8 (SO2ArC), 142.8 (SO2ArC), 141.8 
(SO2ArC), 141.7 (SO2ArC), 140.0 (ArC), 139.6 (ArC), 137.7 (ArC), 135.7, 135.0, 133.2, 
133.2, 130.8, 130.4, 130.3, 129.9, 129.3, 129.3, 129.1, 128.8, 127.8, 127.7, 127.4, 127.4, 
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126.2, 125.5 (ArC), 121.1, 112.3, 111.3, 55.8 (OCH3), 55.5 (OCH3); IR (KBr) 3438, 3008, 
1596, 1478, 1383, 1319 (SO2), 1264 (OCH3), 1156 (SO2), 1106, 1023 (OCH3), 839, 751, 687, 
598 (SO2) cm
-1
; ESI-MS C19H16O3S Calc. (M + H
+
) = 325.0893, found (M + H
+
) = 325.0905; 
Anal. calcd for [4(C19H16O3S) ·H2O] C, 69.38; H, 5.06; found C, 69.58; H, 5.48. Calculation 
of H2O is based on 
1
H NMR. 
6.3.8 Synthesis of 2-nitro-4'-(phenylsulfonyl)-1,1'-biphenyl 62 (Biphenyl 19) 
 
Neat ((1E,3E,5E)-6-(2-nitrophenyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 47 (45 mg, 
0.0936 mmol) was stirred at 170 
o
C for 1 hour. The resulting brown oil was cooled to room 
temperature and purified using flash chromatography on silica gel with dichloromethane and 
recrystallized from dichloromethane and petroleum ether to give a white solid 31 % yield (10 
mg). 
 
m.p. 118-122
 o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 8.10 – 
7.94 (m, 5H), 7.81 – 7.52 (m, 5H), 7.49 – 7.34 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 148.6 
(NO2C), 142.8 (NO2CC), 141.3 (SO2C), 141.2 (SO2C), 134.8 (NO2CCC), 133.5, 132.9, 131.9, 
129.5, 129.3, 128.9, 128.0, 127.8, 124.6; IR (KBr) 3430, 1632, 1525 (NO2), 1351 (SO2), 
1317 (NO2), 1156 (SO2), 1107, 735, 595 (NO2), 565 (SO2) cm
-1
; ESI-MS C18H13NO4S Calc. 
(M + H
+
) = 340.0638, found (M + H
+
) = 340.0645; Anal. calcd for [2(C18H13NO4S) · H2O] C, 
62.06; H, 4.05; N, 4.02; found C, 62.17; H, 3.71; N, 3.89. The calibration is based on the 
1
H 
NMR. 
6.3.9 Synthesis of 4-nitro-4'-(phenylsulfonyl)-1,1'-biphenyl 63 (Biphenyl 20) 
 
 
Neat 1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl]-4-nitrobenzene 45 (58 mg, 
0.12 mmol) was stirred at 170 
o
C for 1 hour. The resulting brown oil was cooled to room 
temperature and purified using flash chromatography on silica gel with ethyl 
acetate/petroleum ether (20:80–50:50) and recrystallized from dichloromethane and 
petroleum ether to give a white solid, 40 % yield (21 mg). 
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m.p. 198-202
 o
C (dichloromethane/petroleum ether); 
1
H NMR (300 MHz, CDCl3) δ 8.35 – 
8.30 (m, 2H), 8.11 – 7.98 (m, 4H), 7.84 – 7.70 (m, 4H), 7.65 – 7.51 (m, 3H); 13C NMR (75 
MHz, CDCl3) δ 147.8 (NO2C), 145.4 (NO2CCHCHC), 143.6 (SO2ArC), 141.8 (SO2ArC), 
141.3 (SO2CCHCHC), 133.5, 129.4, 128.5, 128.3, 128.3, 127.7, 124.3; IR (KBr) 3420, 3071, 
1592, 1518 (NO2), 1338 (NO2), 1315 (SO2), 1155 (SO2), 1107, 832, 730, 601 (NO2), 571 
(SO2) cm
-1
; ESI-MS C18H13NO4S (M + H
+
) = 340.0638, found (M + H
+
) = 340.0645. 
 
6.4.1 Synthesis of 4-(3-oxo-propenyl)-benzoic acid methyl ester 64 
99
 
 
 
4-Formyl-benzoic acid methyl ester (338 mg, 2.05 mmol) and (triphenylphosphoranylidene) 
acetaldehyde (625 mg, 2.05 mmol) were refluxed in toluene (7 mL) for 24 hours. The 
resulting solution was evaporated under reduced pressure and purified using flash 
chromatography on silica gel with ethyl acetate/petroleum ether (100:20) to give a light green 
solid, 34 % yield (134 mg). 
 
1
H NMR (300 MHz, CDCl3) δ 9.75 (d, J = 7.6 Hz, 1H, C(O)H), 8.11 – 8.08 (m, 2H, Ar), 
7.65 – 7.62 (m, 2H, Ar), 7.51 (d, J = 16.0 Hz, 1H, PhCH=CH), 6.78 (dd, J = 16.0, 7.6 Hz, 1H, 
CH=CHC(O)H), 3.94 (s, 3H, CH3); ESI-MS C11H10O3 Calc. (M + H
+
) = 191.0703 found (M 
+ H
+
) = 191.0706. Matches known data.
99
 
 
6.4.2 Synthesis of 3-p-tolyl-propenal 65
99
 
 
 
4-Methyl-benzaldehyde (0.18 mL, 1.5 mmol) and (triphenylphosphoranylidene)acetaldehyde 
(456 mg, 1.5 mmol) were dissolved in toluene and refluxed for 24 hours. The resulting 
solution was evaporated under reduced pressure and purified using flash chromatography on 
silica gel with ethyl acetate/petroleum ether (100:20) to give a yellow oil, 64 % yield (142 
mg). 
1
H NMR (300 MHz, CDCl3) δ 9,63 (d, J = 7.8 Hz, 1H, C(O)H), 7.42 (d, J = 3.5 Hz, 1H, 
PhCH=CH), 7.33 (d, J = 7.9 Hz, 2H, Ar), 7.27 (d, J = 7.9 Hz, 2H, Ar), 6.64 (dd, J = 16.0, 7.8 
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Hz, 1H, CH=CHC(O)H), 2.35 (s, 3H, CH3); ESI-MS C10H10O Calc. (M + H
+
) = 147.0804, 
found (M + H
+
) = 147.0810. Matches known data.
100
 
6.3 General method for the fluorescence study of biphenyl compounds 
6.3.1 Preparation of solutions 
Biphenyl 55 (2.4 mg) was weighed out and dissolved in chloroform (100 mL) using a 100 mL 
volumetric flask. The resulting solution, solution A, was stored in dark as a parent solution. 
Solution A (1 mL) was transferred to another 100 mL volumertric flask and made up to 100 
mL using chloroform. The resulting solution B was then examined in the fluorescence study.  
 
Solution A (0.1 mL) was transferred to a 10 mL volumetric flask and gently blown dry. 
Methanol (10 mL) was added to the volumetric flask and shaken to ensure complete 
dissolution of biphenyl 55. The resulting solution was then examined in the fluorescence 
study.  
 
Solutions of biphenyl 55 were prepared in different solvents at same concentration (0.00024 
mg/mL, 0.712 × 10
-3
 mM) using this method. This method was applied in the preparation of 
biphenyl 55 solutions in toluene, acetic acid, ethylene glycol, dichloromethane, n-hexane and 
acetonitrile and also to all biphenyls (56-61) in chloroform and methanol.  
6.3.2 Fluorescence study 
A UV-vis spectrum of solution B of biphenyl 55 (in chloroform) was obtained using a 
Unicam UV 540 spectrometer. The UV-vis spectrum was recorded with a maximum 
absorption at 340 nm. The fluorescence (excitation and emission spectra) for solution B was 
obtained using a JASCO FP-6300 spectrofluorometer.  The maximum absorption of 340 nm 
for solution B was used as an excitation parameter to generate the emission spectrum. 
Emission maximum of solution B was recorded at 433 nm. This emission maximum of 433 
nm for solution B was then used as an emission parameter to generate the excitation spectrum, 
with a maximum at 346 nm. This method was applied to solutions of biphenyl 55 in methanol 
toluene, acetic acid, ethylene glycol, dichloromethane, n-hexane and acetonitrile and also to 
all biphenyls (56-61) in chloroform and methanol.  
 
Quantum yields Q were calculated using Q = QR(I/IR)(ODR/OD)(n
2
/n
2
R) where the “Q” is 
quantum yield; “I” is the integrated intensity of emission spectrum (which was calculated 
using “origin” software); “OD” is the optical density, it is the corrected absorbance which 
corresponds to the maximum emission in UV-absorption spectrum (base line corrected using 
“origin” software before being applied to the quantum yield calculation.); “n” is the refractive 
index of the solvent; subscript “R” refers to the reference fluorophore of known quantum 
yield.  
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The intergrated intensity of solution B was calculated 15784.32109; “OD” of solution B is 
0.01757; n
2
 of solution B is 1.4458
2
. 
 
Quinine sulfate in 0.1 M H2SO4 was chosen as the reference for calculating quantum yield of 
biphenyl 55 and was prepared at the same concentration as solution B and called solution C. 
UV-absorption spectrum of solution C was obtained along with the emission spectrum after 
excitation at 340 nm (same wavelength as used for biphenyl 55). The integrated intensity of 
solution C was calculated 5754.789124; “ODR” of solution C is 0.0445; n
2
R of solution C is 
1.355
2
; quantum yield QR was 0.577. Therefore the quantum yield of solution B was 
calculated = (15784.32 109/ 5754.789124) × (0.01757 / 0.0445) × (1.4458
2
 / 1.355
2
) × 0.58 = 
0.71. 
 
The reference material should have maximum absorption (excitation parameter) close to 
sample at the same temperature as the reference material was excited at the same wavelength 
as the sample. 
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Appendix 
Selected spectra 
 
Spectra 1: 
1
H NMR of ((1E,3E,5E)-6-(2-Nitrophenyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 47 
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Spectra 2: 
1
H NMR of 4-((1E,3E,5E)-4,6-Bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl)-N,N-dimethylaniline 
48 
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Spectra 3: 
1
H NMR of ((1E,3E,5E)-6-(4-Chlorophenyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 49 
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Spectra 4: 
1
H NMR of ((1E,3E,5E)-6-(4-Methoxyphenyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 
50 
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Spectra 5:
 1
H NMR of 4-((1E,3E,5E)-4,6-Bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl)benzonitrile 51 
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Spectra 6: 
1
H NMR of Methyl 4-((1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl)benzoate 52 
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Spectra 7: 
1
H NMR of ((1E,3E,5E)-6-(p-Tolyl)hexa-1,3,5-triene-1,3-diyldisulfonyl)dibenzene 53 
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Spectra 8: 
1
H NMR of N,N-dimethyl-4'-(phenylsulfonyl)-[1,1'-biphenyl]-4-amine 55 
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 Spectra 9: 
1
H NMR of 4-Methyl-4'-(phenylsulfonyl)-1,1'-biphenyl 56 
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Spectra 10: 
1
H NMR of Methyl 4'-(phenylsulfonyl)-[1,1'-biphenyl]-4-carboxylate 57 
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Spectra 11: 
1
H NMR of 
1
H NMR of 4-Methoxy-4'-(phenylsulfonyl)-1,1'-biphenyl 58 
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Spectra 12: 
1
H NMR of 4'-(Phenylsulfonyl)-[1,1'-biphenyl]-4-carbonitrile 60 
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Spectra 13: 
1
H NMR of 2-methoxy-4'-(phenylsulfonyl)-1,1'-biphenyl 61 
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Spectra 14: 
1
H NMR of 2-Nitro-4'-(phenylsulfonyl)-1,1'-biphenyl 62 
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Spectra 15: 
1
H NMR of 4-Nitro-4'-(phenylsulfonyl)-1,1'-biphenyl 63 
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UV-absorption spectra of compound 55 recorded at a lower concentration  
The UV-absorption spectra were also recorded at a lower concentration (0.712×10
-3
 mM) as 
this was required for quantum yield calculation, Figure 0.1-0.6 
 
 
Figure 0.1 Absorption spectra of 55 (in chloroform at 0.712×10
-3
 mM) 
 
 
Figure 0.2 Absorption spectra of 55 (in methanol and acetic acid at 0.712×10
-3
 mM) 
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Figure 0.3 Absorption spectra of 55 (in ethylene glycol, hexane and acetonitrile at 0.712×10
-3
 
mM) 
 
 
Figure 0.4 Absorption spectra of 55 (in toluene at 0.712×10
-3
 mM) 
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Figure 0.5 Absorption spectra of 55 (in dichloromethane at 0.712×10
-3
 mM) 
 
Figure 0.6 Absorption spectra of 55 (in n-hexane at 0.712×10
-3
 mM) 
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Molecular orbital energies 
 63 
 
HOMO                               LUMO 
           E = -0.235 au                           E = -0.127 au 
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60 
 
HOMO                                  LUMO 
E = -0.215 au                            E = -0.093 au 
57 
 
HOMO                               LUMO 
          E = -0.222 au                          E = -0.101 au 
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59 
 
HOMO                           LUMO 
E = -0.230 au                      E = -0.110 au 
58 
 
               HOMO                                LUMO 
             E = -0.195 au                            E = -0.083 au 
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61 
 
 
HOMO of isomer a                       LUMO of isomer a 
E = -0.199 au                            E = -0.055 au 
 
 
HOMO of isomer b                        LUMO of isomer c 
E = -0.198 au                           E = -0.082 au 
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62 
 
HOMO                            LUMO 
            E = -0.230 au                        E = -0.119 au 
 
56 
 
HOMO                                LUMO 
E = -0.209 au                          E = -0.086 au 
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Table 0.11: Crystal data for 1-[(1E,3E,5E)-4,6-bis(phenylsulfonyl)hexa-1,3,5-trien-1-yl] 
-4-nitrobenzene 45 
Identification code  45 
Empirical formula  C24H19NO6S2 
Formula weight  481.52 
Temperature  149.9(1) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P 1 
Unit cell dimensions a = 5.86394(16) Å  
 b = 8.2153(3) Å  
 c = 11.8849(4) Å  
Volume 556.78(3) Å3 
Z 1 
Density (calculated) 1.430 Mg/m3 
Absorption coefficient 0.280 mm-1 
F(000) 249 
Crystal size 0.40 x 0.20 x 0.20 mm3 
Theta range for data collection 2.994 to 25.348°. 
Index ranges -7<=h<=7, -9<=k<=9, -14<=l<=7 
Reflections collected 3499 
Independent reflections 2552 [R(int) = 0.0122] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.95971 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2552 / 3 / 298 
Goodness-of-fit on F2 1.158 
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Final R indices [I>2sigma(I)] R1 = 0.0336, wR2 = 0.0998 
R indices (all data) R1 = 0.0351, wR2 = 0.1012 
Absolute structure parameter 0.03(10) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.385 and -0.217 e.Å-3 
Table 0.12: Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for 45. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________
_____  
 x y z U(eq) 
___________________________________________________________________________
_____   
S(1) 4500(1) 2382(1) 650(1) 21(1) 
S(2) 123(2) 7415(1) 2102(1) 24(1) 
O(1) 2097(5) 2404(4) 545(3) 25(1) 
O(3) -2182(6) 7481(4) 1888(3) 39(1) 
O(2) 6214(5) 1314(4) -49(3) 27(1) 
O(4) 1499(6) 8812(4) 1834(3) 34(1) 
O(5) 18173(6) 11565(5) -3166(4) 49(1) 
N(1) 16100(7) 11765(5) -2676(4) 20(1) 
O(6) 15123(7) 13115(4) -2467(4) 45(1) 
C(1) 14743(8) 10315(6) -2341(4) 25(1) 
C(2) 15799(8) 8789(6) -2597(4) 28(1) 
C(3) 14504(7) 7433(6) -2247(4) 27(1) 
C(4) 12167(8) 7604(6) -1643(4) 26(1) 
C(5) 11167(8) 9172(6) -1399(5) 31(1) 
C(6) 12442(8) 10528(6) -1748(4) 28(1) 
C(7) 10858(8) 6136(6) -1304(4) 30(1) 
C(8) 8641(8) 6099(6) -678(4) 30(1) 
C(9) 7580(7) 4578(6) -312(4) 29(1) 
C(10) 5451(7) 4407(6) 367(4) 24(1) 
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C(11) 3950(7) 5760(5) 920(4) 25(1) 
C(12) 1679(8) 5724(6) 1392(4) 28(1) 
C(13) -23(8) 6810(5) 3559(4) 28(1) 
C(14) -1809(10) 5811(6) 4121(5) 42(1) 
C(15) -1908(13) 5231(8) 5209(6) 57(2) 
C(16) -250(14) 5626(10) 5751(6) 68(2) 
C(17) 1536(13) 6649(10) 5252(7) 72(2) 
C(18) 1664(9) 7256(7) 4099(5) 42(1) 
C(19) 4593(7) 1975(5) 2123(4) 21(1) 
C(20) 6679(8) 1365(5) 2383(4) 26(1) 
C(21) 6726(9) 1021(6) 3525(5) 34(1) 
C(22) 4740(9) 1301(6) 4390(4) 35(1) 
C(23) 2677(9) 1919(7) 4125(5) 37(1) 
C(24) 2584(8) 2252(6) 2977(4) 28(1) 
___________________________________________________________________________
_____ 
Table 0.13: Bond lengths [Å] and angles [°] for 45 
. 
_____________________________________________________  
S(1)-O(2)  1.435(3) 
S(1)-O(1)  1.441(3) 
S(1)-C(19)  1.779(5) 
S(1)-C(10)  1.780(5) 
S(2)-O(4)  1.427(3) 
S(2)-O(3)  1.428(3) 
S(2)-C(12)  1.758(5) 
S(2)-C(13)  1.763(5) 
O(5)-N(1)  1.230(5) 
N(1)-O(6)  1.227(6) 
N(1)-C(1)  1.463(6) 
C(1)-C(2)  1.380(6) 
C(1)-C(6)  1.381(6) 
C(2)-C(3)  1.383(6) 
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C(2)-H(2)  0.9300 
C(3)-C(4)  1.400(6) 
C(3)-H(3)  0.9300 
C(4)-C(5)  1.397(7) 
C(4)-C(7)  1.463(6) 
C(5)-C(6)  1.376(7) 
C(5)-H(5)  0.9300 
C(6)-H(6)  0.9300 
C(7)-C(8)  1.348(6) 
C(7)-H(7)  0.9300 
C(8)-C(9)  1.437(7) 
C(8)-H(8)  0.9300 
C(9)-C(10)  1.339(6) 
C(9)-H(9)  0.9300 
C(10)-C(11)  1.460(6) 
C(11)-C(12)  1.327(6) 
C(11)-H(11)  0.9300 
C(12)-H(12)  0.9300 
C(13)-C(18)  1.369(7) 
C(13)-C(14)  1.400(7) 
C(14)-C(15)  1.347(8) 
C(14)-H(14)  0.9300 
C(15)-C(16)  1.343(11) 
C(15)-H(15)  0.9300 
C(16)-C(17)  1.393(11) 
C(16)-H(16)  0.9300 
C(17)-C(18)  1.422(9) 
C(17)-H(17)  0.9300 
C(18)-H(18)  0.9300 
C(19)-C(20)  1.385(6) 
C(19)-C(24)  1.388(6) 
C(20)-C(21)  1.379(7) 
C(20)-H(20)  0.9300 
C(21)-C(22)  1.387(7) 
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C(21)-H(21)  0.9300 
C(22)-C(23)  1.377(7) 
C(22)-H(22)  0.9300 
C(23)-C(24)  1.391(7) 
C(23)-H(23)  0.9300 
C(24)-H(24)  0.9300 
 
O(2)-S(1)-O(1) 119.34(19) 
O(2)-S(1)-C(19) 108.53(19) 
O(1)-S(1)-C(19) 108.58(19) 
O(2)-S(1)-C(10) 107.7(2) 
O(1)-S(1)-C(10) 107.74(19) 
C(19)-S(1)-C(10) 103.9(2) 
O(4)-S(2)-O(3) 119.7(2) 
O(4)-S(2)-C(12) 109.5(2) 
O(3)-S(2)-C(12) 107.5(2) 
O(4)-S(2)-C(13) 108.6(2) 
O(3)-S(2)-C(13) 108.9(2) 
C(12)-S(2)-C(13) 101.2(2) 
O(6)-N(1)-O(5) 123.1(4) 
O(6)-N(1)-C(1) 118.9(4) 
O(5)-N(1)-C(1) 118.0(4) 
C(2)-C(1)-C(6) 122.1(4) 
C(2)-C(1)-N(1) 119.6(4) 
C(6)-C(1)-N(1) 118.3(4) 
C(1)-C(2)-C(3) 118.7(4) 
C(1)-C(2)-H(2) 120.6 
C(3)-C(2)-H(2) 120.6 
C(2)-C(3)-C(4) 120.7(4) 
C(2)-C(3)-H(3) 119.7 
C(4)-C(3)-H(3) 119.7 
C(5)-C(4)-C(3) 118.8(4) 
C(5)-C(4)-C(7) 122.5(4) 
C(3)-C(4)-C(7) 118.7(4) 
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C(6)-C(5)-C(4) 120.9(4) 
C(6)-C(5)-H(5) 119.6 
C(4)-C(5)-H(5) 119.6 
C(5)-C(6)-C(1) 118.8(4) 
C(5)-C(6)-H(6) 120.6 
C(1)-C(6)-H(6) 120.6 
C(8)-C(7)-C(4) 125.6(5) 
C(8)-C(7)-H(7) 117.2 
C(4)-C(7)-H(7) 117.2 
C(7)-C(8)-C(9) 121.1(5) 
C(7)-C(8)-H(8) 119.5 
C(9)-C(8)-H(8) 119.5 
C(10)-C(9)-C(8) 125.7(5) 
C(10)-C(9)-H(9) 117.2 
C(8)-C(9)-H(9) 117.2 
C(9)-C(10)-C(11) 124.0(4) 
C(9)-C(10)-S(1) 116.8(4) 
C(11)-C(10)-S(1) 119.2(3) 
C(12)-C(11)-C(10) 126.1(4) 
C(12)-C(11)-H(11) 117.0 
C(10)-C(11)-H(11) 117.0 
C(11)-C(12)-S(2) 121.1(4) 
C(11)-C(12)-H(12) 119.4 
S(2)-C(12)-H(12) 119.4 
C(18)-C(13)-C(14) 121.4(5) 
C(18)-C(13)-S(2) 119.7(4) 
C(14)-C(13)-S(2) 118.8(4) 
C(15)-C(14)-C(13) 121.1(6) 
C(15)-C(14)-H(14) 119.5 
C(13)-C(14)-H(14) 119.5 
C(16)-C(15)-C(14) 118.7(7) 
C(16)-C(15)-H(15) 120.7 
C(14)-C(15)-H(15) 120.7 
C(15)-C(16)-C(17) 123.0(6) 
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C(15)-C(16)-H(16) 118.5 
C(17)-C(16)-H(16) 118.5 
C(16)-C(17)-C(18) 118.6(7) 
C(16)-C(17)-H(17) 120.7 
C(18)-C(17)-H(17) 120.7 
C(13)-C(18)-C(17) 117.1(6) 
C(13)-C(18)-H(18) 121.4 
C(17)-C(18)-H(18) 121.4 
C(20)-C(19)-C(24) 121.8(4) 
C(20)-C(19)-S(1) 118.6(3) 
C(24)-C(19)-S(1) 119.6(3) 
C(21)-C(20)-C(19) 118.3(4) 
C(21)-C(20)-H(20) 120.9 
C(19)-C(20)-H(20) 120.9 
C(20)-C(21)-C(22) 120.7(4) 
C(20)-C(21)-H(21) 119.7 
C(22)-C(21)-H(21) 119.7 
C(23)-C(22)-C(21) 120.7(5) 
C(23)-C(22)-H(22) 119.7 
C(21)-C(22)-H(22) 119.7 
C(22)-C(23)-C(24) 119.5(5) 
C(22)-C(23)-H(23) 120.2 
C(24)-C(23)-H(23) 120.2 
C(19)-C(24)-C(23) 119.0(4) 
C(19)-C(24)-H(24) 120.5 
C(23)-C(24)-H(24) 120.5 
Table 0.14: Anisotropic displacement parameters (Å2x 103) for 45 
The anisotropic displacement factor exponent takes the form: - 2[ h2 a*2U11 + ... + 2 h k 
a* b* U12 ] 
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___________________________________________________________________________
___  
 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________
___  
S(1) 20(1)  21(1) 22(1)  -3(1) -6(1)  -1(1) 
S(2) 23(1)  22(1) 26(1)  -3(1) -7(1)  2(1) 
O(1) 24(2)  26(2) 28(2)  -2(1) -10(1)  -3(1) 
O(3) 30(2)  41(2) 49(2)  -10(2) -19(2)  9(2) 
O(2) 28(2)  28(2) 25(2)  -5(1) -5(1)  1(1) 
O(4) 39(2)  21(2) 38(2)  1(2) 0(2)  -3(1) 
O(5) 42(2)  36(2) 66(3)  7(2) -1(2)  -11(2) 
N(1) 24(2)  18(2) 16(2)  2(2) -2(2)  -7(2) 
O(6) 60(2)  27(2) 41(2)  0(2) 4(2)  -10(2) 
C(1) 31(2)  27(2) 19(2)  1(2) -9(2)  -4(2) 
C(2) 25(2)  30(2) 27(3)  -1(2) 1(2)  -3(2) 
C(3) 26(2)  27(2) 28(3)  0(2) -3(2)  2(2) 
C(4) 25(2)  28(2) 23(3)  0(2) -3(2)  -5(2) 
C(5) 25(2)  33(3) 32(3)  -8(2) 0(2)  0(2) 
C(6) 29(2)  28(2) 26(3)  -6(2) -3(2)  0(2) 
C(7) 29(2)  31(3) 32(3)  -3(2) -10(2)  0(2) 
C(8) 32(2)  33(3) 25(3)  -1(2) -6(2)  -2(2) 
C(9) 25(2)  30(2) 31(3)  0(2) -6(2)  -2(2) 
C(10) 29(2)  27(2) 16(2)  0(2) -8(2)  -2(2) 
C(11) 23(2)  25(2) 25(3)  2(2) -5(2)  -5(2) 
C(12) 36(3)  24(2) 23(2)  -1(2) -9(2)  1(2) 
C(13) 30(2)  26(2) 25(3)  -6(2) -2(2)  6(2) 
C(14) 45(3)  38(3) 34(3)  -5(2) 8(3)  -1(2) 
C(15) 72(4)  56(4) 33(4)  0(3) 6(3)  9(3) 
C(16) 87(5)  71(5) 29(4)  14(3) 11(4)  34(4) 
C(17) 77(5)  93(6) 54(5)  -34(4) -37(4)  36(5) 
C(18) 43(3)  52(3) 37(3)  -10(3) -19(3)  7(3) 
C(19) 22(2)  20(2) 23(2)  0(2) -7(2)  -1(2) 
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C(20) 21(2)  28(2) 28(3)  1(2) -5(2)  1(2) 
C(21) 34(3)  33(3) 38(3)  2(2) -17(2)  1(2) 
C(22) 47(3)  41(3) 19(3)  1(2) -13(2)  -7(2) 
C(23) 38(3)  42(3) 27(3)  1(2) 1(2)  1(2) 
C(24) 24(2)  31(2) 27(3)  2(2) -5(2)  1(2) 
___________________________________________________________________________
___ 
Table 0.15.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 
10 3) for 45. 
___________________________________________________________________________
_____  
 x  y  z  U(eq) 
___________________________________________________________________________
_____  
  
H(2) 17351 8675 -2998 37 
H(3) 15191 6397 -2415 36 
H(5) 9619 9300 -995 40 
H(6) 11766 11569 -1587 37 
H(7) 11619 5143 -1541 39 
H(8) 7785 7075 -480 39 
H(9) 8448 3628 -570 37 
H(11) 4652 6738 944 32 
H(12) 897 4787 1345 36 
H(14) -2946 5545 3736 55 
H(15) -3100 4569 5578 74 
H(16) -296 5197 6494 89 
H(17) 2621 6928 5663 93 
H(18) 2843 7927 3728 55 
H(20) 8014 1192 1802 34 
H(21) 8103 597 3718 44 
H(22) 4802 1069 5156 45 
H(23) 1355 2112 4710 48 
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H(24) 1197 2654 2784 36 
___________________________________________________________________________
_____  
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Table 0.21: Crystal data for 4-nitro-4’-(phenylsulfonyl)-1,1’-biphenyl 63 
Identification code  63 
Empirical formula  C18H13NO4S 
Formula weight  339.35 
Temperature  149.9(1) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 13.1110(9) Å  
 b = 7.6752(5) Å  
 c = 15.2536(13) Å  
Volume 1513.47(19) Å3 
Z 4 
Density (calculated) 1.489 Mg/m3 
Absorption coefficient 0.237 mm-1 
F(000) 704 
Crystal size 0.30 x 0.30 x 0.25 mm3 
Theta range for data collection 2.898 to 25.346°. 
Index ranges -15<=h<=12, -9<=k<=6, -18<=l<=14 
Reflections collected 5783 
Independent reflections 2766 [R(int) = 0.0426] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.89631 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2766 / 0 / 217 
Goodness-of-fit on F2 0.963 
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Final R indices [I>2sigma(I)] R1 = 0.0538, wR2 = 0.0965 
R indices (all data) R1 = 0.1011, wR2 = 0.1145 
Extinction coefficient n/a 
Largest diff. peak and hole 0.230 and -0.374 e.Å-3 
 Table 0.22 Atomic coordinates ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for 63. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________
_____  
 x y z U(eq) 
___________________________________________________________________________
_____   
S(1) 7046(1) 6567(1) 827(1) 30(1) 
O(1) 7553(2) 5780(3) 152(1) 37(1) 
O(2) 6629(2) 8301(3) 698(2) 36(1) 
O(3) 12214(2) 8002(3) 7186(2) 41(1) 
O(4) 13202(2) 6202(3) 6627(2) 50(1) 
N(1) 12403(2) 7051(3) 6580(2) 34(1) 
C(1) 11637(2) 6940(3) 5765(2) 25(1) 
C(2) 10686(2) 7721(4) 5747(2) 28(1) 
C(3) 9963(2) 7621(4) 4979(2) 27(1) 
C(4) 10182(2) 6778(3) 4224(2) 23(1) 
C(5) 11161(2) 6007(3) 4278(2) 27(1) 
C(6) 11880(2) 6061(3) 5046(2) 28(1) 
C(7) 9407(2) 6704(3) 3396(2) 23(1) 
C(8) 8571(2) 7866(4) 3244(2) 28(1) 
C(9) 7862(2) 7834(4) 2472(2) 28(1) 
C(10) 7951(2) 6604(4) 1824(2) 25(1) 
C(11) 8763(2) 5415(4) 1958(2) 29(1) 
C(12) 9479(2) 5482(4) 2731(2) 28(1) 
C(13) 6057(2) 5167(4) 1045(2) 24(1) 
C(14) 5242(2) 5830(4) 1410(2) 30(1) 
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C(15) 4493(2) 4708(4) 1602(2) 38(1) 
C(16) 4554(3) 2948(4) 1428(2) 35(1) 
C(17) 5368(3) 2295(4) 1072(2) 38(1) 
C(18) 6130(2) 3396(4) 880(2) 36(1) 
___________________________________________________________________________
_____ 
 Table 0.23: Bond lengths [Å] and angles [°] for 63. 
_____________________________________________________  
S(1)-O(2)  1.439(2) 
S(1)-O(1)  1.447(2) 
S(1)-C(13)  1.758(3) 
S(1)-C(10)  1.766(3) 
O(3)-N(1)  1.234(3) 
O(4)-N(1)  1.226(3) 
N(1)-C(1)  1.464(4) 
C(1)-C(6)  1.370(4) 
C(1)-C(2)  1.380(4) 
C(2)-C(3)  1.380(4) 
C(2)-H(2)  0.9300 
C(3)-C(4)  1.392(4) 
C(3)-H(3)  0.9300 
C(4)-C(5)  1.403(4) 
C(4)-C(7)  1.485(4) 
C(5)-C(6)  1.377(4) 
C(5)-H(5)  0.9300 
C(6)-H(6)  0.9300 
C(7)-C(12)  1.396(4) 
C(7)-C(8)  1.402(4) 
C(8)-C(9)  1.373(4) 
C(8)-H(8)  0.9300 
C(9)-C(10)  1.387(4) 
C(9)-H(9)  0.9300 
C(10)-C(11)  1.392(4) 
C(11)-C(12)  1.381(4) 
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C(11)-H(11)  0.9300 
C(12)-H(12)  0.9300 
C(13)-C(14)  1.382(4) 
C(13)-C(18)  1.388(4) 
C(14)-C(15)  1.374(4) 
C(14)-H(14)  0.9300 
C(15)-C(16)  1.381(4) 
C(15)-H(15)  0.9300 
C(16)-C(17)  1.371(4) 
C(16)-H(16)  0.9300 
C(17)-C(18)  1.377(4) 
C(17)-H(17)  0.9300 
C(18)-H(18)  0.9300 
 
O(2)-S(1)-O(1) 119.88(13) 
O(2)-S(1)-C(13) 108.40(13) 
O(1)-S(1)-C(13) 108.66(13) 
O(2)-S(1)-C(10) 106.74(14) 
O(1)-S(1)-C(10) 107.26(13) 
C(13)-S(1)-C(10) 104.90(14) 
O(4)-N(1)-O(3) 123.1(3) 
O(4)-N(1)-C(1) 118.5(3) 
O(3)-N(1)-C(1) 118.3(3) 
C(6)-C(1)-C(2) 121.8(3) 
C(6)-C(1)-N(1) 119.4(3) 
C(2)-C(1)-N(1) 118.8(3) 
C(1)-C(2)-C(3) 118.9(3) 
C(1)-C(2)-H(2) 120.5 
C(3)-C(2)-H(2) 120.5 
C(2)-C(3)-C(4) 121.4(3) 
C(2)-C(3)-H(3) 119.3 
C(4)-C(3)-H(3) 119.3 
C(3)-C(4)-C(5) 117.4(3) 
C(3)-C(4)-C(7) 121.0(3) 
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C(5)-C(4)-C(7) 121.5(3) 
C(6)-C(5)-C(4) 121.8(3) 
C(6)-C(5)-H(5) 119.1 
C(4)-C(5)-H(5) 119.1 
C(1)-C(6)-C(5) 118.6(3) 
C(1)-C(6)-H(6) 120.7 
C(5)-C(6)-H(6) 120.7 
C(12)-C(7)-C(8) 116.9(3) 
C(12)-C(7)-C(4) 121.6(3) 
C(8)-C(7)-C(4) 121.4(3) 
C(9)-C(8)-C(7) 121.9(3) 
C(9)-C(8)-H(8) 119.0 
C(7)-C(8)-H(8) 119.0 
C(8)-C(9)-C(10) 119.9(3) 
C(8)-C(9)-H(9) 120.0 
C(10)-C(9)-H(9) 120.0 
C(9)-C(10)-C(11) 119.6(3) 
C(9)-C(10)-S(1) 120.1(2) 
C(11)-C(10)-S(1) 120.3(2) 
C(12)-C(11)-C(10) 119.7(3) 
C(12)-C(11)-H(11) 120.1 
C(10)-C(11)-H(11) 120.1 
C(11)-C(12)-C(7) 121.8(3) 
C(11)-C(12)-H(12) 119.1 
C(7)-C(12)-H(12) 119.1 
C(14)-C(13)-C(18) 120.9(3) 
C(14)-C(13)-S(1) 119.7(2) 
C(18)-C(13)-S(1) 119.3(2) 
C(15)-C(14)-C(13) 118.9(3) 
C(15)-C(14)-H(14) 120.5 
C(13)-C(14)-H(14) 120.5 
C(14)-C(15)-C(16) 120.4(3) 
C(14)-C(15)-H(15) 119.8 
C(16)-C(15)-H(15) 119.8 
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C(17)-C(16)-C(15) 120.5(3) 
C(17)-C(16)-H(16) 119.7 
C(15)-C(16)-H(16) 119.7 
C(16)-C(17)-C(18) 120.0(3) 
C(16)-C(17)-H(17) 120.0 
C(18)-C(17)-H(17) 120.0 
C(17)-C(18)-C(13) 119.2(3) 
C(17)-C(18)-H(18) 120.4 
C(13)-C(18)-H(18) 120.4 
_____________________________________________________________  
 Table 0.24:   Anisotropic displacement parameters  (Å2x 103) for 63. The anisotropic 
displacement factor exponent takes the form: -2 2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
___________________________________________________________________________
___  
 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________
___  
S(1) 26(1)  32(1) 33(1)  1(1) 10(1)  -5(1) 
O(1) 29(1)  55(2) 31(1)  -5(1) 15(1)  -7(1) 
O(2) 34(1)  30(1) 45(2)  9(1) 9(1)  -3(1) 
O(3) 44(2)  36(1) 42(2)  -10(1) 4(1)  1(1) 
O(4) 34(1)  48(2) 65(2)  -9(1) -4(1)  15(1) 
N(1) 30(2)  27(2) 45(2)  0(1) 4(2)  -3(1) 
C(1) 26(2)  14(2) 34(2)  2(1) 5(2)  -6(1) 
C(2) 31(2)  21(2) 37(2)  -2(2) 16(2)  -1(1) 
C(3) 26(2)  22(2) 36(2)  2(2) 14(2)  2(1) 
C(4) 24(2)  14(1) 32(2)  2(1) 11(2)  -2(1) 
C(5) 32(2)  18(2) 36(2)  -1(2) 17(2)  0(1) 
C(6) 28(2)  19(2) 39(2)  1(2) 12(2)  0(1) 
C(7) 26(2)  16(2) 31(2)  4(1) 17(2)  -3(1) 
C(8) 26(2)  23(2) 37(2)  -3(2) 12(2)  -2(1) 
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C(9) 25(2)  22(2) 39(2)  0(2) 11(2)  2(1) 
C(10) 22(2)  25(2) 31(2)  0(2) 13(1)  -7(1) 
C(11) 32(2)  23(2) 36(2)  -2(2) 16(2)  -1(1) 
C(12) 27(2)  21(2) 37(2)  3(2) 12(2)  4(1) 
C(13) 21(2)  26(2) 26(2)  4(1) 4(1)  -3(1) 
C(14) 29(2)  25(2) 37(2)  1(2) 9(2)  1(1) 
C(15) 31(2)  39(2) 49(2)  5(2) 20(2)  1(2) 
C(16) 32(2)  33(2) 42(2)  7(2) 8(2)  -8(2) 
C(17) 40(2)  25(2) 51(3)  -7(2) 10(2)  -4(2) 
C(18) 30(2)  33(2) 48(2)  -4(2) 14(2)  2(2) 
___________________________________________________________________________
___  
Table 0.25: Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) 
for 63. 
___________________________________________________________________________
_____  
 x  y  z  U(eq) 
___________________________________________________________________________
_____  
  
H(2) 10534 8306 6243 37 
H(3) 9316 8127 4966 35 
H(5) 11329 5444 3781 36 
H(6) 12517 5513 5076 36 
H(8) 8495 8683 3679 36 
H(9) 7323 8637 2385 36 
H(11) 8824 4580 1528 38 
H(12) 10024 4690 2812 36 
H(14) 5201 7016 1524 39 
H(15) 3941 5136 1850 49 
H(16) 4038 2201 1554 46 
H(17) 5406 1107 961 50 
H(18) 6686 2959 643 47 
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___________________________________________________________________________
_____  
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Table 0.31: Crystal data for ((1E,3E,5E)-6-(4-methoxyphenyl)hexa-1,3,5-triene-1,3 
-diyldisulfonyl)dibenzene 50  
Identification code  50 
Empirical formula  C25H22O5S2 
Formula weight  466.54 
Temperature  150.0(1) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 5.84331(18) Å  
 b = 25.5606(8) Å  
 c = 14.9540(5) Å  
Volume 2233.49(12) Å3 
Z 4 
Density (calculated) 1.387 Mg/m3 
Absorption coefficient 0.274 mm-1 
F(000) 976 
Crystal size 0.50 x 0.25 x 0.20 mm3 
Theta range for data collection 3.157 to 25.350°. 
Index ranges -7<=h<=7, -30<=k<=30, -18<=l<=18 
Reflections collected 28233 
Independent reflections 4078 [R(int) = 0.0479] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.98856 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4078 / 0 / 291 
Goodness-of-fit on F2 1.018 
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Final R indices [I>2sigma(I)] R1 = 0.0384, wR2 = 0.0838 
R indices (all data) R1 = 0.0463, wR2 = 0.0875 
Extinction coefficient n/a 
Largest diff. peak and hole 0.341 and -0.328 e.Å-3 
Table 0.32: Atomic coordinates ( x 104) and equivalent isotropic displacement parameters 
(Å2x 103) for 50. U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________
_____  
 x y z U(eq) 
___________________________________________________________________________
_____   
S(1) 1960(1) 6051(1) 4947(1) 24(1) 
S(2) 5195(1) 6598(1) 2097(1) 23(1) 
O(2) 4415(3) 6044(1) 4976(1) 30(1) 
O(4) 7592(3) 6482(1) 2030(1) 31(1) 
O(3) 3711(3) 6487(1) 1352(1) 31(1) 
O(5) -9912(3) 4151(1) 665(1) 38(1) 
O(1) 733(3) 5756(1) 5609(1) 36(1) 
C(1) -9532(6) 4200(1) -275(2) 47(1) 
C(2) -8338(4) 4368(1) 1232(2) 28(1) 
C(3) -8856(4) 4346(1) 2135(2) 27(1) 
C(4) -7374(4) 4555(1) 2761(2) 26(1) 
C(5) -5346(4) 4802(1) 2506(2) 23(1) 
C(6) -4853(4) 4818(1) 1593(2) 31(1) 
C(7) -6311(4) 4600(1) 964(2) 32(1) 
C(8) -3885(4) 5027(1) 3193(2) 24(1) 
C(9) -2019(4) 5328(1) 3090(2) 23(1) 
C(10) -848(4) 5533(1) 3857(2) 23(1) 
C(11) 1003(4) 5851(1) 3872(2) 21(1) 
C(12) 2101(4) 6076(1) 3088(2) 21(1) 
C(13) 4158(4) 6295(1) 3058(2) 21(1) 
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C(14) 4940(4) 7268(1) 2371(2) 22(1) 
C(15) 2966(4) 7534(1) 2135(2) 27(1) 
C(16) 2781(5) 8058(1) 2349(2) 34(1) 
C(17) 4527(5) 8308(1) 2807(2) 36(1) 
C(18) 6470(5) 8036(1) 3053(2) 36(1) 
C(19) 6696(4) 7515(1) 2836(2) 28(1) 
C(20) 1017(4) 6708(1) 5015(2) 25(1) 
C(21) -1131(4) 6805(1) 5366(2) 35(1) 
C(22) -1874(5) 7319(1) 5425(2) 48(1) 
C(23) -512(6) 7724(1) 5130(2) 48(1) 
C(24) 1597(6) 7622(1) 4781(2) 42(1) 
C(25) 2393(5) 7113(1) 4719(2) 30(1) 
___________________________________________________________________________
_____ 
Table 0.33: Bond lengths [Å] and angles [°] for 50. 
_____________________________________________________  
S(1)-O(2)  1.4351(17) 
S(1)-O(1)  1.4376(17) 
S(1)-C(20)  1.769(2) 
S(1)-C(11)  1.775(2) 
S(2)-O(4)  1.4356(17) 
S(2)-O(3)  1.4372(18) 
S(2)-C(13)  1.745(2) 
S(2)-C(14)  1.766(2) 
O(5)-C(2)  1.367(3) 
O(5)-C(1)  1.430(3) 
C(1)-H(1A)  0.9600 
C(1)-H(1B)  0.9600 
C(1)-H(1C)  0.9600 
C(2)-C(7)  1.385(3) 
C(2)-C(3)  1.386(3) 
C(3)-C(4)  1.381(3) 
C(3)-H(3)  0.9300 
C(4)-C(5)  1.397(3) 
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C(4)-H(4)  0.9300 
C(5)-C(6)  1.396(3) 
C(5)-C(8)  1.453(3) 
C(6)-C(7)  1.383(4) 
C(6)-H(6)  0.9300 
C(7)-H(7)  0.9300 
C(8)-C(9)  1.343(3) 
C(8)-H(8)  0.9300 
C(9)-C(10)  1.432(3) 
C(9)-H(9)  0.9300 
C(10)-C(11)  1.354(3) 
C(10)-H(10)  0.9300 
C(11)-C(12)  1.456(3) 
C(12)-C(13)  1.327(3) 
C(12)-H(12)  0.9300 
C(13)-H(13)  0.9300 
C(14)-C(15)  1.384(3) 
C(14)-C(19)  1.389(3) 
C(15)-C(16)  1.383(4) 
C(15)-H(15)  0.9300 
C(16)-C(17)  1.383(4) 
C(16)-H(16)  0.9300 
C(17)-C(18)  1.380(4) 
C(17)-H(17)  0.9300 
C(18)-C(19)  1.380(4) 
C(18)-H(18)  0.9300 
C(19)-H(19)  0.9300 
C(20)-C(21)  1.385(3) 
C(20)-C(25)  1.386(3) 
C(21)-C(22)  1.386(4) 
C(21)-H(21)  0.9300 
C(22)-C(23)  1.379(5) 
C(22)-H(22)  0.9300 
C(23)-C(24)  1.366(4) 
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C(23)-H(23)  0.9300 
C(24)-C(25)  1.384(4) 
C(24)-H(24)  0.9300 
C(25)-H(25)  0.9300 
 
O(2)-S(1)-O(1) 118.27(11) 
O(2)-S(1)-C(20) 108.81(11) 
O(1)-S(1)-C(20) 107.51(12) 
O(2)-S(1)-C(11) 109.55(11) 
O(1)-S(1)-C(11) 108.46(11) 
C(20)-S(1)-C(11) 103.18(11) 
O(4)-S(2)-O(3) 119.36(11) 
O(4)-S(2)-C(13) 107.96(11) 
O(3)-S(2)-C(13) 109.84(11) 
O(4)-S(2)-C(14) 107.44(11) 
O(3)-S(2)-C(14) 108.73(11) 
C(13)-S(2)-C(14) 102.11(10) 
C(2)-O(5)-C(1) 117.8(2) 
O(5)-C(1)-H(1A) 109.5 
O(5)-C(1)-H(1B) 109.5 
H(1A)-C(1)-H(1B) 109.5 
O(5)-C(1)-H(1C) 109.5 
H(1A)-C(1)-H(1C) 109.5 
H(1B)-C(1)-H(1C) 109.5 
O(5)-C(2)-C(7) 124.6(2) 
O(5)-C(2)-C(3) 116.0(2) 
C(7)-C(2)-C(3) 119.4(2) 
C(4)-C(3)-C(2) 120.3(2) 
C(4)-C(3)-H(3) 119.8 
C(2)-C(3)-H(3) 119.8 
C(3)-C(4)-C(5) 121.3(2) 
C(3)-C(4)-H(4) 119.3 
C(5)-C(4)-H(4) 119.3 
C(6)-C(5)-C(4) 117.4(2) 
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C(6)-C(5)-C(8) 123.8(2) 
C(4)-C(5)-C(8) 118.8(2) 
C(7)-C(6)-C(5) 121.6(2) 
C(7)-C(6)-H(6) 119.2 
C(5)-C(6)-H(6) 119.2 
C(6)-C(7)-C(2) 120.0(2) 
C(6)-C(7)-H(7) 120.0 
C(2)-C(7)-H(7) 120.0 
C(9)-C(8)-C(5) 128.4(2) 
C(9)-C(8)-H(8) 115.8 
C(5)-C(8)-H(8) 115.8 
C(8)-C(9)-C(10) 120.2(2) 
C(8)-C(9)-H(9) 119.9 
C(10)-C(9)-H(9) 119.9 
C(11)-C(10)-C(9) 127.8(2) 
C(11)-C(10)-H(10) 116.1 
C(9)-C(10)-H(10) 116.1 
C(10)-C(11)-C(12) 125.4(2) 
C(10)-C(11)-S(1) 115.87(18) 
C(12)-C(11)-S(1) 118.47(17) 
C(13)-C(12)-C(11) 126.6(2) 
C(13)-C(12)-H(12) 116.7 
C(11)-C(12)-H(12) 116.7 
C(12)-C(13)-S(2) 122.30(19) 
C(12)-C(13)-H(13) 118.9 
S(2)-C(13)-H(13) 118.9 
C(15)-C(14)-C(19) 121.2(2) 
C(15)-C(14)-S(2) 119.23(18) 
C(19)-C(14)-S(2) 119.57(19) 
C(16)-C(15)-C(14) 118.9(2) 
C(16)-C(15)-H(15) 120.5 
C(14)-C(15)-H(15) 120.5 
C(15)-C(16)-C(17) 120.3(2) 
C(15)-C(16)-H(16) 119.8 
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C(17)-C(16)-H(16) 119.8 
C(18)-C(17)-C(16) 120.2(2) 
C(18)-C(17)-H(17) 119.9 
C(16)-C(17)-H(17) 119.9 
C(19)-C(18)-C(17) 120.3(3) 
C(19)-C(18)-H(18) 119.9 
C(17)-C(18)-H(18) 119.9 
C(18)-C(19)-C(14) 119.1(2) 
C(18)-C(19)-H(19) 120.5 
C(14)-C(19)-H(19) 120.5 
C(21)-C(20)-C(25) 120.9(2) 
C(21)-C(20)-S(1) 118.4(2) 
C(25)-C(20)-S(1) 120.68(19) 
C(20)-C(21)-C(22) 118.7(3) 
C(20)-C(21)-H(21) 120.7 
C(22)-C(21)-H(21) 120.7 
C(23)-C(22)-C(21) 120.6(3) 
C(23)-C(22)-H(22) 119.7 
C(21)-C(22)-H(22) 119.7 
C(24)-C(23)-C(22) 120.1(3) 
C(24)-C(23)-H(23) 119.9 
C(22)-C(23)-H(23) 119.9 
C(23)-C(24)-C(25) 120.6(3) 
C(23)-C(24)-H(24) 119.7 
C(25)-C(24)-H(24) 119.7 
C(24)-C(25)-C(20) 119.1(3) 
C(24)-C(25)-H(25) 120.5 
C(20)-C(25)-H(25) 120.5 
_____________________________________________________________  
 
Table 0.34: Anisotropic displacement parameters (Å2x 103) for 50. The anisotropic 
displacement factor exponent takes the form: -2 2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
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___________________________________________________________________________
___  
 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________
___  
S(1) 24(1)  28(1) 20(1)  5(1) -1(1)  -4(1) 
S(2) 25(1)  23(1) 20(1)  0(1) 3(1)  0(1) 
O(2) 25(1)  39(1) 27(1)  5(1) -4(1)  -1(1) 
O(4) 28(1)  31(1) 33(1)  4(1) 11(1)  4(1) 
O(3) 40(1)  32(1) 22(1)  -2(1) -1(1)  -4(1) 
O(5) 37(1)  40(1) 37(1)  -9(1) -3(1)  -11(1) 
O(1) 36(1)  44(1) 26(1)  14(1) -1(1)  -11(1) 
C(1) 60(2)  47(2) 35(2)  -9(1) -7(1)  -15(2) 
C(2) 28(1)  19(1) 36(1)  -4(1) -2(1)  -1(1) 
C(3) 23(1)  22(1) 36(1)  -2(1) 8(1)  -4(1) 
C(4) 30(1)  19(1) 28(1)  -1(1) 7(1)  -1(1) 
C(5) 24(1)  15(1) 29(1)  0(1) 1(1)  2(1) 
C(6) 29(1)  30(1) 33(1)  4(1) 4(1)  -8(1) 
C(7) 38(2)  34(1) 25(1)  2(1) 3(1)  -8(1) 
C(8) 27(1)  17(1) 27(1)  2(1) 2(1)  3(1) 
C(9) 26(1)  17(1) 27(1)  2(1) 1(1)  2(1) 
C(10) 24(1)  20(1) 26(1)  4(1) 2(1)  2(1) 
C(11) 23(1)  19(1) 22(1)  2(1) -3(1)  1(1) 
C(12) 24(1)  16(1) 22(1)  -1(1) -1(1)  2(1) 
C(13) 25(1)  18(1) 21(1)  -1(1) 2(1)  4(1) 
C(14) 24(1)  22(1) 18(1)  4(1) 3(1)  -2(1) 
C(15) 26(1)  31(1) 24(1)  -1(1) -2(1)  1(1) 
C(16) 39(2)  28(1) 36(2)  5(1) -3(1)  10(1) 
C(17) 49(2)  20(1) 41(2)  1(1) 2(1)  1(1) 
C(18) 38(2)  27(1) 44(2)  1(1) -5(1)  -10(1) 
C(19) 24(1)  27(1) 34(1)  6(1) -4(1)  -3(1) 
C(20) 29(1)  30(1) 16(1)  -5(1) -4(1)  -1(1) 
C(21) 27(1)  49(2) 30(1)  -12(1) -2(1)  -5(1) 
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C(22) 34(2)  68(2) 42(2)  -29(2) -7(1)  14(2) 
C(23) 61(2)  39(2) 44(2)  -20(1) -16(2)  15(2) 
C(24) 68(2)  29(2) 28(2)  -6(1) -5(1)  -4(1) 
C(25) 39(2)  32(1) 21(1)  -5(1) 4(1)  -4(1) 
___________________________________________________________________________
___ 
Table 0.35: Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for 50. 
___________________________________________________________________________
_____  
 x  y  z  U(eq) 
___________________________________________________________________________
_____  
  
H(1A) -9453 4564 -432 62 
H(1B) -10770 4038 -596 62 
H(1C) -8119 4032 -429 62 
H(3) -10209 4188 2320 35 
H(4) -7733 4532 3365 33 
H(6) -3512 4979 1404 40 
H(7) -5931 4610 361 42 
H(8) -4296 4955 3780 31 
H(9) -1486 5402 2519 30 
H(10) -1428 5435 4410 30 
H(12) 1277 6065 2555 27 
H(13) 5078 6286 3567 28 
H(15) 1782 7363 1837 35 
H(16) 1477 8244 2184 45 
H(17) 4391 8661 2950 47 
H(18) 7632 8206 3366 47 
H(19) 8006 7331 3000 37 
H(21) -2055 6532 5558 46 
H(22) -3305 7391 5665 63 
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H(23) -1031 8067 5170 62 
H(24) 2507 7897 4583 54 
H(25) 3830 7045 4482 40 
___________________________________________________________________________
_____   
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Table 0.41: Crystal data for 4’-methoxy-4’-(phenylsulfonyl)-1,1’-biphenyl 58 
Identification code  58 
Empirical formula  C19H16O3S 
Formula weight  324.38 
Temperature  296.3(1) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21 
Unit cell dimensions a = 6.7378(3) Å  
 b = 7.9901(4) Å  
 c = 15.1328(7) Å  
Volume 805.31(7) Å3 
Z 2 
Density (calculated) 1.338 Mg/m3 
Absorption coefficient 0.213 mm-1 
F(000) 340 
Crystal size 0.40 x 0.30 x 0.25 mm3 
Theta range for data collection 3.059 to 25.349°. 
Index ranges -7<=h<=8, -7<=k<=9, -18<=l<=12 
Reflections collected 3173 
Independent reflections 2209 [R(int) = 0.0230] 
Completeness to theta = 25.242° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.88553 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2209 / 1 / 209 
Goodness-of-fit on F2 1.056 
Final R indices [I>2sigma(I)] R1 = 0.0384, wR2 = 0.0854 
R indices (all data) R1 = 0.0482, wR2 = 0.0909 
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Absolute structure parameter 0.09(7) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.121 and -0.238 e.Å-3 
Table 0.42 Atomic coordinates ( x 104) and equivalent isotropic displacement parameters 
(Å2x 103) for 58. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
___________________________________________________________________________
_____  
 x y z U(eq) 
___________________________________________________________________________
_____   
S(1) 3306(1) 6276(1) 8194(1) 51(1) 
O(3) -7038(3) 5910(4) 2516(2) 63(1) 
O(1) 5232(3) 6173(6) 7916(2) 78(1) 
O(2) 2783(5) 7717(3) 8680(2) 73(1) 
C(1) -8817(6) 6888(7) 2420(3) 92(2) 
C(2) -5735(4) 6031(5) 3287(2) 45(1) 
C(3) -3971(5) 5107(5) 3334(2) 57(1) 
C(4) -2576(5) 5127(5) 4082(2) 50(1) 
C(5) -2827(4) 6058(5) 4835(2) 39(1) 
C(6) -4575(5) 6991(5) 4769(2) 58(1) 
C(7) -6016(5) 6977(5) 4017(3) 58(1) 
C(8) -1323(4) 6067(5) 5663(2) 40(1) 
C(9) 582(5) 5386(6) 5687(2) 57(1) 
C(10) 1968(5) 5410(5) 6455(3) 59(1) 
C(11) 1486(4) 6135(6) 7221(2) 46(1) 
C(12) -381(5) 6803(5) 7218(2) 54(1) 
C(13) -1765(5) 6759(5) 6453(2) 54(1) 
C(14) 3001(5) 4485(5) 8839(2) 41(1) 
C(15) 3875(6) 3007(5) 8648(3) 61(1) 
C(16) 3683(7) 1625(6) 9156(4) 82(1) 
C(17) 2663(7) 1718(7) 9851(4) 88(2) 
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C(18) 1789(8) 3191(8) 10055(3) 87(2) 
C(19) 1956(5) 4602(5) 9549(2) 59(1) 
___________________________________________________________________________
_____ 
Table 0.43: Bond lengths [Å] and angles [°] for 58. 
_____________________________________________________  
S(1)-O(1)  1.426(2) 
S(1)-O(2)  1.438(3) 
S(1)-C(14)  1.761(4) 
S(1)-C(11)  1.772(3) 
O(3)-C(2)  1.353(4) 
O(3)-C(1)  1.420(5) 
C(1)-H(1A)  0.9600 
C(1)-H(1B)  0.9600 
C(1)-H(1C)  0.9600 
C(2)-C(7)  1.375(5) 
C(2)-C(3)  1.392(5) 
C(3)-C(4)  1.358(5) 
C(3)-H(3)  0.9300 
C(4)-C(5)  1.393(5) 
C(4)-H(4)  0.9300 
C(5)-C(6)  1.384(4) 
C(5)-C(8)  1.487(4) 
C(6)-C(7)  1.380(5) 
C(6)-H(6)  0.9300 
C(7)-H(7)  0.9300 
C(8)-C(9)  1.390(5) 
C(8)-C(13)  1.391(4) 
C(9)-C(10)  1.376(5) 
C(9)-H(9)  0.9300 
C(10)-C(11)  1.378(5) 
C(10)-H(10)  0.9300 
C(11)-C(12)  1.366(4) 
C(12)-C(13)  1.372(5) 
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C(12)-H(12)  0.9300 
C(13)-H(13)  0.9300 
C(14)-C(15)  1.370(5) 
C(14)-C(19)  1.374(5) 
C(15)-C(16)  1.362(6) 
C(15)-H(15)  0.9300 
C(16)-C(17)  1.344(7) 
C(16)-H(16)  0.9300 
C(17)-C(18)  1.372(7) 
C(17)-H(17)  0.9300 
C(18)-C(19)  1.377(6) 
C(18)-H(18)  0.9300 
C(19)-H(19)  0.9300 
 
O(1)-S(1)-O(2) 120.1(2) 
O(1)-S(1)-C(14) 107.7(2) 
O(2)-S(1)-C(14) 108.03(15) 
O(1)-S(1)-C(11) 107.30(13) 
O(2)-S(1)-C(11) 106.5(2) 
C(14)-S(1)-C(11) 106.52(18) 
C(2)-O(3)-C(1) 118.5(3) 
O(3)-C(1)-H(1A) 109.5 
O(3)-C(1)-H(1B) 109.5 
H(1A)-C(1)-H(1B) 109.5 
O(3)-C(1)-H(1C) 109.5 
H(1A)-C(1)-H(1C) 109.5 
H(1B)-C(1)-H(1C) 109.5 
O(3)-C(2)-C(7) 125.6(3) 
O(3)-C(2)-C(3) 116.4(3) 
C(7)-C(2)-C(3) 118.1(3) 
C(4)-C(3)-C(2) 121.0(3) 
C(4)-C(3)-H(3) 119.5 
C(2)-C(3)-H(3) 119.5 
C(3)-C(4)-C(5) 122.3(3) 
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C(3)-C(4)-H(4) 118.9 
C(5)-C(4)-H(4) 118.9 
C(6)-C(5)-C(4) 115.8(3) 
C(6)-C(5)-C(8) 121.5(3) 
C(4)-C(5)-C(8) 122.7(3) 
C(7)-C(6)-C(5) 122.7(3) 
C(7)-C(6)-H(6) 118.6 
C(5)-C(6)-H(6) 118.6 
C(2)-C(7)-C(6) 120.1(3) 
C(2)-C(7)-H(7) 120.0 
C(6)-C(7)-H(7) 120.0 
C(9)-C(8)-C(13) 116.7(3) 
C(9)-C(8)-C(5) 122.0(3) 
C(13)-C(8)-C(5) 121.3(3) 
C(10)-C(9)-C(8) 121.5(3) 
C(10)-C(9)-H(9) 119.2 
C(8)-C(9)-H(9) 119.2 
C(9)-C(10)-C(11) 120.0(3) 
C(9)-C(10)-H(10) 120.0 
C(11)-C(10)-H(10) 120.0 
C(12)-C(11)-C(10) 119.7(3) 
C(12)-C(11)-S(1) 120.0(3) 
C(10)-C(11)-S(1) 120.3(3) 
C(11)-C(12)-C(13) 120.1(3) 
C(11)-C(12)-H(12) 120.0 
C(13)-C(12)-H(12) 120.0 
C(12)-C(13)-C(8) 121.9(3) 
C(12)-C(13)-H(13) 119.0 
C(8)-C(13)-H(13) 119.0 
C(15)-C(14)-C(19) 120.7(4) 
C(15)-C(14)-S(1) 119.6(3) 
C(19)-C(14)-S(1) 119.6(3) 
C(16)-C(15)-C(14) 120.0(4) 
C(16)-C(15)-H(15) 120.0 
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C(14)-C(15)-H(15) 120.0 
C(17)-C(16)-C(15) 120.1(5) 
C(17)-C(16)-H(16) 120.0 
C(15)-C(16)-H(16) 120.0 
C(16)-C(17)-C(18) 120.7(5) 
C(16)-C(17)-H(17) 119.6 
C(18)-C(17)-H(17) 119.6 
C(17)-C(18)-C(19) 120.2(4) 
C(17)-C(18)-H(18) 119.9 
C(19)-C(18)-H(18) 119.9 
C(14)-C(19)-C(18) 118.3(4) 
C(14)-C(19)-H(19) 120.8 
C(18)-C(19)-H(19) 120.8 
_____________________________________________________________  
 
 
Table 0.44: Anisotropic displacement parameters (Å2x 103) for 58. The anisotropic 
displacement factor exponent takes the form: -2 2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
___________________________________________________________________________
___  
 U11 U22  U33 U23 U13 U12 
___________________________________________________________________________
___  
S(1) 54(1)  53(1) 46(1)  4(1) 5(1)  -14(1) 
O(3) 56(1)  72(2) 57(1)  1(2) -5(1)  4(2) 
O(1) 50(1)  121(3) 63(1)  17(2) 8(1)  -29(2) 
O(2) 108(2)  39(2) 66(2)  -7(2) -7(2)  -8(2) 
C(1) 60(2)  123(5) 85(3)  1(3) -9(2)  21(3) 
C(2) 45(2)  42(2) 48(2)  7(2) 8(1)  -3(2) 
C(3) 68(2)  54(3) 49(2)  -11(2) 10(2)  16(2) 
C(4) 50(2)  49(2) 51(2)  -2(2) 7(2)  16(2) 
C(5) 44(2)  33(2) 42(2)  4(2) 14(1)  2(2) 
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C(6) 55(2)  69(3) 51(2)  -8(2) 13(2)  17(2) 
C(7) 43(2)  71(3) 62(2)  -3(2) 9(2)  18(2) 
C(8) 41(1)  36(2) 45(2)  1(2) 12(1)  0(2) 
C(9) 51(2)  75(3) 47(2)  -11(2) 13(2)  11(2) 
C(10) 45(2)  80(3) 54(2)  -4(2) 8(2)  15(2) 
C(11) 50(2)  46(2) 42(2)  5(2) 10(1)  -8(2) 
C(12) 59(2)  63(3) 43(2)  -4(2) 17(2)  8(2) 
C(13) 49(2)  68(3) 46(2)  -3(2) 16(2)  10(2) 
C(14) 38(2)  42(2) 41(2)  -2(2) 1(2)  -3(2) 
C(15) 59(2)  55(3) 67(3)  -10(2) 4(2)  1(2) 
C(16) 76(3)  49(3) 110(4)  -3(3) -23(3)  6(2) 
C(17) 79(3)  74(4) 97(4)  43(3) -30(3)  -23(3) 
C(18) 91(3)  108(5) 66(3)  24(3) 25(2)  -20(3) 
C(19) 63(2)  63(3) 56(2)  6(2) 22(2)  3(2) 
___________________________________________________________________________
___ 
Table 0.45 Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) 
for 58. 
___________________________________________________________________________
_____  
 x  y  z  U(eq) 
___________________________________________________________________________
_____  
  
H(1A) -9559 6631 2896 119 
H(1B) -9624 6640 1856 119 
H(1C) -8470 8054 2442 119 
H(3) -3745 4466 2846 74 
H(4) -1412 4496 4092 65 
H(6) -4786 7654 5251 75 
H(7) -7179 7610 4004 76 
H(9) 929 4903 5173 74 
H(10) 3230 4937 6457 77 
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H(12) -714 7288 7734 70 
H(13) -3035 7206 6464 70 
H(15) 4599 2946 8173 79 
H(16) 4259 617 9021 107 
H(17) 2548 773 10199 114 
H(18) 1081 3237 10537 113 
H(19) 1376 5608 9684 77 
___________________________________________________________________________
_____   
 
 
 
